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Menopause is defined as a permanent physiological, or natural, cessation of menstrual 
cycle. It plays an important role in the development of ocular surface dryness symptoms and 
there is an increased prevalence of dry eye in women, especially those aged over 50. Despite 
the high prevalence of dry eye in post-menopausal women (PMW), very few studies have 
been undertaken to understand dry eye disease in a group of PMW who are not on Hormone 
Replacement Therapy (HRT). Studies in the past on PMW have primarily focused on the 
relationship between HRT and dry eye.  Hence, a series of studies were undertaken to 
understand the clinical aspects of dry eye and their relationship to a variety of tear film 
components, in a group of PMW with and without symptoms of dry eye. 
 
The specific aims of each chapter were as follows:  
 
• Chapter 4: To characterize symptoms of dry eye using questionnaires, namely Ocular 
Surface Disease Index Questionnaire© (OSDI) and the Indiana Dry Eye Questionnaire 
(DEQ). 
• Chapter 5: To characterize clinical signs and symptoms in participants who present with 
and without symptoms of dry eye. 
• Chapter 6: To compare tear osmolality and ferning patterns in participants with and 
without dry eye symptoms. 
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• Chapter 7: To investigate the potential relationship between subjective symptoms and 
clinical signs with tear film lipocalin and lysozyme concentrations in participants with 
and without dry eye symptoms. 
• Chapter 8: To optimize a technique for the isolation of total RNA (ribo nucleic acid) and 
total protein derived from conjunctival epithelial cells collected via conjunctival 
impression cytology (CIC). 
• Chapter 9: To quantify the expression of MUC1 (mucin1) and MUC16 (mucin16) mRNA 
and protein and to investigate the potential relationship between mucin expression and 
tear film breakup time in a group of participants with and without dry eye symptoms. 
 
Methods 
• Chapter 4: Participants were categorized as being symptomatic or asymptomatic of dry 
eye based on their response to the OSDI questionnaire. These results were then compared 
to the DEQ, which has questions related to the frequency of ocular surface symptoms and 
their diurnal intensity. 
• Chapter 5: Non invasive tear breakup time (NITBUT) was evaluated using the ALCON 
Eyemap®. Tear volume was assessed using the Phenol Red Thread (PRT) test and bulbar 
conjunctival hyperemia was measured using objective (SpectraScan PR650© 
Spectrophotometer) and subjective (slit lamp) methods.  
• Chapter 6: Tears were collected via capillary tube. A freezing point depression 
osmometer was used to measure the osmolality of the tear film. The tear ferning test was 
performed and evaluated for the quality of ferning, based on the Rolando grading system.  
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• Chapter 7: Tears were collected via capillary tube and an eye wash method. Tear 
lysozyme and lipocalin concentrations were determined via Western blotting.    
• Chapter 8: CIC was collected using either Millipore (MP) or Poly Ether Sulfone (PES) 
membranes. RNA and protein isolation was performed using two different RNA isolation 
techniques. Two methods of protein isolation from CIC discs were evaluated. RT-PCR of 
mRNA for MUC1 and western blotting of lipoxygenase type 2 protein (LOX2) was 
performed to confirm the collection of intact RNA and total protein respectively. 
• Chapter 9: Tears were collected via capillary tube and an eye wash method. CIC was 
collected using MP membrane. Expression of MUC1 and MUC16 mRNA was assessed 
via real time PCR. Expression of both membrane-bound and soluble MUC1 and MUC16 
were quantified via Western blotting. 
 
Results 
• Chapter 4: The OSDI total score and sub scores for the Non Dry Eye (NDE) and Dry Eye 
(DE) groups were significantly different (NDE =7.43 ± 7.71 vs DE = 24.87 ± 13.89; 
p<0.001). The DEQ scores showed that the DE group exhibited a higher frequency and 
intensity of symptoms than the NDE group, which worsened as the day progressed 
(p<0.001). 
• Chapter 5: The DE group exhibited a significantly shorter NITBUT (5.3 ± 1.7 vs 7.0 ± 
2.7 secs; p=0.0012). Tear volume was significantly lower for the DE group (19.3 ± 
5.1mm vs. 16.3 ± 5.6mm; p=0.031). Bulbar hyperemia was significantly higher in the DE 
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group for both objective (u’ = 0.285 ± 0.006 vs. 0.282 ± 0.006; p=0.005) and subjective 
techniques (48.4 ± 10.0 vs 40.6 ± 10.4; p=0.0011). 
• Chapter 6: Osmolality values in DE individuals were significantly higher than the NDE 
(328.1 ± 20.8 vs. 315.1 ± 11.3 mOsm/kg; p = 0.02). There was a significant difference 
between the DE and NDE participants for the ferning patterns (p = 0.019). No significant 
correlation between tear osmolality and tear ferning was noted (DE: r = 0.12; p>0.05, 
NDE: r = -0.17; p>0.05).  
• Chapter 7: No difference in tear lysozyme or lipocalin concentration was found between 
DE and NDE groups, irrespective of tear collection method. Method of collection 
significantly influenced absolute concentrations (p<0.008). 
• Chapter 8: There was no significant difference between the two procedures used to 
isolate RNA and protein from CIC membranes (p>0.05). Total RNA yield was greater 
with the MP membrane. The mean yield of protein extracted from MP membrane using 
the two protein isolation techniques also did not show a significant difference. 
• Chapter 9: No difference was found in the expression of either MUC1 or MUC16 protein 
or mRNA expression between symptomatic DE and NDE (p>0.05). Weak correlations 
were found between the NITBUT values compared with either soluble or membrane 







• Chapter 4: Questionnaires are useful tools to symptomatically divide participants into dry 
eyed and non dry eyed candidates. However, the questionnaire used to categorise patients 
can impact on the outcome variables determined.  
• Chapter 5: Post-menopausal women with dry eye symptoms demonstrate shorter 
NITBUT, lower tear volume and increased bulbar conjunctival hyperemia than those who 
have no symptoms. 
• Chapter 6: Tear osmolality in DE is higher than in NDE. There is a tendency towards less 
ferning in persons over 50 years of age, regardless of their symptoms. 
• Chapter 7: Comparison of clinical data with lipocalin and lysozyme concentrations failed 
to reveal statistically significant correlations. The concentration of either protein was not 
associated with tear stability or secretion. 
• Chapter 8: The total RNA yield was greater with the MP membrane. RNeasy™ Mini 
(RN) (Qiagen) method is recommended due to enhanced speed as well as on-column 
isolation and DNase digestion capabilities. CIC with MP membranes followed by 
immediate freezing and then extraction and processing facilitates the collection of total 
protein from human conjunctival cells. 
• Chapter 9: No difference was found in the expression of either MUC1 or MUC16 protein 
or mRNA expression between symptomatic PMW and asymptomatic controls.  
 
In this PhD project, over 125 participants were screened, and a total of 86 
postmenopausal participants were enrolled. The table below (table A-1) represents the total 
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number of participants (out of the 86 enrolled participants) who participated in the following 
clinical and analytical studies. For the purpose of these studies, “postmenopausal” was 
defined as no menses for at least one year, not associated with hysterectomy. Participants 
were over 50 years of age. 
 
Table A-1: Number of participants involved in the studies 
 
Study Number of post-menopausal women who completed the study 
Assessment of Ocular Surface Dryness Using Dry Eye 
Questionnaires in Postmenopausal Females 82 
Clinical Signs and Symptoms in Postmenopausal 
Females with Symptoms of Dry Eye 83 
Tear Osmolality and Ferning Patterns in 
Postmenopausal Women 37 
Tear Lipocalin and Lysozyme Concentrations in 
Postmenopausal Women 85 
Expression of MUC1 and MUC16 in Tears and 
Conjunctival Epithelial Cells Collected from 






I sincerely thank my supervisor Dr. Lyndon Jones for his guidance. He has been very 
encouraging, supportive and has been helping me strive for the very best. He has been a great 
source of motivation for me in terms of learning and teaching.  
 I would like to express my sincere gratitude to my committee members, Dr. 
Christopher Hudson and Dr. Thomas Singer. Thanks for your guidance. I would like to 
acknowledge my external examiners Dr. Kelly Nichols (The Ohio State University) and Dr. 
Maud Gorbet (Systems Design Engineering, University of Waterloo) for reviewing my thesis 
and providing valuable comments.  
I would also like to thank Dr. Michelle Senchyna (Alcon Research Ltd), for her 
guidance with the molecular biological and analytical aspects of my thesis. 
My special thanks to Drs. Desmond Fonn and Trefford Simpson and the Centre for 
Contact Lens Research team for their help, affection and support. You have made my stay 
here in Waterloo very pleasant and enjoyable. 
I would like to express sincere gratitude to the research associates, Elizabeth Heikkila 
and Miriam Heynen for their continuous support from the start to the end of this project. I 
also thank the students in Dr. Jones’s lab for their help. Thanks to Robin Jones for help with 
instrumentation.  
I thank the graduate officers, graduate coordinators, staff and faculty of the School of 
Optometry and fellow graduate students in vision science.  
This research was funded by grants from Alcon Research Ltd, Canada Foundation for 
Innovation, Natural Sciences and Engineering Research Council of Canada, and the 
  x
Canadian Optometric Education Trust Fund (COETF). I would also like to thank the 
American Optometric Foundation and CIBA Vision for providing me with an Ezell 
fellowship. 
Finally, I would like to thank my parents and my brother for their love, support and 





To my parents and brother. 
  xii
Table of Contents 
ABSTRACT ....................................................................................................................................................... III 
ACKNOWLEDGEMENTS .............................................................................................................................. IX 
DEDICATION................................................................................................................................................... XI 
TABLE OF CONTENTS.................................................................................................................................XII 
LIST OF FIGURES........................................................................................................................................ XIX 
LIST OF TABLES....................................................................................................................................... XXIII 
1 INTRODUCTION.......................................................................................................................................1 
REFERENCES.......................................................................................................................................................3 
2 LITERATURE REVIEW ON DRY EYE.................................................................................................5 
2.1 DRY EYE DEFINITION AND CLASSIFICATION..........................................................................................5 
2.2 CLASSIFICATION OF DRY EYE ...............................................................................................................9 
2.2.1 Aqueous tear deficient dry eye (ADDE)........................................................................................10 
2.2.2 Evaporative dry eye ......................................................................................................................12 
2.2.3 Ageing and dry eye .......................................................................................................................14 
2.3 PREVALENCE OF DRY EYE ..................................................................................................................17 
2.4 CAUSATIVE MECHANISMS OF DRY EYE ...............................................................................................19 
2.4.1 Tear film instability ......................................................................................................................20 
2.4.2 Tear hyperosmolality ....................................................................................................................21 
2.5 RISK FACTORS FOR DRY EYE ..............................................................................................................24 
2.5.1 Age, gender and sex hormones .....................................................................................................24 
2.5.2 Contact lens wear .........................................................................................................................24 
2.5.3 Refractive surgery.........................................................................................................................24 
2.5.4 Environmental factors and computer use .....................................................................................24 
2.6 IMPACT OF DRY EYE ...........................................................................................................................25 
2.7 THE TEAR FILM...................................................................................................................................26 
  xiii
2.8 LAYERS OF THE TEAR FILM.................................................................................................................29 
2.8.1 The lipid layer of the tear film ......................................................................................................29 
2.8.2 The aqueous layer.........................................................................................................................33 
2.8.3 The mucous layer..........................................................................................................................38 
2.9 THE OCULAR SURFACE .......................................................................................................................47 
2.9.1 Conjunctiva...................................................................................................................................47 
2.9.2 Corneal epithelium .......................................................................................................................47 
2.10 METHODS TO STUDY DRY EYE............................................................................................................48 
2.10.1 Dry eye questionnaires (DEQ).................................................................................................49 
2.10.2 Assessment of tear film stability...............................................................................................50 
2.10.3 Assessment of tear osmolality ..................................................................................................50 
2.10.4 Assessment of ocular surface staining .....................................................................................51 
2.10.5 Analytical tests of tears and ocular surface.............................................................................51 
2.11 TREATMENT AND MANAGEMENT OF DRY EYE ....................................................................................51 
2.11.1 Tear supplements and lubricants .............................................................................................52 
2.11.2 Tear retention ..........................................................................................................................52 
2.11.3 Anti inflammatory therapy and biological tear substitutes ......................................................52 
2.11.4 Secretogogues ..........................................................................................................................53 
2.11.5 Essential fatty acids .................................................................................................................53 
2.11.6 Environmental strategies .........................................................................................................53 
REFERENCES.....................................................................................................................................................55 
3 MATERIALS AND METHODS .............................................................................................................85 
3.1 SUBJECTS ...........................................................................................................................................85 
3.1.1 Inclusion criteria ..........................................................................................................................86 
3.1.2 Exclusion criteria .........................................................................................................................86 
3.2 INFORMED CONSENT AND COMPLETION OF DRY EYE QUESTIONNAIRE................................................87 
3.3 OBJECTIVE BULBAR CONJUNCTIVAL REDNESS....................................................................................88 
  xiv
3.4 NON INVASIVE TEAR BREAK UP TIME .................................................................................................90 
3.5 PHENOL RED THREAD TEST.................................................................................................................91 
3.6 TEAR COLLECTION USING CAPILLARY TUBE .......................................................................................92 
3.7 TEAR OSMOLALITY MEASUREMENTS..................................................................................................94 
3.8 TEAR FERNING ...................................................................................................................................96 
3.9 SLIT LAMP EVALUATION.....................................................................................................................97 
3.10 COLLECTION OF TEARS USING EYE WASH TECHNIQUE ........................................................................97 
3.11 CONJUNCTIVAL IMPRESSION CYTOLOGY (CIC) ..................................................................................98 
3.11.1 Method .....................................................................................................................................98 
3.11.2 CIC procedure .........................................................................................................................99 
3.12 CORNEAL AND CONJUNCTIVAL STAINING.........................................................................................102 
3.13 ANALYTICAL PROCEDURES ..............................................................................................................104 
3.13.1 Total protein isolation from the CIC samples........................................................................104 
3.13.2 Total protein determination ...................................................................................................104 
3.13.3 Quantification of individual lacrimal gland tear proteins (lipocalin and lysozyme) .............105 
3.13.4 Detection of MUC 1 and 16 from tears and CIC samples .....................................................108 
3.13.5 Isolation of RNA from CIC samples.......................................................................................110 
3.13.6 Precautions and handling RNA..............................................................................................111 
3.13.7 RNA quality and quantity assessment and cDNA synthesis ...................................................112 
3.13.8 Real time qPCR......................................................................................................................113 
3.14 AVERAGING AND POOLING OF CLINICAL AND BIOLOGICAL DATA .....................................................114 
REFERENCES...................................................................................................................................................115 
4 ASSESSMENT OF OCULAR SURFACE DRYNESS USING DRY EYE QUESTIONNAIRES IN 
POSTMENOPAUSAL FEMALES .................................................................................................................117 
4.1 ABSTRACT........................................................................................................................................117 
4.2 INTRODUCTION.................................................................................................................................119 
4.3 MATERIALS AND METHODS .............................................................................................................121 
  xv
4.4 STATISTICAL ANALYSIS....................................................................................................................123 
4.5 RESULTS ..........................................................................................................................................124 
4.5.1 OSDI classification.....................................................................................................................124 
4.5.2 DEQ responses ...........................................................................................................................126 
4.6 DISCUSSION .....................................................................................................................................139 
4.7 CONCLUSION....................................................................................................................................142 
REFERENCES...................................................................................................................................................143 
5 CLINICAL SIGNS AND SYMPTOMS IN POSTMENOPAUSAL FEMALES WITH SYMPTOMS 
OF DRY EYE....................................................................................................................................................147 
5.1 ABSTRACT........................................................................................................................................147 
5.2 INTRODUCTION.................................................................................................................................149 
5.3 MATERIALS AND METHODS .............................................................................................................151 
5.4 STATISTICAL ANALYSIS....................................................................................................................154 
5.5 RESULTS ..........................................................................................................................................154 
5.6 DISCUSSION .....................................................................................................................................159 
5.7 CONCLUSION....................................................................................................................................163 
REFERENCES...................................................................................................................................................165 
6 TEAR OSMOLALITY AND FERNING PATTERNS IN POSTMENOPAUSAL WOMEN..........171 
6.1 ABSTRACT........................................................................................................................................171 
6.2 INTRODUCTION.................................................................................................................................173 
6.3 MATERIALS AND METHODS .............................................................................................................175 
6.3.1 Osmometry..................................................................................................................................176 
6.3.2 Tear ferning ................................................................................................................................177 
6.3.3 Statistical analysis ......................................................................................................................178 
6.4 RESULTS ..........................................................................................................................................178 









7.3.1 Participants ................................................................................................................................193 
7.3.2 Subjective symptoms ...................................................................................................................194 
7.3.3 Objective measurements .............................................................................................................194 
7.3.4 Analytical techniques..................................................................................................................195 
7.3.5 Tear collection............................................................................................................................195 
7.3.6 Electrophoresis and immunoblotting..........................................................................................196 
7.4 STATISTICAL ANALYSIS....................................................................................................................196 
7.5 RESULTS ..........................................................................................................................................197 
7.5.1 Subjective symptoms ...................................................................................................................197 
7.5.2 Objective measurements .............................................................................................................199 
7.5.3 Tear total protein........................................................................................................................200 
7.5.4 Tear film lipocalin concentration ...............................................................................................201 
7.5.5 Tear film lysozyme concentration ...............................................................................................203 
7.6 DISCUSSION .....................................................................................................................................206 
7.7 CONCLUSION....................................................................................................................................210 
REFERENCES...................................................................................................................................................211 
8 METHOD OPTIMIZATION FOR THE ISOLATION OF TOTAL RNA AND TOTAL PROTEIN 






8.3.1 Isolation of RNA .........................................................................................................................221 
8.3.2 Isolation of total protein .............................................................................................................223 
8.4 STATISTICAL ANALYSIS....................................................................................................................226 
8.5 RESULTS ..........................................................................................................................................226 
8.6 DISCUSSION .....................................................................................................................................233 
8.7 CONCLUSION....................................................................................................................................235 
REFERENCES...................................................................................................................................................236 
9 EXPRESSION OF MUC1 AND MUC16 IN TEARS AND CONJUNCTIVAL EPITHELIAL 
CELLS COLLECTED FROM POSTMENOPAUSAL WOMEN EXPERIENCING SYMPTOMS OF 




9.3.1 Participants ................................................................................................................................244 
9.3.2 Subjective symptoms ...................................................................................................................245 
9.3.3 Objective measurements .............................................................................................................245 
9.3.4 Analytical techniques..................................................................................................................245 
9.3.5 Statistical analysis ......................................................................................................................249 
9.4 RESULTS ..........................................................................................................................................250 
9.4.1 Subjective symptoms ...................................................................................................................250 
9.4.2 Tear total protein........................................................................................................................254 
9.4.3 Expression of MUC1 protein in tears and conjunctival epithelial cells .....................................254 
9.4.4 Expression of MUC16 protein in tears and conjunctival epithelial cells ...................................255 
9.4.5 Expression of MUC1 mRNA in conjunctival epithelial cells ......................................................257 
9.4.6 Expression of MUC16 mRNA in conjunctival epithelial cells ....................................................258 
9.4.7 Correlation between mucin expression and NITBUT.................................................................260 




10 GENERAL DISCUSSION AND CONCLUSIONS..............................................................................273 





List of Figures 
Figure 2-1: NEI/Industry workshop classification of dry eye .................................................. 7 
Figure 2-2: Etiological causes of dry eye ................................................................................. 8 
Figure 2-3: Schematic of lacrimal functional unit .................................................................... 9 
Figure 2-4: Causative mechanisms of dry eye........................................................................ 23 
Figure 2-5: Wolff’s three-layered structure, consisting of an anterior lipid layer, middle 
aqueous layer and deeper mucin layer ................................................................. 27 
Figure 2-6: Proposed structure of precorneal tear film........................................................... 28 
Figure 2-7: Representation of tear producing glands.............................................................. 30 
Figure 2-8: Diagram of the tear film and its interface with the ocular surface epithelium..... 40 
Figure 2-9: The structure of membrane associated mucins .................................................... 41 
Figure 2-10: The structure of secreted mucins ....................................................................... 42 
Figure 3-1: SpectraScan PR650© Spectrophometer ............................................................... 89 
Figure 3-2: The black measuring spot of the photometer ....................................................... 89 
Figure 3-3 : ALCON Eyemap® model EH-290 topography system...................................... 90 
Figure 3-4: Distortions or discontinuities in the reflected image of the concentric ring pattern
.............................................................................................................................. 91 
Figure 3-5: Phenol red thread test........................................................................................... 91 
Figure 3-6: Single-use, graduated, disposable glass capillary tubes (Wiretol-Micropipettes) 93 
Figure 3-7: Tear collection using a disposable capillary tube ................................................ 93 
Figure 3-8: Loading tear samples for osmolality measurement.............................................. 95 
  xx
Figure 3-9: Model 3100 Tear Osmometer .............................................................................. 95 
Figure 3-10: Uniform, abundant tear ferning, with no spaces between ferning (grade1)....... 96 
Figure 3-11: Collection of eyewash tears ............................................................................... 98 
Figure 3-12: Large Millipore MF™ membrane filters were used to make discs of 10mm 
diameter for impression cytology ........................................................................ 99 
Figure 3-13: Impression cytology of the superior bulbar conjunctiva.................................. 100 
Figure 3-14: Impression cytology of the temporal bulbar conjunctiva................................. 101 
Figure 3-15: Flowchart showing the schematic of sample processing from the CIC disc from 
left and right eye ................................................................................................ 102 
Figure 3-16: Multiskan Microplate Spectrphotometer ......................................................... 105 
Figure 3-17: Amersham Pharmacia Biotech PhastSystem™ ................................................ 107 
Figure 3-18: SE600 Vertical gel unit .................................................................................... 110 
Figure 3-19: Beckman DU530 Life Science UV/Visible Spectrophotometer...................... 112 
Figure 3-20: Applied Biosystems: 7500 Real Time PCR System ........................................ 114 
Figure 4-1: Frequency of symptoms in NDE participants using DEQ................................. 127 
Figure 4-2: Frequency of symptoms in DE participants using DEQ.................................... 128 
Figure 4-3: Diurnal intensity of symptoms of dry eye in NDE participants......................... 130 
Figure 4-4: Diurnal intensity of symptoms of dry eye in DE participants ........................... 131 
Figure 4-5: Morning (am) middle of the day (mid day) and evening (pm) symptom mean 
intensity score reported by dry eyed and non dry eyed PMW........................... 132 
Figure 4-6: Morning (am) middle of the day (mid day) and evening (pm) symptom mean 
intensity score reported by dry eyed and non dry eyed PMW........................... 133 
  xxi
Figure 4-7: Frequency of self diagnosis of dry eye vs doctors diagnosis of dry eye............ 134 
Figure 6-1: Tear film samples in the Model 3100 Tear Osmometer .................................... 177 
Figure 6-2: OSDI Questionnaire: Graph representing the total score, ocular symptoms, vision 
related, and environmental factors ..................................................................... 179 
Figure 6-3: Osmolality in dry eyed (DE) and non dry eyed (NDE) participants.................. 179 
Figure 6-4: Tear ferning patterns in postmenopausal women .............................................. 181 
Figure 7-1: Box plots of tear secretion as measured by phenol red thread test .................... 199 
Figure 7-2: Box plots of non invasive tear film break-up measurements............................. 200 
Figure 7-3: Box plots of tear film protein concentration ...................................................... 201 
Figure 7-4: Box plots of mean tear film lipocalin concentration.......................................... 202 
Figure 7-5: Box plots of mean tear film lipocalin concentration as a function of dry eye 
symptom severity ............................................................................................... 203 
Figure 7-6: Box plots of mean tear film lysozyme concentration ........................................ 204 
Figure 8-1: Flowchart showing the schematic of sample processing from the CIC disc for 
method optimization of RNA isolation.............................................................. 223 
Figure 8-2: Flowchart showing the schematic of sample processing from the CIC disc for 
method optimization of protein.......................................................................... 225 
Figure 8-3: RNA integrity gel............................................................................................... 227 
Figure 8-4: RT-PCR amplification of MUC1 and GAPDH mRNA..................................... 228 
Figure 8-5: Impression cytology of normal conjunctiva (Hematoxylin and Eosin stain- H&E)
............................................................................................................................ 229 
Figure 8-6: Mean yield of protein using EB and EB + PI .................................................... 230 
  xxii
Figure 8-7: Western blot and regression analysis for LOX 2 quantification........................ 231 
Figure 8-8: Mean yield of LOX 2 ......................................................................................... 232 
Figure 9-1: Box plots of non invasive tear film break-up measurements............................. 253 
Figure 9-2: Western blot for MUC16 ................................................................................... 256 
Figure 9-3: Regression analysis for MUC 16 quantification................................................ 256 
 
  xxiii
List of Tables 
Table 2-1: Epidemiological data from dry eye studies ........................................................... 18 
Table 2-2: Major components of human tear protein ............................................................. 35 
Table 2-3: Summary of information on human tear film in various dry eye conditions 
(adapted from DEWS report)............................................................................... 46 
Table 2-4: Summary of information on human ocular surface in various dry eye conditions 
(adapted from DEWS report)............................................................................... 48 
Table 3-1: List of participants who discontinued from the study ........................................... 85 
Table 3-2: Oligonucleotide primers and probes used for relative expression analysis......... 114 
Table 4-1: Summary of Ocular Surface Disease Index© scores .......................................... 125 
Table 4-2: Response to questions on medication usage in DEQ .......................................... 136 
Table 4-3: Response to questions related to allergies in DEQ.............................................. 136 
Table 4-4: Relief provided by dry eye treatment .................................................................. 137 
Table 4-5: Correlation between OSDI total score and frequency of symptoms of dry eye 
(Questions 4 to 12 from DEQ)........................................................................... 138 
Table 5-1: Summary of Ocular Surface Disease Index© scores .......................................... 156 
Table 5-2: Summary of clinical measures in sub groups...................................................... 158 
Table 6-1: Represents the percentage distribution of dry eyed and non dry eyed participants 
showing ferning patterns (grade I to IV)............................................................ 180 
Table 7-1: Summary of Ocular Surface Disease Index© scores .......................................... 198 
Table 7-2: Summary of correlations between subjective and objective measures of dry eye 
and tear film lipocalin and lysozyme concentrations......................................... 205 
  xxiv
Table 8-1: Comparison of RNA quality and yield obtained via various cell collection and 
processing methods ............................................................................................ 226 
Table 9-1: Sequence of primers and probes used for gene amplification in Real Time RT-
PCR .................................................................................................................... 249 
Table 9-2: Summary of Ocular Surface Disease Index© Scores.......................................... 252 
Table 9-3: Summary of PM1 study biomarker data.............................................................. 257 
Table 9-4: Summary of PM2 study biomarker data.............................................................. 259 
Table 9-5: Summary of correlations between NITBUT and mucin expression in PM1 study
............................................................................................................................ 260 




List of Symbols and Abbreviations 
µg  micrograms 
µl   microlitre 
AU  arbitrary units 
bp  base pair 
BSA  bovine serum albumin 
CCLR  Centre for Contact Lens Research 
CCLRU Cornea and Contact Lens Research Unit 
cDNA  complimentary deoxyribonucleic acid 
CIC   conjunctival impression cytology 
CsCl  Cesium chloride 
ddH2O double distilled water 
DE  dry eye 
DEQ  dry eye questionnaire 
DES  dry eye syndrome 
DEWS   dry eye workshop 
DNA  deoxyribonucleic acid 
DNAse deoxyribonuclease 
DTT   Dithiothreitol  
EB  extraction buffer 
EDTA   Ethylenediamine tetra acetic acid  
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
  xxvi
GLB  gel loading buffer  
H&E  hematoxylin and eosin stain 
HRT  hormone replacement therapy 
KCl  Potassium chloride 
KCS  keratoconjunctivitis sicca 
KDa   KiloDalton  
l  wavelength 
L  Litre 
LOX2  lipoxygenase type 2 
mg  milligram 
ml   millilitre  
mm  millimetre 
mM   millimolar  
mOsm/Kg milli osmoles/kilogram 
MP  millipore 
mRNA  messenger ribo nucleic acid 
MUC  mucin 
mw  molecular weight 
NaCl  sodium chloride 
NDE   non dry eye 
ng   nanogram  
NITBUT  non-invasive tear break up time 
  xxvii
nm  nanometre 
NS  not significant 
OD   optical density  
OSDI   ocular surface disease index 
PBS  phosphate buffered saline 
PBS-T  phosphate buffered saline with 0.05% Tween® 20  
PCR  Polymerase chain reaction 
PES  poly ether sulphone 
pg  picogram 
PI  protease inhibitor 
PM1  postmenopausal women study 1 
PM2  postmenopausal women study 2 
PMW  postmenopausal women 
PRT  phenol red thread test 
PVDF   polyvinylidene difluoride  
qPCR  quantitative polymerase chain reaction 
R2   correlation coefficient  
rcf  relative centrifugal force 
Rn  normalized reporter dye fluorescence 
RN  Rneasy™ Mini kit 
RNA  ribo nucleic acid 
RNAse ribonuclease 
  xxviii
RT-PCR Reverse Transcription - polymerase chain reaction 
SD   standard deviation 
SDS   sodium dodecyl sulphate  
SDS-PAGE  sodium dodecyl sulphate-polyacrylamide gel electrophoresis  
SIDEQ subjective evaluation of symptoms of dryness questionnaire 
TBS   Tris-buffered saline  
TBS-T  Tris-buffered saline with 0.05% Tween® 20  
TFT  tear ferning test 
TOS  total score 
Tris   Tris (hydroxymethyl) aminomethane  
TZ  TRIzol™ 
UV   ultraviolet  
v/v  volume to volume 
w/v  weight to volume 
WB   Western blotting  
β  Beta 
° C  degree Celsius 
 1
1 Introduction 
Dry eye syndrome is one of the most frequently encountered ocular conditions.  
Dry eye is a common source of discomfort that can seriously affect a patient’s quality of 
life, especially in the elderly population.1, 2 Epidemiological studies have found that 
women are more likely to report dry eye symptoms than men3, 4 and it is a condition that 
has a multifactorial etiology, which, in most cases, is always chronic and progressive.5 
There are many subjective and objective methods to test for dry eye.  However, to date, 
there is no single test or combination of tests known to conclusively diagnose this 
disease.  
A key aspect of dry eye that remains a major problem is the lack of association 
between the symptoms and signs of dry eye6-14 and the poor test reproducibility of 
objective tests,15 making it difficult to assess disease progression or the impact of 
treatments on symptoms. Currently, the major management for those patients with dry 
eye disease consists of palliative regimens such as lubricating drops, which target 
symptoms alone, with no treatment modality available that truly “treats” the underlying 
cause of the disease. The necessity for characterizing and understanding the underlying 
biomarkers in the tears and ocular surface cells that are involved in the disease process 
may be beneficial in targeting towards treatment strategies. 
Many factors are involved in the development of dry eye. Of these, age, gender 
and hormonal effects have captured much attention over the past years. However, to-date, 
no specific study has been conducted on a group of postmenopausal women (who are not 
on hormone replacement therapy) to examine commonly reported dry eye symptoms, in 
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conjunction with a systematic analysis of the presence of various biomarkers in their tears 
and conjunctival epithelial cells. 
 
Hence the focus of this thesis was as follows: 
• Assessment of ocular surface dryness using dry eye questionnaires, including the 
Allergan Ocular Surface Disease Index (OSDI) and Indiana Dry Eye 
Questionnaire (DEQ) in postmenopausal women (chapter 4). 
• Assessment of clinical signs (Non invasive tear break up time, Phenol red thread 
test, subjective and objective bulbar conjunctival redness) and symptoms (OSDI 
scores) in postmenopausal women with symptoms of dry eye (chapter 5). 
• Assessment of tear osmolality and ferning patterns in postmenopausal women 
with symptoms of dry eye (chapter 6). 
• Assessment of tear lipocalin and lysozyme concentrations (capillary and eye wash 
tear collection) in postmenopausal women with symptoms of dry eye (chapter 7). 
• Optimization of a method for the isolation of total RNA and total protein from 
human conjunctival epithelial cells collected via impression cytology (Chapter 8). 
• Evaluation of the expression of MUC1 and MUC16 mRNA and protein levels in 
tears and conjunctival epithelial cells collected from postmenopausal women with 
symptoms of dry eye (chapter 9). 
The remainder of the thesis is composed of a literature review of dry eye (Chapter 2), 
a methods chapter introducing the subjects, clinical and analytical methods used in the 
study (Chapter 3), and general discussion and conclusions & recommendations for future 
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2 Literature Review on Dry Eye 
2.1 Dry eye definition and classification 
The National Eye Institute/Industry workshop in 1995 defined dry eye as “a 
disorder of the tear film due to deficiency or excessive tear evaporation which causes 
damage to the interpalpebral ocular surface and is associated with symptoms of ocular 
discomfort”.1 This report divided dry eye primarily in two groups, namely tear deficient 
dry eye and evaporative dry eye (Figure 2-1). In light of extensive research in the area of 
dry eye over the past 10 years, and an improved understanding of the pathophysiological 
mechanisms, symptoms, tear hyperosmolality and effects of dry eye on vision, a new 
definition has been proposed. The most recent definition proposed by the International 
Dry Eye Workshop conducted in 2007 defines dry eye as a “multifactorial ocular surface 
disease diagnosed by symptoms of discomfort and signs of visual disturbance, tear film 
instability and ocular surface damage, accompanied by increased osmolarity of the tear 
film and ocular surface inflammation.”2 The terms “aqueous-deficient dry eye” and 
“evaporative dry eye” were removed from the earlier definition, but are still retained in 
the etiopathogenic classification of dry eye and reflects an improved understanding of dry 
eye (Figure 2-2).  
 Dry eye is believed to be a disturbance of the ocular surface functional unit. The 
ocular surface functional unit comprises the ocular surface (cornea, conjunctiva, 
meibomian glands), lacrimal glands, lids and the sensory and motor nerves that connect 
them.3 (Figure 2-3) The overall function of the lacrimal gland functional unit is to 
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preserve the integrity of the tear film, the transparency of the cornea, and the quality of 
the image projected onto the retina.3-5 
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Figure 2-1: NEI/Industry workshop classification of dry eye  
The two main types and causative factors of dry eye are shown in the flowchart.1 Reprinted from CLAO Journal. Lemp MA. Report of the 




Figure 2-2: Etiological causes of dry eye  
The left hand box illustrates the influence of environment on the risk of an individual to develop dry eye.2 DEWS definition and classification of 
dry eye.2 Reprinted from The Ocular Surface Journal. The definition and classification of dry eye disease: report of the Definition and 
Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:75-92, with permission from Elsevier. 
 9
 
Figure 2-3: Schematic of lacrimal functional unit  
Reprinted from Experimental Eye Research, Stern ME, Gao J, Siemasko KF, Beuerman 
RW, Pflugfelder SC. The role of the lacrimal functional unit in the pathophysiology of 
dry eye.5 Exp Eye Res 2004;78:409-16, with permission from Elsevier. 
 
2.2 Classification of dry eye 
The current classification system shown in Figure 2-2 is an updated version of 
that presented in the NEI/Industry workshop report. Aqueous-deficient dry eye has two 
major groupings, Sjogren’s syndrome dry eye and non-Sjogren’s syndrome dry eye. 
Evaporative dry eye may be either intrinsic or extrinsic. Intrinsic refers to situations 
where the regulation of evaporative loss from the tear film is directly affected and 
extrinsic evaporative dry eye includes those etiologies that increase evaporation by their 
pathological effects on the ocular surface.  
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2.2.1 Aqueous tear deficient dry eye (ADDE) 
Tear deficient dry eye is caused by either a failure in transporting lacrimal fluid to 
the conjunctival sac (resulting in a decreased amount of tears in the conjunctival sac) or a 
disorder in lacrimal gland function. Due to the reduced tear aqueous pool, the tear film 
osmolality is increased. Tear film hyperosmolality causes hyperosmolality of the ocular 
surface cells and hence triggers a cascade of inflammatory events, involving different 
signaling pathways and resulting in the generation of numerous inflammatory 
cytokines.6,7 These include interleukin (IL)1 alpha, IL1 beta, tumor necrosis factor (TNF) 
alpha and various matrix metalloproteinases (eg MMP-9). Inflammatory mediators are 
generated from the lacrimal gland itself in cases of lacrimal gland dysfunction and 
inflammation (which can be found in tears) or from the cornea and conjunctiva. ADDE 
has been further classed into Sjogren’s syndrome, an autoimmune disorder affecting the 
lacrimal and salivary glands, and non-Sjogren’s syndrome tear deficient dry eye, which 
includes other causes of aqueous deficiency. 
2.2.1.1 Sjogren’s syndrome dry eye (SSDE) 
Sjogren’s syndrome is a chronic autoimmune disorder of the exocrine glands, 
with associated lymphocytic infiltration of the affected glands. Sjogren’s syndrome is the 
most under-diagnosed autoimmune disease,8, 9 which affects about 0.3% of the population 
10 and occurs mainly in women (>90%).11, 12  The exocrinopathy can be either a primary 
disorder (primary Sjogren’s syndrome) or it can be associated with other connective 
tissue diseases (secondary Sjogren’s syndrome), such as rheumatoid arthritis, systemic 
lupus erythematosis or systemic sclerosis.13 
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The etiology of Sjogren’s syndrome is not very well understood, however viral, 
neural, genetic and environmental factors are all thought to contribute to the 
condition.14,15 Sjogren’s syndrome is a T-cell driven autoimmune disease and can be 
characterized by focal lymphocytic infiltration of the lacrimal and salivary glands,16 
presence of circulating autoantibodies produced by B cells17 and increased expression of 
several proinflammatory cytokines.11 These inflammatory cells impair the functions of 
the lacrimal gland, causing tear deficient dry eye.9 The sub-classifications of aqueous 
deficient dry eye are illustrated in Figure 2-2.  
2.2.1.2 Non Sjogren’s syndrome dry eye (NSSDE) 
There is no associated systemic autoimmune feature involved in NSSDE. The 
reduction in tear secretion is caused by other factors, including primary lacrimal gland 
deficiencies that may be age related,18 due to congenital alacrima (absence of lacrimal 
gland)19, 20 or familial dysautonomia ( a disorder of the autonomic nervous system which 
affects the development and survival of sensory, sympathetic and some parasympathetic 
neurons in the autonomic and sensory nervous system, resulting in various symptoms, 
including inability to produce tears).21 
Lacrimal gland infiltration due to sarcoidosis,22 lymphoma,23 AIDS,24 graft versus 
host disease,25, 26 lacrimal gland excision27, 28 or denervation29 may cause secondary 
lacrimal gland deficiency that is associated with NSSDE. Obstruction of the lacrimal 
gland and accessory lacrimal gland ducts can lead to ADDE. Conditions which cause 
scarring of the cornea such as chemical burns,30 cicatricial and mucous membrane 
phemphigoid, erythema multiforme and trachoma can all produce lacrimal obstruction, 
resulting in tear deficient dry eye.13  A reduction in the sensory impulses from the ocular 
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surface can cause dry eye by either decreasing reflex-induced lacrimal secretion or by 
reducing the blink rate, which leads to excessive evaporation of tears.31 Corneal 
sensitivity reduction due to contact lens wear or post LASIK surgery can possibly cause 
symptoms of dry eye.32, 33 Large population based studies have also identified diabetes 
mellitus as a risk factor for dry eye disease.34-36 
2.2.2 Evaporative dry eye 
In patients with evaporative dry eye, there is increased tear evaporation from the 
ocular surface, with normal lacrimal gland tear production and flow. However, 
occasionally a combination of both aqueous deficiency and increased evaporation may 
contribute to the dry eye condition. Evaporative dry eye can be due to either intrinsic 
disease factors (affecting lid structures or dynamics) or it may be extrinsic, where ocular 
surface disease occurs due to some extrinsic factor. Intrinsic factors are further classified 
into oil deficient (due to meibomian gland disorders), lid related, blink rate related and 
surface change. Extrinsic factors include ocular surface disorders caused due to vitamin 
A deficiency, use of topical drugs and effects due to their preservatives, contact lens wear 
and ocular allergies. All of these causative factors for evaporative dry eye are illustrated 
in Figure 2-2. 2 
2.2.2.1 Effect of the environment 
Environmental factors can play an important role in dry eye. As quoted in the 
DEWS workshop report, the term “environment” is used to describe psychological 
variations between individuals, (milieu interieur) as well as the conditions that they 
encounter (milieu exterieur). Low relative humidity conditions and the general 
occupational environment all contribute towards the conditions that an individual 
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encounters. Factors such as low blink rate behavior37 (which increases the evaporative 
loss between blinks),38 ageing, androgen levels, and systemic drugs can contribute 
towards psychological variations between individuals. 
2.2.2.2 Environmental factors (milieu interieur) 
People using anti-histamines, antispasmodics, diuretics or steroids have a higher 
incidence of dry eye, but people using angiotensin converting enzyme (ACE) inhibitors 
have a lower incidence. Although arthritis and thyroid disease are not associated with the 
incidence of dry eye, arthritis is more likely to develop in people with dry eye, suggesting 
that dry eye may precede the development of arthritis.36 The evaporation of tears 
increases with increasing palpebral aperture width, and is hence the most in upgaze.38 
Ageing18 and androgen deficiency39 may be triggering factors in causing dry eye. 
2.2.2.3 Environmental factors (milieu exterieur) 
An indoor working environment, low blink rates, particularly in those workers 
using visual display terminals (VDT) in air-conditioned workplaces, has been identified 
as the main environmental causative factor of dry eye.40 The reduction in blink rate due to 
VDT use results in increased dry eye symptoms.41 Environmental irritants associated with 
‘sick building syndrome’ have been reported to cause ocular irritation and tear film 
instability in office workers.42, 43 It has also been shown that low humidity levels in 
planes during long-haul flights and changes in blink pattern may cause dry eye 
symptoms.44 Other activities associated with decreased blinking and increases in 
palpebral aperture width have been reported to carry a risk for the development of dry 
eye symptoms.  
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2.2.3 Ageing and dry eye 
Ageing, a normal biological process occurring on a cellular and tissue level, may 
affect the tear film, with the ageing process leading to decreased function. Dry eye is 
more common in older patients45 and recent epidemiological studies have consistently 
shown that the prevalence of dry eye symptoms increases with age,35, 46-50 with the 
prevalence reaching a plateau after the mid 80’s.51 There is a related reduction in tear 
production18 and increased meibomian gland dysfunction52 with age. There is a decrease 
in reflex secretion of tears with age, particularly after 40 years of age.53 This reduction in 
reflex tear production is attributed to decreased corneal sensitivity with age.54 Earlier 
studies have shown a decrease in basal tear secretion with aging.55, 56 However, later 
studies of tear turnover by modern fluorophotometric methods do not show an age-related 
variation in tear production.57 The rate of tear film evaporation has been shown to be 
constant throughout life,58 but has been reported to increase with age in another 
publication.18 Ageing can also associated with decreased tear volume and flow, increased 
osmolality,18, 59 decreased tear film stability60 and alteration in the composition of tear 
film lipids.61  
Clinical observations suggest that dry eye occurs more in women, particularly 
after menopause. However, women seek eye-care more frequently than men,51 potentially 
skewing this observation. Recent epidemiological studies support the fact that there is a 
higher prevalence of dry eye among women.62 A higher proportion of females have 
aqueous tear deficiency than men10 and an increased prevalence of all categories of 
treated dry eye occurs in women, compared with men.63  
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Sex hormones are believed to play a significant role in causing dry eye.39 A 
reduction in sex hormones, such as androgens, occurs in both males and females with 
increasing age.39, 61 The hormonal changes that accompany menopause can also play an 
important role in the production of dry eye symptoms.8, 64, 65 Estrogen therapy, which is 
commonly taken by postmenopausal women, are also thought to be a risk factor for the 
development of dry eye.50, 66 A significant decrease in androgen levels is also associated 
with meibomian gland dysfunction.67 
2.2.3.1 Postmenopausal women and hormone replacement therapy  
Large epidemiological studies have clearly shown that the prevalence of dry eye is 
greater among women than in men, especially women aged 50 and over.50 More women 
complain of dry eye symptoms and show clinical signs than men.62  
Menopause may play an important role in the development of dry eye.8, 64 The 
impact of hormones on the incidence and course of dry eye, especially in postmenopausal 
women has been noted.64 Researchers have demonstrated the presence of α-type and β-
type estrogen receptors in the epithelia of several ocular tissues and have suggested that 
sex steroid hormones may play a role in the development of certain ocular diseases.68, 69 
Evidence demonstrates that the meibomian glands of the lids contain androgen, estrogen 
and progesterone receptor mRNA and protein within the acinar epithelial cells, and that 
these respond to androgen precursor by increasing their production and release of 
lipids.70, 71  
Studies conducted by Sullivan et al72-74 and others75, 76 have clearly demonstrated 
that the meibomian gland is an androgen target organ and that androgens impact 
meibomian gland function, regulate the quality and quantity of lipid produced and 
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promote the formation of the tear film lipid layer. Hence, any deficiency associated with 
androgens can cause meibomian gland dysfunction and an increase in the signs and 
symptoms of dry eye.72-74 The decline in the levels of total androgen with ageing in both 
sexes,77, 78 particularly in females upon the onset of menopause, coincides with the 
increased appearance of meibomian gland dysfunction and ageing.79 
Hormone replacement therapy (HRT) refers to the administration of estrogens and 
progesterones to post-menopausal women and is commonly used to reduce signs and 
symptoms of post menopause.80 HRT is an established method for alleviating menopausal 
complaints 80 and had been previously thought to be beneficial for the cardiovascular 
system. HRT has also been shown to improve bone density and lipid metabolism.80 
However, various deleterious effects following HRT administration,81-83 including an 
increased risk of cancer, have been reported.82  There are confounding results in the 
literature regarding the risks and benefits of HRT on dry eye.66, 84 Schaumberg et al62 
suggested that women who had HRT with estrogen and estrogen plus 
medroxyprogesterone acetate were at an increased risk of dry eye syndrome. Other 
studies have shown the opposite effect.85, 86  
HRT which has estrogen, progesterone and androgen activity with high tissue 
specificity has shown an improvement in the values of Schirmer’s test and tear break up 
time (TBUT).87 Schaumberg et al66 also suggested estrogen therapy alone caused ocular 
dryness and that a balance between androgens and estrogens are important in determining 
the risk of dry eye syndrome. It was hence suggested that addition of progesterone along 
with estrogen therapy may be beneficial.66  
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2.3 Prevalence of dry eye 
Reports suggest that a large number of patients with dry eye problems visit eye-
care professionals, with one in every four patient visits to an ophthalmologist being 
related to complaints of dry eye45 and 17% of visits to eye centers being due to dry eye.40 
About one-third of the general population have occasional symptoms of dry eye.88 Table 
2-1 lists some of the major epidemiological studies that were undertaken in the past 10 
years and these results indicate that the prevalence of dry eye ranges from 3.5% to 
approximately 55%. The criteria used to confirm a “dry eye diagnosis”, as shown in 
Table 2-1, differs widely between studies, resulting in great difficultly when attempting 
to compare results across studies. The majority of studies have used symptoms as 
diagnostic criteria, as dry eye is largely a symptom-driven disease. In addition to 
differences in dry eye definition, other factors such as variability in sampling techniques, 
age groups, geographical variations, measurement techniques, cut-off values for these 
measures and racial differences all contribute to differences in the results obtained.89 Due 
to the lack of a single diagnostic test or a combination of tests to effectively diagnose dry 
eye, many studies have reported a lack of correlation between symptoms and signs of the 
disease.59, 90, 91 
Studies undertaken in the US estimate that over 3.2 million women and 1.6 million 
men aged over 50 years suffer from moderate to severe dry eye.50, 92, 93 One of the reports 
46 suggests that diagnosing dry eye by symptoms alone is acceptable because dry eye 
rarely progresses to the stage of causing ocular damage without symptoms being present. 
However, more recent reports suggests that symptoms alone are inadequate for 
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diagnosing dry eye because the same symptoms can be experienced by patients with a 
large range of ocular surface conditions and tear film disorders.62,87 
 





Diagnostic criteria Prevalence 






• at least one symptom 
• moderate to severe 
symptoms 










History of diagnosed dry eye or 
dry eye symptoms  
7.8% 
 
Physicians Health study I 
&II 92, 93 (1998 & 2002) 
25, 655 
 (>50, 55yrs) 
Severe symptoms of dryness and 








Questionnaires based on symptoms 
and self diagnosis 
28.7% 




Based on symptoms 14.4% 
 
The Shihpai Eye Study 62 
(2003) 
2038 subjects 
(≥ 65 years) 










1 or more of 6 symptoms present 
often or all of the time  
27.5% 
Salisbury Eye Evaluation 
study 94-96   





• Schirmer test ≤ 5 mm or 








All 3 criteria had to be positive: 
• More than one chronic 
symptoms 
• Rose Bengal score ≥ 4 or 
Fluorescein score ≤ 1 
• TBUT ≤ 5 sec or Schirmer 
test with anasthesia 
• ≤ 5mm or Cotton thread 
test ≤ 10mm or tear fluid 








• Rose Bengal > 3 
• Schirmer Test < 8 mm in 5 
mins 
• Tear Break Up Time < 8 
secs 
• 2 or more signs 
• Severe Symptoms not 













Two of the following tests had to 
be positive: 
• Schirmer-I test ≤ 
10mm/5min 
• TBUT ≤10 sec 




2.4 Causative mechanisms of dry eye 
Recent evidence has shown that certain mechanisms can play an important role in 
initiating or exaggerating dry eye. They are thought to be related to tear film stability and 
tear hyperosmolality. 
 20
2.4.1 Tear film instability  
The stability of the tear film is dependant on the quantity and quality of various 
components of the tear film, including tear viscosity, surface tension, meniscus radius, 
and initial and final film thicknesses.98 When the tear film ruptures or tear break-up 
appears, it may produce tear film hyperosmolality and local drying of the exposed 
surface, leading to the excitation of inflammatory cell markers at the ocular surface, 
epithelial damage and cell death by apoptosis. This may cause a disturbance of the 
glycocalyx and goblet cell mucins.2 These various disturbances exacerbate tear film 
instability, triggering a vicious cycle of events, graphically shown in Figure 2-4.  
Various factors contribute towards the destabilization of the tear film.99-101 
Disturbances of the lipid layer result in increased evaporation of the tear film. Holly99 
proposed that the rapid break-up of tears could be due to the contamination of the mucin 
layer by inward movement of the superficial lipid, creating small hydrophobic areas 
which do not adequately support the aqueous phase. Liotet et al100 suggested that the 
inability of the corneal epithelial cells to manufacture a glycocalyx may result in 
insufficient sites for mucous layer attachment, and this may be a major factor in 
determining tear stability.100  
Van der Waals dispersion forces (attractive or repulsive forces between 
molecules) within the mucous layer may also cause disruption of the tear film.101 Tear 
drainage due to gravity or a rising film height reaching the effective range of the 
dewetting intermolecular forces may also be responsible for the breakup of the tear 
film.98, 102  These factors independently would be inadequate to cause tear film break-up, 
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however a combination of them will likely be adequate to cause disruption of the tear 
film.  
2.4.2 Tear hyperosmolality 
Tear hyperosmolality is thought to be one of the core mechanisms causing 
inflammation of the ocular surface (Figure 2-4) and is considered a central mechanism 
causing ocular surface damage and symptoms of dry eye. An increase in tear film 
osmolality is due to evaporation of tears from the ocular surface and/or a decrease in the 
production of tears from the lacrimal glands, or a combination of both events.  
The terms osmolality and osmolarity are unfortunately used interchangeably and 
the terminology associated with calculated and measured osmotic activity is not 
consistent in the literature. Osmotic concentration determinations are typically expressed 
as either milliosmoles/kilogram (mOsm/kg) of solvent, referred to as “osmolality”, or 
milliosmoles/liter (mOsm/L) of solution, referred to as osmolarity. When the osmotic 
concentration is derived by an osmometer, in laboratories that use a method such as 
freezing point depression of water (or the vapor pressure technique), the concentration is 
expressed in terms of solvent and is appropriately referred to as “osmolality”.103, 104 If it is 
expressed in terms of solution, the term osmolarity is appropriate.92 The osmolarity of a 
solution is the total  concentration of dissolved particles in a solution, irrespective of their 
size, density, molecular weight or electric charges.105  
Tear osmolarity increases in dry eye, indicating an increased concentration of 
dissolved particles in the tear film volume. Inflammatory events are subsequently 
stimulated, due to hyperosmolarity and are thought to involve mitogen-activated protein 
kinase (MAP kinase) and nuclear factor - kB (NFkB) signaling pathways6 and the 
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generation of  inflammatory cytokines, primarily interlukin 1 α (IL 1 α), interlukin 1 β 
(IL 1 β); tumor necrosis factor α (TNF α) and matrix metalloproteinases (MMPs), which 
initiate inflammatory cells at the ocular surface.8 Stern and Pflugfelder reported that the 
expression of  IL 1 α and β, IL 6, IL 8, TGF β, and TNF α were increased in the 
conjunctival epithelia of patients with Sjogren’s syndrome compared with controls.106 
Inflammatory events lead to apoptosis of epithelial cells, including goblet cells. Zhao et 
al107 and Argueso et al108 demonstrated reduced levels of MUC5AC in dry eye, and 
goblet cell loss is seen is all forms of dry eye. It has been hypothesized that a faster tear 
thinning rate is a risk factor for tear hyperosmolarity2 and a wide variation of thinning 
rates109 have been noticed. Normal individuals with fastest tear thinning rates experience 
increased higher tear osmolarity.110 
Reduced aqueous tear flow, resulting from lacrimal failure, and/or increased 
evaporation from the tear film are the major causes of tear hyperosmolarity. Another 
potential reason is meibomian gland dysfunction (MGD), which leads to an unstable tear 
film lipid layer. Aging and the use of systemic drugs such as antihistamines and anti-
muscarinic agents may induce reduction of aqueous flow. As previously described, 




Figure 2-4: Causative mechanisms of dry eye  
Reprinted from The Ocular Surface Journal. The definition and classification of dry eye disease: report of the Definition and Classification 
Subcommittee of the International Dry Eye WorkShop (2007).2 Ocul Surf 2007;5:75-92, with permission from Elsevier. 
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2.5 Risk factors for dry eye 
Demographic factors including age, sex and many ocular, systemic, interventional 
& environmental factors can be associated or cause dry eye and can also worsen an 
already existing condition. A diet that is deficient in Omega 3 essential fatty acid or 
vitamin A, medications, smoking, alcohol, and menopausal status may contribute toward 
the risk factors for dry eye. 
2.5.1 Age, gender and sex hormones 
As explained in section 2.2.3 dry eye symptoms increase with age, especially in 
women and sex hormones are believed to play a role in causing dry eye.39 
2.5.2 Contact lens wear 
The prevalence of symptomatic dry eye in contact lens wearers occurs in 50-80% 
of wearers. Discontinuations and drop outs from lens wear are primarily due to symptoms 
of discomfort and dryness.2, 111, 112 
2.5.3 Refractive surgery 
Dry eye can occur as a complication of laser in-situ keratomileusis (LASIK) 
surgery.31, 113-116 LASIK may result in lacrimal dysfunction and decreased goblet cell 
density, leading to reduced tear production and an unstable tear film.114, 117 
2.5.4 Environmental factors and computer use 
An indoor working environment can cause symptoms of  ocular irritation,118 
particularly in those who use computers119, 120 in air-conditioned workplaces, has been 
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identified as the main environmental causative factor of dry eye.1 Low humidity, poor air 
quality, and pollution are other risks that may cause dry eye.121, 122  
  
2.6 Impact of dry eye 
Dry eye can interfere with day-to-day activities, including reading, computer use, 
night driving and watching television123, 124 and can severely impair patient quality of 
life.124, 125 Schiffman et al.126 showed that the mean comorbidity-adjusted patient 
preference score values were similar for severe forms of dry eye and moderate to severe 
angina pectoris.126 The economic impact of dry eye has to be assessed in terms of the cost 
of the visits to eye care professionals, treatment costs and the impact of the condition on 
the health and productivity of the patient.127 A decade ago, 7-10 million Americans used 
artificial tears on prescription or as self-medication, at an annual cost of $100 million.128 
With growing knowledge of dry eye, this annual cost has significantly increased. 
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2.7 The tear film 
Of all the components that constitute the lacrimal functional unit, the tear film is by 
far the most dynamic. It provides nutrients, a communication pathway, distributes 
regulatory factors and provides a pathway for cells to reach the epithelium.  The tear film 
consists of a variety of different components, including electrolytes, salts, protein and 
peptides. Studies provide evidence that specific proteins or peptides in the tear film can 
be used as diagnostic biomarkers for dry eye, ocular surface diseases,129 and even certain 
systemic disease states, such as diabetes mellitus.130, 131 
The tear film has a number of specific functions: 
1. It lubricates and nurtures the anterior tissues of the eye. 
2. It provides a regular optical surface for the eye’s optical system, by filling the 
irregularities of the corneal epithelium.  
3. Oxygen dissolved in the tear film is the only source for normal aerobic 
metabolism of the corneal epithelium and stroma. 
4. It is an integral part of the ocular surface defence mechanism.132  
5. It also functions as a method to remove cellular debris and metabolic waste from 
the cornea and conjunctiva.  
 
The integrity and normal functioning of the tear film is maintained by a complex 
physiological mechanism, which includes adequate production of the various components 
by different glands, stability of the various layers on the ocular surface and timely 
drainage through the lacrimal ducts. Any disruption in the physiology or stability of the 
tear film may result in dry eye. 
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In 1946, Wolff 133 presented a classic description of the tear film, in which it was 
composed of a three-layered structure, consisting of an anterior lipid layer, middle 
aqueous layer and deeper mucin layer (Figure 2-5).  
 
Figure 2-5: Wolff’s three-layered structure, consisting of an anterior lipid layer, 
middle aqueous layer and deeper mucin layer 
Image adapted from http://www.lea-test.fi/en/eyes/images/pict7b.jpg 
Another model with six layers has also been proposed by Tiffany,134 which 
included the original three layers proposed by Wolff, along with air-lipid, lipid-aqueous 
and aqueous-mucus interfaces. More recently it has been suggested that there are 
dissolved mucins in the aqueous layer, which decrease in concentration towards the lipid 
layer.135 The most currently accepted current concept is that the tear film is a bilayered 
structure, consisting of an aqueous/mucinous phase, with an overlying superficial lipid 
phase (Figure 2-6).136  However, despite the intervening 60 year period, the original 3 
layered Wolff model is still accepted as being a valuable concept.137  
Lipid layer 
Aqueous layer  
Mucin layer  
 28
 
Figure 2-6: Proposed structure of precorneal tear film  
The precorneal tear film consists of a superficial lipid layer, a middle aqueous/mucin phase that 
contains soluble mucins, aqueous fluid, electrolytes, and proteins that are secreted by the lacrimal 
glands, and ocular surface epithelium. This layer is anchored to the underlying superficial corneal 
epithelium by chemical attractions to the epithelial membrane mucins (glycocalyx). Reprinted 
from Cornea. The Diagnosis and Management of Dry Eye. A Twenty-five–Year Review. Cornea 
2000, 19(5): 644–649, with permission from Lippincott Williams & Wilkins, Inc. 
 
The thickness of the tear film is vitally important to understand, because the 
thickness determines the tear volume from which evaporation occurs when the eyes are 
open.138 However, there is no agreement among researchers on the “true” thickness of the 
tear film. Various studies to investigate tear film thickness have been performed, using a 
variety of techniques, and these studies have quoted tear film thickness ranges 
from1.5µm to 45µm.139-143  Prydal et al found the tear film thickness to be 34-45µm with 
coherence interferometry and confocal microscopy.139, 140  More recently, King-Smith et 
al,141 using wavelength- dependent interferometry, have reported the thickness of the tear 
film to be 1.5-4.7µm in normal subjects.  
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2.8 Layers of the tear film 
2.8.1 The lipid layer of the tear film 
Lipid forms the superficial/outermost layer of the tear film and is derived primarily from 
the meibomian glands in the eyelids.144 It consists of an outer non-polar lipid layer and an 
inner polar layer.145 The meibomian glands are richly innervated by both sympathetic and 
parasympathetic neurons.146 Glands of Moll and lash follicle glands of Zeis contribute 
some lipid (Figure 2-7).147 It is believed that androgen has an important role to play in the 
functioning of meibomian glands.39, 73, 148 Several studies including clinical models and 
animal studies have shown that androgens increase the size, activity and lipid production 
in the meibomian glands.72, 148 Tear lipocalin enhances the stability and spreading of the 
lipid layer, which decreases the surface tension of aqueous by forming complexes with 
polar lipids.149 
2.8.1.1 Functions of the lipid layer 
1. To provide an effective barrier and prevent evaporation.150, 151  
2. To provide a surfactant layer that acts as an effective bridge between the non-
polar lipid layer and the aqueous mucinous layer.152 
3. To act as a lubricant to facilitate the movement of the eyelids during blinking.153 
4. To maintain compression and expansion of the lipid film during blinks, to prevent 
tear overflow.153 
5. To form a barrier for preventing contamination of the tear film.154  
6. To provide a smooth surface for refraction of the incoming rays of light.153, 155 
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Defects and instability in the lipid layer can be responsible for tear breakup, with 
subsequent dry spots leading to dry eye.156 
 
 
Figure 2-7: Representation of tear producing glands 
Image adapted and modified from anatomy.ipui.edu/.../Eye04/palp.jpg 
2.8.1.2 Lipid dynamics and drainage 
With every down-phase of the blink, lipid is squeezed out of the meibomian 
glands and is compressed into the lid margins. On the up-phase of the blink, the lipid 
rapidly spreads upwards over the aqueous layer, suggesting that the lower eyelid 
reservoir is the major contributor to the spreading lipid.137 Most of the excretion of the 
lipid layer occurs by bulk flow over the lid margin and onward to the neighboring skin 
and lashes. 137 Some of the lipid, mainly polar, mixes with the aqueous layer and is 
drained via the naso-lacrimal drainage pathway.154 
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2.8.1.3 Thickness of the lipid layer 
Various interferometric techniques have been used in the past to study thickness 
of the lipd layer. Studies using specular microscopy have reported lipid thickness values 
of 100 nm.157,158 Techniques such as specular reflectometry have shown the lipid 
thickness to be 13-70 nm.159 Using photometric reflectometry, the lipid thickness was 
found to be 32-46 nm.160  
2.8.1.4 Composition of the lipid layer 
It is believed that the lipid layer has two distinct regions. There is a relatively 
thick outer layer, containing nonpolar lipids such as wax esters, sterol esters, 
hydrocarbons, and triglycerides; and a thin polar inner layer, predominantly consisting of 
phospholipids.161 The polar phase of the lipid layer owes its surfactant properties which 
facilitate mixing with both aqueous and non-polar lipids It acts base for the more 
superficially located non-polar lipids.145 The major classes of lipids are the wax 
monoesters and sterol esters, which comprise approximately three-quarters of the 
meibomian gland fluid.145, 162, 163 
2.8.1.5 Physical properties of lipid 
Although isolated meibomian lipids do not spread over saline, the lipid layer 
spreads well over the aqueous phase of the tear film.158 The refractive index of the lipid 
layer varies with wavelength and temperature. Tiffany154 estimated the refractive index of 
meibomian lipid to be 1.4766 at 589 nm and 35°C.  
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2.8.1.6 Methods to quantify lipids 
Meibomian gland lipid can be obtained by squeezing the eyelid margin to express 
meibum,164-166  by gently sucking meibum out of each glandular orifice162 or collecting 
tear samples.152, 167 These samples are then dissolved in an organic solvent and separated 
into their various lipid classes. One of the most widely used techniques to study lipids is 
analysis by high pressure liquid chromatography (HPLC) with or without mass 
spectroscopy (MS), or by gas chromatography followed by mass spectroscopy (GC-MS). 
In both the HPLC and GC methods, separation of lipids is followed by mass 
determination. Various other techniques are also available to study meibum samples. 
Approaches such as derivative gas chromatography electron ionization mass 
spectrometry (GC/EI-MC), positive chemical ionization, negative chemical ionization 
(NCI) of chloride adducts, electrospray tandem mass spectrometry (ES-MS/MS), matrix-
assisted laser desorption/ionization time-of-flight (MALDI-TOF), fast atom 
bombardment (FAB), atmospheric pressure chemical ionization (APCI) MS and APCI 
liquid chromatography (LC)/APCI-MS have been used for mass spectrometric analysis of 
acylglycerides, which are comprised of mono-, di-, and triglycerides.168 
2.8.1.7 Tear lipids in dry eye 
Analysis of lipid components has shown a considerable decrease in triglycerides 
and cholesterol, and monounsaturated fatty acids (specifically oleic acid), in patients with 
obstructive meibomian gland dysfunction, chronic blepharitis and viscous meibum.165, 169 
These changes in the lipid composition may be associated with tear film instability. Polar 
lipids may define the structural organization of the overlying non-polar lipids and loss of 
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these constituents are believed to result in decreased tear breakup time and increased 
aqueous tear evaporation.170 
2.8.2 The aqueous layer 
The aqueous layer of the tear film comprises the bulk of the tear film thickness. 
This intermediary watery phase of the tear film is approximately 6.5-7.5 μm thick143 and 
is mainly produced by the main lacrimal gland, and also by the accessory glands of 
Krause and the accessory glands of Wolfring (Figure 2-7). It contains electrolytes, protein 
enzymes and metabolites. 
2.8.2.1  Aqueous production 
2.8.2.1.1 The lacrimal gland 
The lacrimal gland, the main secretor of the aqueous phase of the tear film, is 
located in the upper outer part of the orbit in a shallow depression in the frontal bone and 
is divided into larger orbital and smaller palpebral lobes. The gland is a multi-lobed, 
tubulo-acinar structure with ducts that terminate at the surface of the eye in the lateral 
portion of the superior fornix.171  
2.8.2.1.2 Accessory lacrimal glands 
The accessory glands comprise the glands of Krause and Wolfring. There are 
more than 20 accessory glands of Krause in the upper conjunctival fornix and about 6-8 
in the lower conjunctival fornix. These glands are located in the substantia propria of the 
conjunctiva. Glands of Wolfring are found in the upper border of the tarsal plate.171 
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2.8.2.2 Components of the aqueous layer 
The bulk of the aqueous component of the tears is not only composed of water, 
but contains numerous electrolytes, proteins, peptide growth factors, vitamins, anti-
microbials, cytokines, immunoglobulins, and hormones. The composition of the tear film 
varies in response to environmental and bodily conditions. Electrolytes present in the tear 
film include sodium, potassium, magnesium, calcium, chloride, bicarbonate, and 
phosphate ions. These are largely responsible for modifying the osmolality of tears,172 act 
as a buffer to maintain pH at a relatively constant level 173 and maintain epithelial 
integrity.174  
To date, over 60 human tear proteins have been identified,175, 176 of which the 
most predominant proteins are lysozyme, lactoferrin, and lipocalin. These proteins are 
secreted in response to an intracellular stimulus and the rate of secretion approximately 
matches the tear flow rate.177, 178 Other important proteins of note include serum albumin, 
IgG, ceruloplasmin, transferrin, and monomeric IgA. Numerous peptide growth factors 
including EGF, HGF, TGF β are also found in the aqueous.176 A recent study by Li et 
al176 characterized the human tear proteome by using multiple proteomic analysis 
techniques, as described in Table 2-2.  
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Table 2-2: Major components of human tear protein  
Reprinted from Clinica Chimica Acta.  Ohashi Y, Dogru M, Tsubota K. Laboratory 
findings in tear fluid analysis. 168 Clin Chim Acta 2006;369:17-28, with permission from 
Elsevier. 
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2.8.2.3 Functions of the aqueous layer 
The functions of the aqueous layer include: 
1. This is quantitatively the most important layer.  
2. It is responsible for creating a conducive environment for the epithelial cells of 
the ocular surface, carrying essential nutrients and oxygen to the cornea, allowing 
cell movement over the ocular surface.171 
3. Lysozyme, 171 lipocalin, lactoferrin and IgA are responsible for antimicrobial 
activity.179, 180 
4. Washing away debris, toxic substance and foreign bodies.  
5. Many of the growth factors that are present in the aqueous phase play a significant 
role in corneal physiology. 171  
2.8.2.4 Physical properties of the aqueous layer 
The normal pH value of the tear film is between 7.14 and 7.82, with a mean value 
of 7.4-7.5, which is similar to plasma pH.181   
2.8.2.5 Tear dynamics and drainage 
The tears are directed from the upper temporal fornix to the lacrimal puncta in 
different ways. Tears move downward by gravity at the lateral canthus to form the lower 
marginal tear strip, capillary attraction then moves tears into the punctum and vertical 
section of the canaliculus, and finally the lid movement during the blink forces the tears 
in the puncta. The rapid closure of the temporal end of the palpebral aperture during the 
blink aids the nasal movement of tears. The same blinking movement forces the tears into 
the lacrimal sac through the canaliculi from each of the lacrimal puncta. The lacrimal sac 
collapses after the blink due to the relaxation of the orbicularis, thus forcing the tears into 
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the nasolacrimal duct. From the nasolacrimal duct, the tears are finally excreted into the 
nasal cavity. The basal tear production of the tear film is 1-2 μl/min and the turnover rate 
is approximately 16%/min in normal subjects.55, 182 
2.8.2.6 Methods to assess major aqueous components (proteins) 
Several assays are available to determine the level of major lacrimal gland 
proteins such as lysozyme183, 184 and lipocalin in tears. Various biochemical assays 
including Enzyme-Linked Immunosorbent Assay (ELISA), High Performance Liquid 
Chromatography (HPLC) and Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) are useful methods, due to their high sensitivity, accuracy 
and ability to target specific proteins. Other techniques, including capillary 
electrophoresis (CE), surface-enhanced laser adsorption/ionization time-of-flight mass 
spectrometry (SELDI-TOF-MS), protein chip array methods, fluorescent antibody and 
ultrastructural techniques have all been used to study proteins.168 
2.8.2.7 Aqueous layer in dry eye 
Lysozyme levels decrease with age and in dry eye syndromes.185 Sjogren’s 
syndrome patients show a decrease in lysozyme, lactoferrin and EGF levels in tears.183, 186  
McCulley187 reported that blepharitis patients with clinically diagnosed KCS had a lower 
mean tear film lysozyme concentration compared to either blepharitis patients with no 
KCS or control subjects. Deficiency of tear lipocalin can lead to the formation of mucous 
strands and cause tear film instability.149 In a study of intolerant contact lens wearers,167 it 
was found that tear lipocalin concentration was significantly elevated compared to a 
control group of tolerant wearers. The concentration of Aquaporin 5 (AQP5), which is a 
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selective water channel protein, was significantly increased in tears of Sjogren’s 
syndrome patients, compared with normal controls.188 
2.8.3 The mucous layer 
2.8.3.1 Production of the mucin layer 
The primary source of tear film mucins is from the goblet cells of the conjunctiva 
and the crypts of Henle in the conjunctival fornices.  A secondary source of mucin is 
from the squamous epithelial cells of the ocular surface (cornea and conjunctiva), 135, 189-
191  with a small contribution from the lacrimal gland. Goblet cell mucin forms a gel in 
the deepest layer of the tear film, while soluble mucin is found in the aqueous layer.192 
Ocular mucins influence the tear-film break up time and play a major role in stabilizing 
and spreading the tear film,193-195 and also play a major lubrication function.193-195 
2.8.3.2 Functions of the mucin layer 
There are several key functions of the mucin layer, which include: 
1. The most important function of mucin is lubrication, facilitating the eyelid 
margins and palpebral conjunctiva to slide smoothly over one another during 
blinking and ocular rotational movements.196  
2. The corneal surface is wettable, however when non-wetting occurs in areas of the 
cornea, mucus plays an important role in overcoming this hydrophobicity.196  
3. Mucus threads cover foreign bodies with a slippery coating, protecting the cornea 
and conjunctiva from abrasion.  
4. Mucus also helps in wetting the ocular surface and in glycocalyx formation.135 
5. The ocular surface glycocalyx acts as a barrier to pathogens.197 
 39
2.8.3.3 Composition and properties of mucins  
Mucins are defined as high molecular weight glycoproteins, that have at least 
50% of their mass is carbohydrate, O-linked to serine and threonine residues present 
within tandem repeats of amino acids in their protein backbone.194, 198-202 They are 
hydrophilic in nature. The carbohydrate chains account for about 70% to 80% of the dry 
weight of mucins.194, 198-202 The molecular mass of mucins range from 3 × 105 to over 4 × 
107 kDa.194, 198-202 
To date, at least 20 distinct human mucins have been cloned (MUC1– MUC20, 
including 3A, 3B, 5AC, and 5B).203-212  Mucins are classified as either transmembrane or 
secretory mucins. Secreted mucins can be further sub-classified as gel-forming or 
soluble, based on their ability to form polymers. Of  these, MUCs 1, 3A, 3B, 4, 12, 13, 
15, 16, 17 and 20 have been characterized as membrane associated.  MUC 2, 5AC, 5B, 6, 
7 and MUC9 are classified as secretory mucins. In this category, MUC 2, 5AC, 5B, 6 are 
categorized as gel-forming mucins and MUC7 & MUC9 are classified as soluble mucins.  
Demonstration of the expression of a specific mucin mRNA, as determined by 
northern blot or PCR and in situ hybridization is often considered as gold standard.201 For 
the demonstration of mucin protein presence and distribution, it is necessary to use 
antibodies that have well-documented specificity.201 
With the above criteria, MUC1, MUC4, and MUC16 have been identified as 
membrane bound mucins in the eye and MUC5AC, MUC2 and MUC7 (small amounts) 
have been identified as secretory mucins. Many of the membrane-associated mucins are 
shed from the epithelial surface and are present as soluble forms in extracellular fluids. 
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Figure 2-8: Diagram of the tear film and its interface with the ocular surface 
epithelium  
Reprinted from Experimental Eye Research. Gipson IK. Distribution of mucins at the ocular 
surface. 201 Exp Eye Res 2004; 78(3)379-88, with permission from Elsevier. 
2.8.3.3.1 Transmembrane mucins 
Transmembrane mucins (Figure 2-9) contain hydrophobic, membrane-spanning 
domains in their carboxyl-terminal region, which anchor them to the apical surface of 
conjunctival and corneal epithelial cells, facilitating formation of the ocular surface 
glycocalyx.217 Inatomi et al191 demonstrated that MUC1 is expressed by both conjunctival 
and corneal epithelial cells, and that MUC4 is expressed only by the conjunctival 
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epithelium.200 Later studies using sensitive assay techniques have detected MUC4 mRNA 
in corneal epithelia at reduced levels.136 Recently, MUC16 mRNA and protein expression 
have been identified in conjunctival and corneal epithelia,218 and MUC13, MUC15, and 
MUC17 mRNA have been detected in the epithelium of the conjunctiva.219 
 
Figure 2-9: The structure of membrane associated mucins  
Reprinted from Experimental Eye Research. Gipson IK. Distribution of mucins at the ocular 
surface, Exp Eye Res 2004; 78(3)379-88, with permission from Elsevier. 
 
2.8.3.3.2 Secretory mucins 
The gel-forming mucins are the largest glycoproteins known, with genes of 15.7 
to 17 kb and deduced proteins of approximately 600 kDa.  The hydrophilic character of 
secreted mucins, which results from their heavy glycosylation, helps to hold fluids on 
epithelial surfaces. MUC5AC, the major gel-forming mucin in tears, is secreted by 
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conjunctival goblet cells.200, 220 It has also been reported that MUC2, also a gel-forming 
mucin, is present in tears, but at levels several orders of magnitude lower than 
MUC5AC.221 MUC7 is a small monomeric, soluble mucin produced by the lacrimal 
gland and conjunctiva.222  
 
 
Figure 2-10: The structure of secreted mucins  
Reprinted from Experimental Eye Research. Gipson IK. Distribution of mucins at the ocular 
surface, Exp Eye Res 2004; 78(3)379-88, with permission from Elsevier. 
 
2.8.3.4 Methods to quantify ocular surface mucins  
2.8.3.4.1 Impression cytology for mucin mRNA and protein analysis 
Impression cytology allows for the collection of apical and subapical cells of the 
conjunctival epithelium, as well as goblet cells. It is a simple, non invasive technique to 
collect 2-5 layers of conjunctival epithelial cells and is explained in greater detail in 
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Chapters 3, 8 and 9. This method is particularly useful for the analysis of mucins, as 
membrane-associated and gel-forming mucins are present in the suprabasal cells of the 
conjunctival and in the goblet cells, respectively.223   
Cloning and characterization of mucin genes has facilitated the use of polymerase 
chain reaction (PCR) to determine the mucin mRNA repertoire in cells collected by 
impression cytology. The only drawback of this method is that the yield of starting 
material may be low, which in many cases requires pooling of the left and right eye 
impression cytology samples. RNA isolation from the filter discs that are used to collect 
the sample, reverse-transcription into cDNA, and real-time quantitative reverse 
transcription polymerase chain reaction (RT-PCR) analysis of the mucin mRNA content 
can be determined.108  Impression cytology is also suitable for mucin protein analysis by 
immunofluorescence and flow cytometry. Brush cytology (for mRNA and protein 
analysis) is comparatively invasive.224 
2.8.3.4.2 ELISA assay and immunoblot assay of tears 
Polyacrylamide gel electrophoresis (PAGE) has been used for many years for 
analysis of proteins in human tears. However, the heavy glycosylation and sticky nature 
of mucins remains a challenge when attempting to study them. It is thus appropriate to 
partially deglycosylate the sample to facilitate access of the antibody to the mucin 
apoprotein. The amount of membrane-associated mucin shed into the tear film by the 
ocular surface epithelia can be assessed by immunoblot analysis. The presence of MUC4 
and MUC1 in tears has also been detected by immunoblot analysis of human tear fluid 
collected by Schirmer strips.225 
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2.8.3.4.3 Conjunctival biopsy for immunolocalization and in situ hybridization 
Conjunctival biopsies from living donors for mucin analysis, even though 
invasive, allow localization of the specific sites of mucin mRNA synthesis and protein 
expression through all the cell layers of the epithelium. Following biopsy, distribution of 
mucin mRNA and protein can be analyzed by in situ hybridization (ISH) and 
immunological techniques, respectively.191, 200 Immunohistochemistry, when performed 
individually, may lead to errors due to poor characterization of the mucin antibodies and 
to the sticky nature of mucins, which induces nonspecific binding.  
Researchers often prefer to use a combination of ISH and immunohistochemistry 
to demonstrate mucin distribution. The presence and distribution of MUC1 and MUC16 
transcripts have been demonstrated by ISH in corneal and conjunctival epithelia.191, 218 
The presence of tandem repeated sequences in the nucleotide sequence of mucins has 
facilitated their analysis by ISH, since probes to the tandem repeat bind at multiple sites 
along the mucin mRNA detection.226  
2.8.3.5 Mucins in dry eye syndrome 
Studies indicate that mucin gene expression and translation, as well as mucin post-
translational processing are affected in dry eye conditions.201 Real-time quantitative PCR 
have shown a significant decrease in RNA transcripts for MUC5AC in the conjunctival 
epithelium of patients with Sjogrens syndrome, compared with normal individuals.108  
Flow cytometry analysis has also shown a decrease in the percentage of MUC5AC-
positive conjunctival cells.215 Protein levels of MUC5AC assessed by ELISA are also 
significantly reduced in the tear fluid in dry eye.108  Alterations in membrane-associated 
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mucins are noticed in non-Sjogren’s syndrome dry eye227 and Sjogren’s syndrome dry 
eye.214   
From samples obtained via conjunctival impression cytology, a significant 
difference in the binding pattern of an antibody against a carbonate epitope antibody 
(H185) carried by MUC16 to conjunctival epithelium in normal eyes when compared 
with those of patients with non-Sjogren’s dry eye has been recently demonstrated.213 A 
trend towards decrease in MUC1 mRNA was also noted. It was also demonstrated that 
during keratinization of the ocular surface epithelia, the pattern of expression of 
glycosyltransferases that initiate O-glycosylation on mucins is altered, which may lead to 
alterations in carbohydrate structures on the mucins.228 Table 2-3 summarizes a body of 
information on human tear film in various dry eye conditions 
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Table 2-3: Summary of information on human tear film in various dry eye 
conditions (adapted from DEWS report)  
 KCS NSS SS MGD Androgen deficiency 
CL  dry 
eye References 
Tears - clinical 
assessment  
↓ Volume  
↑ Osmolality 
X X X X X X 75, 105, 110, 229, 230 
↑Evaporation X   X   1, 231-233 
↓ Meniscus X X X X X X 75, 234, 235 
↓ BUT 
↑ Surface tension 
X X X X X X 75, 152, 236-239 




MUC5AC X  X X   
107, 108 
Lipids  
Changes in lipid 
patterns, distribution   X X   
240, 241 
↓Polar lipids, lipid 




Pro inf. cytokines (IL 
1, 6, 8,  TNF α)   X X   
186, 243, 244 
Proteins  
Change in proteins X      188, 245 
↑ Plasmin levels X      246 
↑ MMP’s    X   247, 248 
↑ Inflammatory 
markers X   X   
249 
↓ Lysozyme and 
lactoferrin       
250 
↑ Phospholipase A2 X     X 167 
 
KCS- keratoconjunctivitis sicca, NSS – non-Sjogren’s syndrome, SS - Sjogren’s syndrome, MGD 
– meibomian gland dysfunction, CL dry eye – contact lens related dry eye. 
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2.9 The ocular surface 
2.9.1 Conjunctiva 
The conjunctiva is a mucous membrane that covers the inner surface of the upper 
and lower lids and extends to the limbus, on the surface of the globe. The conjunctival 
mucous epithelium, a stratified squamous non-keratinizing epithelium of 2 to 10 cell 
layers, is critical in protecting the eye from external stimuli and maintaining a healthy 
ocular surface.251 The limbal epithelium is believed to be about 10 cells deep. The 
conjunctival epithelium has secretory goblet cells.251  In conjunction with mucin secreted 
by conjunctival goblet cells (MUC5AC), the membrane-associated mucins of apical 
corneal and conjunctival epithelium (MUC1, MUC4 &MUC16) protect and hydrate the 
ocular surface.199, 218, 220 The inflammatory cytokines secreted by the conjunctival 
epithelium are involved in the pathogenesis of ocular surface diseases such as 
keratoconjunctivitis sicca.186 
2.9.2 Corneal epithelium 
The corneal epithelium comprises an outer stratified squamous non-keratinized 
epithelium and inner stroma, with keratocytes and cuboidal endothelium. There are 5 to 7 
corneal epithelial cell layers. The outermost apical cell layer has microplicae and exhibits 
a prominent filamentous glycocalyx, which plays a vital role in mucin and tear film 
spreading over the surface of the eye.251 The membrane-associated mucins are the major 
components of the glycocalyx, along the apical cell-tear film interface.194, 199 Table 2-4 
summarizes the information on human ocular surface in various dry eye conditions. 
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Table 2-4: Summary of information on human ocular surface in various dry eye 
conditions (adapted from DEWS report) 
 KCS NSS/Aqueous SS CL wear LASIK References 
Mucins  
↓ Goblet cells X X X ↑ X 252-257 
↓ MUC5AC X  X   107, 108 
Alteration in mucin 
glycosylation X   X  
216, 258-260 
Change in membrane 
associated mucins  X X   
108, 213, 253, 258 
Conjunctival epithelial 
changes  
↑ Stratification X     228, 261 
Epithelial proliferation   X   262 
Changes to nuclear 
structure X  X   
263-265 
↑Apoptosis X X X   266 
Changes in innervation  X X  X 267-270 
↑ Infections X     250, 271 
↑ Keratinization   X   272-274 
Inflammatory markers 
on epithelial cells X X X   
275, 276 
Ocular surface damage 
– NaFl, LG, RB 
staining 




KCS- keratoconjunctivitis sicca, NSS – non-Sjogren’s syndrome, SS - Sjogren’s syndrome, MGD 
– meibomian gland dysfunction, CL dry eye – contact lens related dry eye. 
2.10 Methods to study dry eye  
Complete clinical and analytical assessment of the tears and ocular surface is 
necessary to diagnose the severity and monitor the development and progression of dry 
eye. A variety of tests and diagnostic criteria are used by clinicians and researchers to 
characterise dry eye. Large epidemiological studies conducted in the past 10 years have 
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chosen different diagnostic criteria to study dry eye, which complicates comparisons and 
development of cut off values in its diagnosis. Recent reports have suggested strict 
templates and criteriae to help clinicians and researchers accurately confirm a dry eye 
diagnosis.280 
Symptoms play a key role in the diagnosis, and hence validated dry eye 
questionnaires are valuable tools for routine screening procedure. Tear evaluation 
procedures include tear osmolality tests, TBUT and tear function tests. Evaluation of 
tears and ocular surface tissue samples to study inflammatory components in tears in dry 
eye still remains a challenge, due to the inadequate volume of tears or starting material 
(epithelial cells).  
The global features of dry eye can be studied by utilizing the following types of 
diagnostic tests: 
2.10.1 Dry eye questionnaires (DEQ) 
It is difficult to arrive at a specific diagnostic standard for dry eye, in both clinical 
and research settings. Clinicians typically rely on case history and subjective symptoms 
to diagnose and categorize dry eye.281, 282  There are a variety of questionnaires 
available,88, 283-288 ranging from single item score questionnaires289  to extensive 
questionnaires (eg. 57 questions)124 targeting a variety of areas, including diurnal 
variation237, 286, 290 of commonly occurring symptoms. The epidemiology subcommittee 
of the DEWS workshop has identified questionnaires that are validated and used in large 
studies.65 Dry eye symptom questionnaires are also useful in assessing responses to dry 
eye therapy and DEQ’s are discussed in more detail in chapter 4.  
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2.10.2 Assessment of tear film stability 
Tear film stability has traditionally been assessed using the tear break-up time 
(TBUT) following the instillation of sodium fluorescein. Although this method is easy to 
perform, there are some disadvantages including variations in the concentration, pH of 
fluorescein, volume of fluorescein used, presence of preservatives and the invasiveness of 
the procedure itself.291 Instillation of fluorescein in itself alters the quality and quantity of 
the tear film.292 A non-invasive approach to measuring TBUT in the diagnosis of dry eye 
has been reported to be valuable for assessment of TBUT and has shown a high 
sensitivity and specificity.293, 294 This method allows the evaluation of the tear film by 
eliminating the physical disturbance of the tear film from the instillation of fluorescein, 
along with the possibility of reflex tearing.291  The exact mechanism behind the tear 
breakup is not clearly understood and three different hypotheses of tear breakup have 
been proposed, as described in section 2.4.1 
2.10.3 Assessment of tear osmolality 
Tear osmolality is often considered a “gold standard” in the evaluation of subjects 
with dry eye.295-297 As an objective method, hyperosmolality is a single attractive 
parameter for characterizing dry eye. However, a lack of available equipment and the fact 
that most osmometers require a large volume of tears (typically 5-10µl),298, 299 limits its 
use in many dry eye subjects, particularly those with severe disease.299, 300  A recent study 
based on a meta analysis on published data in determining referent values for diagnosis of 
dry eye, has shown the cut off value to be 315.6 mOsm/Kg.301 Tear osmolality is 
discussed in more detail in chapter 6. 
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2.10.4 Assessment of ocular surface staining 
The use of vital dyes, including fluorescein and lissamine green, to grade ocular 
surface staining using different quantification methods is commonly used in dry eye 
studies.1, 277 278, 279 Among the various quantitation  scales available, three are widely 
accepted and used in dry eye studies, namely the van Bijsterveld scale,278 the Oxford 
system279 and the CLEK system.1, 277  
2.10.5 Analytical tests of tears and ocular surface 
Samples of tears collected with fine glass capillary tubes demonstrate higher 
lacrimal gland proteins when compared to invasive collection methods such as those 
using filter paper and cellulose sponges. These latter methods stimulate the conjunctiva, 
induce serum leakage, and result in a higher proportion of plasma proteins.168 The 
relative proportions of the proteins present in an individual tear sample depend on the 
method of tear collection.302 Non invasive techniques (including impression cytology and 
minimally invasive brush cytology) are useful to study inflammatory biomarkers. 
Impression cytology is discussed further in Chapters 3, 8 and 9. 
2.11 Treatment and management of dry eye 
Despite the high prevalence of dry eye, it remains a condition without complete 
cure.51 The conventional current management strategy for dry eye management is to 
prescribe lubricant eye drops to provide temporary symptomatic relief,63, 303, 304 in 
conjunction with surgical procedures and, more recently, pharmacological therapy to treat 
any underlying inflammation. 
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2.11.1 Tear supplements and lubricants  
Tear supplements or ocular lubricants are typically hypotonic or isotonic buffered 
solutions, which contain electrolytes, surfactants and various viscosity-enhancing agents. 
Tear supplements should ideally be preservative free to avoid the side effects of 
commonly used preservatives such as benzalkonium chloride (BAK)305-308 and EDTA.309, 
310 Solutions containing electrolytes and ions such as potassium311 and bicarbonates312 
have also proven to aid in treating dry eye. Viscosity-enhancing agents313 (macro 
molecular complexes such as hydroxyl methylcellulose - HMC) and hypo-osmotic 
artificial tears314 are also used to alleviate symptoms of ocular dryness. 
2.11.2 Tear retention 
Punctal plugs315-319 (absorbable and non-absorbable) are indicated for 
symptomatic patients with very low Schirmer scores.316  Contact lenses have proven to be 
useful in certain severe dry eye conditions by improving comfort, vision and healing of 
corneal epithelial defects and hence decreasing corneal epitheliopathy.320-323  The use of 
moisture chamber goggles have demonstrated an increase in the periocular humidity324, 
325 and hence tear film thickness.326  
2.11.3 Anti inflammatory therapy and biological tear substitutes 
Based on the current understanding of dry eye, inflammation is one of the key 
components in the pathogenesis of dry eye. Anti-inflammatory agents such as 
cyclosporine, corticosteroids, and tetracyclines are used in the treatment of certain cases 
of dry eye. Clinical trials conducted by Brignole et al327 and Turner et al328 using 
cyclosporine drops have shown a decrease in the expression of immune markers, 
apoptosis markers and cytokines (IL6), in the conjunctival epithelial cells of dry eyed 
 53
individuals. Another study has shown a T lymphocyte decrease in conjunctival tissue 
following the use of cyclosporine.329 Corticosteroids have proven useful in the 
management of patients with Sjogren’s syndrome330, 331 and KCS conditions.332, 333 The 
antibacterial and anti-inflammatory properties of tetracycline makes it clinically viable in 
patients with acne rosacea,334 meibomian gland dysfunction335 and chronic blepharitis.336, 
337 
The use of biological fluids such as serum338-341 (used mainly in severe dry eye 
disease) and saliva (salivary mandibular gland transplantation342, 343) has been reported in 
novel studies looking at dry eye treatment.  
2.11.4 Secretogogues 
There is a list of agents/secretogogues under investigation that may stimulate tear 
secretion and prove to be useful in dry eye treatment. Certain agents stimulate mucin 
secretion (gefarnate,344-346 rebamipide347 and ecabet sodium348), in particular MUC1 
(15(S)HETE).225, 349-352 Diquafosol is a potent aqueous and mucin secreting agent in 
animals139,353-355 and humans356, 357 and reduces ocular surface staining.358 
2.11.5 Essential fatty acids   
Omega 3 fatty acids are known to inhibit the synthesis of lipid mediators and 
prevent the production of cytokines (IL1α and TNFα).359, 360 Orally administered essential 
fatty acids have demonstrated improvements in ocular irritation symptoms and signs.361  
2.11.6 Environmental strategies  
Environmental effects have been explained in section 2.2.2.1. Avoidance of 
systemic medications such as antidepressants and antihistamines may prevent symptoms 
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of ocular dryness. Avoiding low humidity or air-conditioned areas causing environmental 
stress hence prevent increased evaporation of tears or less production.35, 362, 363 Good 
blinking habits364 and the use of VDT terminals below eye level decreas the 
interpalpebral aperture exposure to environment and hence prevent evaporation of 
tears.119, 364-366  
In this chapter, a broad over view of dry eye was discussed. The next chapter will 
focus on the methods undertaken in this PhD project and the subsequent chapters will 
focus on the clinical and analytical studies performed in a unique participant pool.  
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3 Materials and Methods 
 
In this chapter, the number of participants, inclusion and exclusion criteria, the 




Informed consent was obtained from all participants prior to enrolment in this 
investigator masked study. This work received approval from the Office of Research 
Ethics at the University of Waterloo, Waterloo, Ontario, Canada (ORE #11003). All 
subjects were treated in accordance with the tenets of the Declaration of Helsinki (Ethical 
Principles for Medical Research Involving Human Subjects adopted by the 18th World 
Medical Association General Assembly Helsinki, Finland, June 1964).1  
A total of 86 participants were enrolled, of which 82 successfully completed the 
study. Four participants did not complete the study due to the reasons presented in Table 
3-1. Tear samples were collected wherever possible. 
Table 3-1: List of participants who discontinued from the study 
Participant ID Reason for discontinuation 
15, 58, 59 Uncomfortable with impression cytology technique 
25 Allergy to topical anesthetic 
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3.1.1 Inclusion criteria 
Participants were eligible for entry into the study as a dry eyed participant if she: 
1. Was a post–menopausal woman (menses ceased more than 12 months prior to the 
start of the study). 
2. Was at least 50 years of age and had full legal capacity to volunteer. 
3. Had purchased over-the-counter eye drops for dry eye symptoms within the 
previous six months. 
4. Had an oculo-visual examination in the last 2 years. 
5. Had read and signed the Statement of Informed Consent when complete 
eligibility had been confirmed. 
3.1.2 Exclusion criteria 
Participants were ineligible for entry into the study if she: 
1. Ceased menses due to autoimmune disorders, chemotherapy, pelvic irradiation or 
smoking. 
2. Had confirmed Sjogren’s syndrome. 
3. Wore soft or rigid gas permeable contact lenses. 
4. Had any clinically significant lid or conjunctival abnormalities, 
neovascularization, or corneal opacities. 
5. Was aphakic. 
6. Had corneal refractive surgery. 
7. Had ocular surgery in the past year. 
8. Was diabetic. 
9. Had a clinical diagnosis of blepharitis. 
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10. Was taking any anti-glaucoma medication. 
11. Was participating in any other type of clinical or research study. 
             The control group of participants were postmenopausal women (not on HRT) 
with no symptoms of dry eye (did not use any artificial tears) or any other anterior 
segment abnormality. In total, clinical procedures were performed on all 82 participants. 
These participants were sub-divided into various groups for performing the analytical 
procedures (tear analysis and conjunctival epithelial cell analysis for biomarkers). The 
details of each group of subjects for each study are listed in the relevant chapters.  
 
The following sections in this chapter detail the various procedures, in the same order 
they were performed during the clinical visits. 
 
3.2 Informed consent and completion of dry eye questionnaire 
Informed consent was obtained from all the participants prior to enrolment in the 
study. Participants then completed three different dry eye questionnaires (DEQ): 
a. Ocular surface disease index (OSDI)2, 3 – appendix A 
b. Single item score dry eye questionnaire (SIDEQ)4 – appendix B 
c. Indiana DEQ5-7 – appendix C 
OSDI scoring is based on a 0-100 scale, with the highest score representing 
greater disability.2, 3 An OSDI score of 0-12 represents non dry eye; an OSDI score of 13-
22 is categorized as mild dry eye and an OSDI score of 23-32 represents moderate dry 
eye.2,3 The SIDEQ self assessment questionnaire4 assessed the subjects’ ocular 
discomfort due to symptoms of dryness on a 0-4 scale, ranging from “none” to “severe.” 
Participants who reported “none” or “trace” symptoms were grouped in the non-dry eyed 
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group and the remainder were grouped into the dry eyed group. The DEQ includes 
categorical scales to measure the frequency, diurnal intensity, and intrusiveness of 
common ocular surface symptoms and usage of medication.5-7 These will be explained in 
the relevant chapters. 
Averaging and pooling of clinical and biological data is explained in detail in 
section 3.14. 
 
3.3 Objective bulbar conjunctival redness 
Objective bulbar redness was quantified using a SpectraScan PR650© 
Spectrophotometer (Photo Research Inc, Chatsworth, CA) (Figure 3-1). It is a table-top 
device that determines measurements of luminance and chromaticity by measuring the 
absolute intensity at each wavelength and then calculating the equivalent CIE u’ 
(Commission Internationale d'Eclairage) value.8, 9 Previous experiments have 
successfully used u’ values to measure ocular redness.8, 9 Higher u’ values denotes greater 
bulbar conjunctival redness. The chin rest and head rest were cleaned using alcohol 
swabs (Isopropyl alcohol 70%, Becton and Dickinson Canada Inc. Oakville, Ontario). 
The subject sat at the photometer and looked at a fixation light to their left or to the right, 
such that the temporal conjunctiva was aligned with the instrument. The examiner looked 
through the eye piece and positioned the black measuring spot (approximately 19.63 
mm2) of the photometer approximately 2 mm from the temporal limbus on the temporal 
bulbar conjunctiva (Figure 3-2). The spectrophotometer was turned on just before the 
measurement and turned off immediately after, to ensure that the ocular surface 
temperature did not increase. Redness was measured three times on both eyes. Mean 
value (left and right eye) was recorded for use in subsequent analysis. 
 89
 



















Figure 3-2: The black measuring spot of the photometer  
The black measuring spot (approximately 19.63 mm2) of the photometer was aimed 
approximately 2 mm from the temporal limbus on the temporal bulbar conjunctiva to determine 
hyperemia 
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3.4 Non invasive tear break up time 
Tear stability was assessed by performing a non invasive tear breakup time 
(NITBUT) evaluation using the ALCON Eyemap® model EH-290 topography system 
(ALCON, Inc., Forth Worth, Texas, USA).  The instrument has a keratoscope unit that 
produces concentric rings of light, which are reflected off the cornea and imaged in a 
CCD camera (Figure 3-3). The chin rest and head rest were cleaned using alcohol swabs. 
Participants were comfortably seated with their head supported by the forehead and chin 
rest and looked at a fixation light at the centre of the concentric rings of light. Participants 
were asked to blink 3 times before each measurement was taken. NITBUT was 
determined by measuring the time taken for distortions or discontinuities to appear in the 
reflected image of the concentric ring pattern (Figure 3-4). The time (in seconds) for the 
tear-film to rupture (and thus distort the rings) was measured using a stopwatch, to the 
nearest 0.1 of a second. Three measurements were taken in each eye and averaged. The 
mean values obtained in both eyes were then averaged and was used for analysis 
purposes. 
 




Figure 3-4: Distortions or discontinuities in the reflected image of the concentric 
ring pattern 
 
3.5 Phenol red thread test 
Tear volume was assessed using the Phenol Red Thread (PRT) test (ZONE-
QUICK, Showa Yakuhin Kako Co., Ltd. Tokyo, Japan). Two sterilized threads were 
contained in each aluminum package, as shown in Figure 3-5. Each thread was taken out 
by gently peeling the plastic film covering from the unsealed end of the aluminum 
package. The folded 3mm end of the thread was bent open at an angle that allowed easy 
placement onto the palpebral conjunctiva with forceps.  
 
Figure 3-5: Phenol red thread test  
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The PRT was placed at a point approximately 1/3 of the distance from the lateral 
canthus of the lower eyelid, with the eye in primary position. The lower lid was pulled 
down gently, and the folded 3mm portion of the thread was placed on the palpebral 
conjunctiva at the position specified in Figure 3-5. Each eye was tested with the eyes 
open for 15 seconds. During the test the patients were instructed to look straight ahead 
and blink normally. After 15 seconds, the lower lid was gently pulled down, and the 
thread was gently removed with an upward motion. Care was taken to pull the eyelid 
down before removal of the thread to avoid discomfort. The length of the color change on 
the thread, which indicates the wetting length, was measured in millimeters from the very 
tip, regardless of the fold. No topical anesthetic was used. A stop watch was used to 
measure the time. Mean value (left and right eye) was recorded for use in subsequent 
analysis. A break period of 20 minutes was given before the next test was performed. 
 
3.6 Tear collection using capillary tube 
Participants were asked to sit on a reclining chair that was at the maximum 
reclining position. Participants were asked to incline their head towards the tear collector 
and then asked to look up and away from the tear collector. Single-use, graduated, 
disposable, sterile, smoothly polished, fine glass capillary tubes (Wiretol-Micropipettes, 
Drummond Scientific Co., Broomall, PA, USA) were used to collect tear samples (Figure 
3-6). Approximately 6µL of tears were collected from the inferior tear meniscus of each 
subject. Tear collection was performed without corneal anaesthesia.  Collections were 
performed as carefully as possible to reduce reflex tearing and, taking care to ensure that 
the lid margin and corneal surface were not touched (Figure 3-7). The time taken for 
drawing 6µL of the tear sample from each eye was noted. This sample was then carefully 
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transferred to a micro PCR tube (Axygen Maxymim™ Recovery microtubes, Axygen 
Scientific, Inc., California, USA) for use in osmometry, ferning test and protein analysis 
(explained below). The micro PCR tubes were placed on ice. Tears were then pooled 
together, vortexed very briefly, aliquoted into various volumes and immediately 
transferred to storage at -80°C.  
 
 




Figure 3-7: Tear collection using a disposable capillary tube 
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3.7 Tear osmolality measurements 
The Model 3100 Tear Osmometer™ (Advanced Instruments, Inc. Norwood, MA, 
USA) is a diagnostic tool that quantifies tear osmolaltiy for ophthalmic applications. This 
instrument measures the osmolality of nanoliter-sized (0.5 µL) samples by freezing point 
depression. Approximately 0.5µL of the tears collected (as described in section 3.6) from 
the inferior meniscus of the right eye from each participant was transferred to a single-
use, disposable polycarbonate capillary tube. This polycarbonate tube was placed on a 
syringe and the tear sample was dispensed onto a white tip (Figure 3-8). This white tip 
was then loaded on to the freezing point depression osmometer as shown in Figure 3-9. 
Tear samples varied in their time to freeze and the crystal patterns following freezing 
varied widely between participants. Based on the melting point of a 0.5 µL sample, the 
computer-based system automatically determines the osmolality. The final osmolality 
reading was displayed on the computer screen. The procedure was repeated twice and the 
mean value was taken for subsequent analysis. The instrument's operating range as stated 













3.8 Tear ferning 
Approximately 0.5µL to 1 µL of tears collected (as described in section 3.6) from 
the inferior meniscus of the right eye from each participant was carefully pipetted from 
the tube. The Tear Ferning Test (TFT) was performed by dropping 0.5µL of the tear 
sample onto a clean glass microscope slide. This glass slide was allowed to dry at room 
temperature and evaluated at 10X magnification on a light microscope (Zeiss Axiovert 40 
CFL, Carl Zeiss, Göttingen, Germany). The ferning reaction is caused by an interaction 
of electrolytes with macromolecules such as proteins or mucous polysaccharides.10 The 
quality of ferning observed was based on the Rolando grading system,11 which grades the 
ferning patterns from grades 1 (abundant ferning; Figure 3-10) through to grade 4 (no 
ferns) (Figure 6-4 in chapter 6).  Photographs were taken immediately after drying to 
avoid misinterpretation in grading due to alterations in the ferning patterns due to effects 
of temperature and humidity.  
 




3.9 Slit lamp evaluation 
The subject was comfortably seated on a slit lamp biomicroscope (Zeiss slit lamp, 
Carl Zeiss, Göttingen, Germany) with their head supported by a forehead and chin rest. 
The chin rest and head rest were cleaned using alcohol swabs. Lid margins were assessed 
for meibomian gland dysfunction and vascularization. The level of temporal bulbar 
conjunctival hyperemia was graded by the examiner using a modified CCLRU scale, 
which uses a 0-100 scale (0 – negligible, 25 - trace 50 - mild 75 – moderate, 100 – 
severe).8, 12, 13 Mean value (left and right eye) was recorded for use in subsequent 
analysis. All the parameters were assessed under diffuse white light with 16X 
magnification. Corneal and conjunctival staining was not performed during the slit lamp 
examination to avoid interference with the impression cytology procedure. 
 
3.10 Collection of tears using eye wash technique  
Tears were collected using the eye wash technique on a subset of participants (ID 
# 36 to 86 only). This technique allows the collection of tears from dry ocular surfaces 
which is commonly seen in moderate to severe dry eye patients. Participants were asked 
to sit on a reclining chair at the maximum reclining position. With head straight ahead 
and slightly tilted upwards the participants were asked to look down. The upper lid was 
held by one researcher and the lower lid held by another researcher. Sixty micro litres of 
sterile, physiological saline (0.9% NaCl) (Minims, Chauvin Pharmaceuticals Ltd, 
Romford, Essex, UK) in a sterile micropipette (modified in house to a finer, blunt tip) 
(VWR Cat# 14670-366), was instilled onto the superior bulbar region of the un-
anaesthetized ocular surface. Participants were asked to move their eye to the left, to the 
right, up and down, without blinking (lids were held open), then were asked to repeat the 
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eye movements in order to mix the tear fluid content. Tear washes were collected from 
the inferior fornix of each eye using the sterile micropipette (Figure 3-11). The 
participants were asked to tilt their head towards the researcher while removing the eye 
wash solution, in order for the solution to pool in the lateral canthal region. The 
procedure was repeated with the other eye with a fresh sterile micropipette. Eye washes 
were pooled together, vortexed very briefly, then aliquoted into two samples of 5µL and 
the remainder volume was recorded. All the samples were stored immediately on dry ice. 
Eye wash samples were then transferred to -80°C freezer until further use. 
 
Figure 3-11: Collection of eyewash tears 
 
3.11 Conjunctival impression cytology (CIC) 
3.11.1 Method 
Instruments {hole punch, flat forceps (Fisher, catalogue # XX62 000 06) and 
pointed forceps (VWR, catalogue # 25607-856)}, and surgical scissors were sterilized at 
230°C for 9 hours. Gloves (High Five Products Inc, Chicago, Illinois) were worn by the 
researcher. Large round filter paper Millipore MF™ membrane filters 0.45µm (Millipore, 
catalogue # HAWP09000) were placed on Kimwipes in a laminar flow hood for sterility 
purposes. Direct pressure was applied to the large round filter paper membrane using the 
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10 mm diameter canvas punch until paper yields were obtained (Figure 3-12). The filter 
paper discs were then sterilized under UV for 5 minutes. Care was taken to adhere to the 
time period, to avoid the membrane becoming brittle. Using forceps, four discs were 
placed into 1.7 mL sterile eppendorf  tubes (VWR, catalogue # 22234-048).  These were 
used for performing conjunctival impression cytology. In addition to the 10mm diameter 
punch, 8mm and 9mm diameter punches were also used to obtain slightly smaller sized 
membranes for smaller horizontal visible iris diameters. 
 
Figure 3-12: Large Millipore MF™ membrane filters were used to make discs of 
10mm diameter for impression cytology 
3.11.2 CIC procedure 
Participants were comfortably seated in a bench-height laboratory chair with a 
back rest. With the participant’s head slightly reclined upward, 1 drop of topical 
anaesthetic (Alcaine™ 0.5% proparacaine hydrochloride; Alcon Canada Inc, 
Mississauga, Canada) was instilled onto the superior bulbar region of each eye. 
Participants were asked to close their eyes. Following a wait period of 30 seconds, a 
second drop of topical anaesthetic was instilled onto each eye. 
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3.11.2.1 Impression cytology of the superior bulbar region 
Participants were asked to gaze down as far as possible. One researcher held the 
upper lid, while the other researcher placed an appropriately-sized pre-cut Millipore 
MF™ membrane filter gently onto the superior bulbar conjunctiva using the pointed 
forceps. 
The membrane was tapped down gently with the same forceps and left on the eye 
for 5-8 seconds (Figure 3-13). The membrane was then gently removed from the eye with 
the flat edge forceps. The membrane from the right superior bulbar conjunctiva was 
immersed directly into an RNase free 2 ml tube containing 1 ml of RLT lysis buffer 
(Qiagen RNeasy mini kit Cat# 74106) that had 1% β-mercaptoethanol added immediately 
prior to use.  
 
Figure 3-13: Impression cytology of the superior bulbar conjunctiva 
 
3.11.2.2 Impression cytology of the right temporal bulbar region 
Participants were asked to look down as far as possible. One researcher held the 
upper lid open and then the participant was asked to stare directly ahead and to the 
extreme left gaze while the second researcher held the lower lid and then, using the 
pointed forceps, placed the membrane onto the temporal bulbar conjunctiva (Figure 3-
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14). The membrane was tapped down gently with the pointed forceps and the membrane 
was left on the eye for 5-8 seconds.  
 
Figure 3-14: Impression cytology of the temporal bulbar conjunctiva 
 
The membrane was gently removed from the eye with the flat edge forceps. This 
was immersed into the same tube used for the right superior bulbar conjunctiva 
membrane. Care was taken to ensure both membranes were soaked in the lysis buffer and 
kept on dry ice. 
The same procedure was repeated for impression cytology of the left superior 
bulbar conjunctiva. The membrane collected from the left superior bulbar conjunctiva 
was placed into an empty RNase free 2ml tube. Similar steps described above for the 
collection of samples from right temporal bulbar conjunctiva was repeated for the left eye 
also. The participants were asked to look up and to the extreme right to collect the 
temporal bulbar conjunctival samples from the left eye. This membrane was placed into 
the same tube that contained the left superior bulbar conjunctiva membrane (Figure 3-
15). The CIC membranes from the left eye were used for protein analysis. This tube was 




Figure 3-15: Flowchart showing the schematic of sample processing from the CIC 
disc from left and right eye 
   
Following impression cytology, two drops of TheraTears® (Advanced Vision 
Research, Woburn, MA) lubricant tear drops were placed into both left and the right eyes. 
Artificial tears were administered immediately to alleviate the symptoms of mild 
discomfort post-procedure.  
 
3.12 Corneal and conjunctival staining 
Before all the participants exited the study, the eyes were stained with sodium 
fluorescein (NaFl) ophthalmic strips (Fluorets®, Bausch & Lomb). Corneal and 
conjunctival staining type was assessed on a 0 to 100 point scale where 0 represented no 
staining and 100 represented severe staining. Assesment of corneal and conjunctival 
staining was performed on all the participants who had the CIC procedure. Staining was 
Conjunctival Impression cytology 
Right eye – Superior & temporal Left eye – Superior & temporal 
RNA isolation Protein isolation
RT-PCR Western blotting 
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performed to assess the status of the ocular surface post CIC procedure. This data is not 
used in this thesis. 
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3.13 Analytical procedures 
3.13.1 Total protein isolation from the CIC samples  
Total protein isolation from the CIC samples was performed for ID # 1 to 86 
(explained in detail in appendix D). CIC samples were placed on a glass plate with 
adhered cells facing up. 10 µL of Extraction Buffer (EB), containing 50mM Tris and 2% 
SDS, + Complete Protease Inhibitor Cocktail (PI) (Roche Diagnostics, 1X concentration) 
was applied to each membrane. The discs were cut up using a scalpel into 1- 2mm pieces, 
added to an eppendorf tube containing an additional 50µL of EB, boiled for 10 minutes, 
spun at 12,000 relative centrifugal force (VWR Mini Vortexer, VWR International, 
USA), and the supernatant was aliquoted and stored at -80º C.  
3.13.2 Total protein determination  
Total protein determination was performed using the DC Protein Assay Kit™ 
(BioRad, Mississauga, ON, Canada) (Cat # 500-0116) as per the manufacturer’s 
instructions (appendix E). Tear samples and IC supernatant were diluted in distilled 
water. For sample preparation: 0.5µL of capillary tears; 5µL of eye wash or 5µL of IC 
supernatant was added to sufficient Milli-Q water to total 10 µL. All samples and 
standards were assayed in duplicate 5µL aliquots (explained in detail in appendix E).  
Absorbances were read at 750 nm on a Multiskan Microplate Spectrophotometer 
(Thermo Labsystems, Franklin, MA, USA) (Cat# 28010; Figure 3-16). Graphs were 
plotted from the standard readings. Using the standard linear regression equation, the 




Figure 3-16: Multiskan Microplate Spectrphotometer 
 
3.13.3 Quantification of individual lacrimal gland tear proteins (lipocalin and 
lysozyme) 
3.13.3.1 Electrophoresis and immunoblotting  
Electrophoresis and immunoblotting techniques are explained in detail in appendix F. 
In brief, for the analysis of lipocalin, tear samples were diluted to final concentrations of 
10 ng/µL (capillary tears) or 15 ng/µL (eye wash), with modified Laemmli’s buffer (50 
mM Tris-HCl, pH 7.4, 2.5% sodium dodecyl sulfate (SDS) w/v, 2.5% glycerol, 5 mM 
dithiolthreitol (DTT), 0.01% Bromophenol blue). For lysozyme analysis, tear samples 
were first diluted with Laemmil’s buffer to 50 ng/µL (capillary tears) or 25 ng/µL (eye 
wash) and then to final concentrations of 25 ng/µL or 15 ng/µL (capillary and eye wash, 
respectively) with gel loading buffer (60 mM Tris (pH 6.8), 2% glycerol, 2% SDS, 0.01% 
bromophenol blue).  
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To facilitate quantitation of tear samples, standard curves were run on each gel. For 
lipocalin, this was a titration (5 to 30 ng/µL total protein) of pooled human tears collected 
from non dry-eyed volunteers and for lysozyme, a titration (1-10 ng/µL) of human 
neutrophil lysozyme.  
Once prepared, samples and standards were subjected to SDS-PAGE followed by 
Western blotting to PVDF membranes using the PhastSystem™ (GE Healthcare, Baie 
d'Urfe, QC, Canada; Figure 3-17). Lipocalin was identified through incubation with a 
mouse anti-human lipocalin monoclonal antibody (1:20 000) diluted in TBS + 0.05% 
Tween 20 (TBS-T) for 2 hours followed by a 1 hour incubation with goat anti-mouse 
secondary antibody (1:10 000) diluted in TBS-T. Lysozyme was identified using a rabbit 
anti-human lysozyme polyclonal antibody (1:1000) in TBS-T with 5% skim milk powder 
for 2 hours, followed by peroxidase conjugated goat anti-rabbit secondary antibody (1:20 
000) in TBS-T with 5% skim milk powder for 1 hour.  
Immunoreactivity was visualized by incubating with ECL-Plus™ chemiluminescent 
substrate. Optical densities of the resulting bands were quantified from digitized images 
created with a Molecular® Dynamics Storm™ 840 Imager using ImageQuant™ 5.1 (GE 
Healthcare, Baie d'Urfe, QC, Canada). Regression analysis was performed from standard 
curve data to generate standardized values of tear film lipocalin and lysozyme. Lipocalin 
data are expressed as arbitrary units (AU) per µg total protein, whereas lysozyme data are 




Figure 3-17: Amersham Pharmacia Biotech PhastSystem™ 
3.13.3.2 Quantification of densitometric Data 
The concentration of lysozyme and lipocalin in each sample was quantified by 
densitometric analysis using ImageQuant 5.1 software (Molecular Dynamics, Sunnyvale, 
CA, USA). The resultant densitometric peak volumes of the standards were graphed 
versus the appropriate protein concentrations producing a standard curve. Linear 
regression was performed and the equation of the line-of-best-fit was used to calculate 
the lysozyme/lipocalin concentration in the sample extracts. The densitometric volumes 
for the sample extracts were substituted into the equation: 
x = (y – b)/m 
where y is the densitometric volume of the sample extract, m is the slope of the 
line calculated by linear regression, b is the y axis intercept as calculated by linear 
regression, and x is the concentration of purified lysozyme/ lipocalin. In many cases, the 
standard curve was more curved and the best-fit line was found to be a quadratic 
polynomial (SigmaPlot software V9.01) with equation:  
y = yo + ax + bx2 
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where yo, a and b were calculated by the software and x is the densitometric volume of 
the sample extract. For the curved standard curves analyzed this way, r2 values were 
always 0.98 or better with this method.  
3.13.4 Detection of MUC 1 and 16 from tears and CIC samples 
3.13.4.1 Agarose gel electrophoresis and immunoblotting 
Agarose gels (2% agarose (Cambrex Seakem 50150) (w,v), 2.5% glycerol (v/v) 
(EMD chemicals 4750) 1x gel buffer (v/v) (25 mM Tris, pH 8.3, 192 mM glycine, 0.1% 
SDS) (BioRad 162-0147) were poured one day before use. Gel cassettes of 16 cm by 18 
cm were assembled according to manufacturer’s directions. One volume of tears was 
mixed with one volume 2X non-reducing buffer (final concentration 25 mM Tris-HCl pH 
6.8, 2% SDS).  One and a half millimeter thick gels were run at 20 mA constant current 
per gel in 25 mM Tris, pH 8.3, 192 mM glycine, 0.1% SDS, BioRad 162-0147.  To 
facilitate quantitation of tear and IC samples, standard curves were run on each gel. Six 
micrograms of total protein for MUC1 and 4 ug for MUC16 were loaded. Once prepared, 
samples and standards were subjected to agarose gel elecrophoresis. SE600 Vertical gel 
unit (GE Biosciences (Amersham) Cat. No. 80-6479-57) was used for electrophoresis, 
Figure 3-18.  
This was followed by transfer on to nitrocellulose membrane (0.2 uM, 13.5 x 16.5 
cm, BioRad 162-0147) using a vacuum blotter (Biorad 785, Cat. No. 165-5001) and 2 L 
of transfer buffer (600 mM sodium chloride, 60 mM sodium dihydrogen citrate (4x SSC), 
EMD 8310) for 2 hours. Blots were blocked with PBS-T (137 mM NaCl, 2.7 mM KCl,  
10 mM phosphate, pH 7.4, 0.5% Tween 20(v/v) and 0.1% BSA (bovine serum albumin, 
(Sigma A3059) (w/v) for 1 hour at room temperature. MUC 1 was identified using 
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antibody detection with mouse monoclonal anti-human MUC 1 antibody, DF3 (Signet 
Dedham, MA) (1:40) diluted in PBS – T solution overnight at 4oC.  
Blots were rinsed several times in PBS-T and then incubated at room temperature in 
the goat anti-mouse IgG-HRP (Santa Cruz Biotechnology Inc) secondary antibody 
(1:5000) diluted in PBS-T. MUC16 was identified by incubating the blot in monoclonal 
mouse antihuman MUC16 antibody, OC125, (DAKO, Glostrup, Denmark) (1:250) 
diluted in PBS –T overnight at 4C. Blots were rinsed several times in PBS-T and then 
incubated at room temperature in the goat anti-mouse IgG-HRP (Santa Cruz 
Biotechnology Inc) secondary antibody (1:5000) diluted in PBS-T.  Immunoreactivity 
was visualized by incubating with ECL-Plus™ chemiluminescent substrate. Optical 
densities of the resulting bands were quantified from digitized images collected with a 
Molecular® Dynamics Storm™ 840 Imager using ImageQuant™ 5.1 (GE Healthcare, 
Baie d'Urfe, QC, Canada). Regression analysis was performed from standard curve data 
to generate standardized values of MUC 1 and MUC16 as described above for lysozyme 
and lipocalin.  
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Figure 3-18: SE600 Vertical gel unit 
 
3.13.5 Isolation of RNA from CIC samples  
RNA was isolated from the CIC samples using commercially available RNeasy™ 
Mini Kit (Qiagen Cat # 74106) and the DNAse step was performed using the RNase-Free 
DNase Set™ (Qiagen Cat# 79254).  
3.13.5.1 Preparation of RNase-Free DNase   
  DNase stock solution was prepared before using the RNase-free DNase for the 
first time. The solid phase of the DNase (1500Kunitz units14) was dissolved in 550 μl of 
the RNase-free water provided. This was mixed gently by inverting the tube. This stock 
solution was aliquoted into samples of 22µL and stored in -20°C until further use. 
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3.13.5.2 RNA isolation using commercially available RNeasy Mini kit: 
The RNA was isolated from the samples according to manufacturer’s guidelines with 
several modifications (appendix G). Briefly, samples soaked in RLT buffer were 
vortexed and homogenized. One volume of 70% ethanol was added to each sample 
followed by a 15 second vortex. Samples were added to the RNeasy mini spin column 
and centrifuged. DNAse step was performed which included a 15 minute incubation 
period. This was followed by two RPE buffer washes and centrifugation at 8000g. 
RNeasy mini spin column was dried and placed in 2mL collection tubes. 40µL of RNAse 
free water was pipetted onto the column and centrifuged for 1 minute at 8000g to collect 
RNA samples. 
3.13.6 Precautions and handling RNA 
Great care was taken during conjunctival cell sample collection, during and after 
RNA isolation procedures, to avoid RNAse contamination and to maintain an RNAse-
free environment. Nitrile gloves were always worn by the examiner during sample 
collection, during and after RNA isolation procedures to prevent RNAse contamination 
from skin, or from laboratory equipment. Gloves were changed frequently. 
 Disposable polypropylene tubes were used throughout the procedure. These tubes 
were purchased as RNAse-free and did not require subsequent treatment to inactivate 
RNAses. Disposable plugged pipette tips that were meant for RNA work were used for 
pipetting solutions. All laboratory glassware was cleaned with detergent, followed by 
thorough rinsing with MilliQ water and baked at 230°C for at least 9 hours. All solutions 
for RNA work were taken from stocks reserved for RNA work only. The lab bench 
surfaces and equipment (eg. centrifuge, pipette) were routinely treated with RNAase 
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ZAP™ solution (Ambion®, Foster City, CA, USA) to remove surface RNAse 
contamination. Instruments (flat and pointed forceps) used for performing impression 
cytology were sterilized at 230°C for 9 hours.  
3.13.7 RNA quality and quantity assessment and cDNA synthesis 
RNA quantity and quality was assessed by measuring the optical density using a 
Beckman DU530 Life Science UV/Visible Spectrophotometer (Beckman Coulter, 
Fullerton, CA; Figure 3-19), at 260nm and 280nm. Five microliters of sample was diluted 
in 95µL Milli-Q water. Background subtraction of the value obtained at 320 nm was also 
performed. cDNA was synthesized from 8µL of RNA sample using random hexamer 
primers with Superscript™ III First-Strand Synthesis System for RT-PCR (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s instruction.  
 
Figure 3-19: Beckman DU530 Life Science UV/Visible Spectrophotometer 
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3.13.8 Real time qPCR 
Relative expression of genes of interest was performed in multiplex PCR 
reactions containing target and endogenous control oligonucleotide primers in the 
presence of gene-specific dye-labeled Taqman probes (Table 3-2). Two microlitres of 
cDNA was used for amplification in a 50µL PCR reaction containing target (300 nM) 
and endogenous control (100 nM) oligonucleotide primers, control and target Taqman 
probes (100 nM), and Taqman® Universal PCR Master Mix (Applied Biosystems, Foster 
City, CA). Duplicate samples were used for analysis in a 7500 Real Time PCR System 
(Applied Biosystems; Figure 3-20). 
 Conditions used for amplification were as follows: 50°C for two minutes, 
followed by an initial 10 minute denaturing step at 95°C. This was followed by 40 cycles 
of denaturing at 95°C for 30 seconds, annealing at 60°C for 30 seconds and extension at 
72°C for 45 seconds. Normalized reporter dye fluorescence (Rn) data were collected 
during the extension step at each cycle. Collected data were analyzed and fold-expression 
changes were calculated using the comparative method (2-ΔΔCT) of relative quantification 
by SDS software v1.3.1 (Applied Biosystems, Foster City, CA). A sample containing 
0.25 pg of plasmid DNA with cloned target and endogenous fragments was used as a 
calibrator sample for each gene.         
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Figure 3-20: Applied Biosystems: 7500 Real Time PCR System 
 
Table 3-2: Oligonucleotide primers and probes used for relative expression analysis  




















3.14 Averaging and pooling of clinical and biological data 
The data collected from the right and left eye for NITUBT, PRT and subjective and 
objective bulbar conjunctival hyperemia values were averaged for subsequent analysis. 
There was no significant difference noted between these parameters within the two eyes. 
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The tear samples collected using disposable capillary tubes were pooled (section 3.6). 
Tear washes were pooled together and stored at -80oC until use (section 3.10). 
References 
1. Forster HP, Emanuel E, Grady C. The 2000 revision of the Declaration of 
Helsinki: a step forward or more confusion? Lancet 2001;358:1449-53. 
2. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability 
and validity of the Ocular Surface Disease Index. Arch Ophthalmol 
2000;118:615-21. 
3. Walt JG, Rowe MM, Stern KL. Evaluating the functional impact of dry eye: The 
Ocular Surface Disease Index. Drug information Journal 1997;31:1436. 
4. Simmons PA, Vehige JG, Carlisle C, Felix C. Comparison of dry eye signs in 
self-described mild and moderate patients. Invest Ophthalmol Vis Sci 
2003;ARVO E-Abstract 2448. 
5. Begley CG, Chalmers RL, Abetz L, Venkataraman K, Mertzanis P, Caffery BA, 
Snyder C, Edrington T, Nelson D, Simpson T. The relationship between habitual 
patient-reported symptoms and clinical signs among patients with dry eye of 
varying severity. Invest Ophthalmol Vis Sci 2003;44:4753-61. 
6. Begley CG, Caffery B, Chalmers RL, Mitchell GL. Use of the dry eye 
questionnaire to measure symptoms of ocular irritation in patients with aqueous 
tear deficient dry eye. Cornea 2002;21:664-70. 
7. Begley CG, Chalmers RL, Mitchell GL, Nichols KK, Caffery B, Simpson T, 
DuToit R, Portello J, Davis L. Characterization of ocular surface symptoms from 
optometric practices in North America. Cornea 2001;20:610-8. 
8. Sorbara L, Simpson T, Duench S, Schulze M, Fonn D. Comparison of an 
objective method of measuring bulbar redness to the use of traditional grading 
scales. Cont Lens Anterior Eye 2007;30:53-9. 
9. Duench S, Simpson T, Jones LW, Flanagan JG, Fonn D. Assessment of variation 
in bulbar conjunctival redness, temperature, and blood flow. Optom Vis Sci 
2007;84:511-6. 
 116
10. Horwath J, Ettinger K, Bachernegg M, Bodner E, Schmut O. Ocular Ferning test - 
effect of temperature and humidity on tear Ferning patterns. Ophthalmologica 
2001;215:102-7. 
11. Rolando M. Tear mucous ferning test in normal and keratoconjunctivitis sicca 
eyes. Chibret Int J Ophthalmol 1984;2:32-41. 
12. Dumbleton K, Keir N, Moezzi A, Feng Y, Jones L, Fonn D. Objective and 
subjective responses in patients refitted to daily-wear silicone hydrogel contact 
lenses. Optom Vis Sci 2006;83:758-68. 
13. Dumbleton KA, Chalmers RL, Richter DB, Fonn D. Vascular response to 
extended wear of hydrogel lenses with high and low oxygen permeability. Optom 
Vis Sci 2001;78:147-51. 
14. Kunitz M. Crystalline desoxyribonuclease; isolation and general properties; 
spectrophotometric method for the measurement of desoxyribonuclease activity. J 





4 Assessment of Ocular Surface dryness Using Dry Eye 
Questionnaires in Postmenopausal Females 
Srinivasan S, Joyce E, Senchyna M, Jones LW. Assessment of ocular surface dryness 




Aim: To characterize symptoms of dry eye in a group of postmenopausal women (PMW) 
using the Allergan Ocular Surface Disease Index Questionnaire© (OSDI) and Indiana Dry 
Eye Questionnaire (DEQ). 
 
Methods: Eighty two healthy PMW, who were non-contact lens wearers and not on 
hormone replacement therapy, completed two questionnaires. They were categorized as 
being symptomatic or asymptomatic of dry eye based on their response to the OSDI 
questionnaire. The participants also completed the DEQ, which has questions related to 
frequency of ocular surface symptoms and their diurnal intensity. 
 
Results: OSDI responses revealed 43 symptomatic (mild = 16; moderate = 27) and 39 
asymptomatic participants. The OSDI total score for the Non Dry Eye (NDE) and Dry 
Eye (DE) groups were significantly different (NDE =7.43 ± 7.71 vs DE = 24.87 ± 13.89; 
p<0.001). The sub scores for the DE group were also significantly greater than the NDE 
group (p<0.001). The DEQ scores showed that the DE group exhibited a higher 
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frequency and intensity of symptoms than the NDE group (p<0.001), which worsened as 
the day progressed (p<0.001). 
 
Conclusions: Dry eye questionnaires can be used to separate PMW who demonstrate 
symptoms of ocular dryness and may be useful in treatment trials in dry eye. This also 
emphasizes the fact that in addition to clinical assessment, a careful history and the use of 
dry eye questionnaires are necessary for accurate dry eye diagnosis.  
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4.2 Introduction  
Dry eye questionnaires are tools that are frequently used in clinical research to 
screen individuals for the diagnosis of dry eye. They are also employed in clinical 
practice to grade the severity of the disease or to assess the effects of various dry eye 
treatments.1 Dry eye questionnaires are also used in population based studies and to study 
the natural history of disease. The epidemiology sub committee of the Dry Eye Workshop 
2007 (DEWS) has reviewed and identified several questionnaires that were used 
previously,2-14 either in randomized clinical trials or that have been tested or used in 
epidemiological studies.  
When clinicians attempt to classify patients with signs and symptoms of dry eye, 
a wide battery of tests are available. Of these, a careful patient history and the use of dry 
eye questionnaires have been shown to be very useful in the diagnosis of dry eye. Many 
complain of dry eye symptoms that may precede clinically observed ocular surface 
changes.15 In contrast, clinical signs may be observed by practitioners in the absence of 
patient reported symptoms of ocular dryness, and several studies have reported this lack 
of agreement between signs and symptoms of this disease.16-18 The most recent definition 
proposed by the Dry Eye Workshop defines dry eye as a multifactorial ocular surface 
disease diagnosed by symptoms of discomfort and signs of visual disturbance, tear film 
instability and ocular surface damage, accompanied by increased osmolarity of the tear 
film and ocular surface inflammation.19 
Studies have shown that clinicians rely to a large degree on their case history, 
with the patient’s input regarded as an important tool to diagnose and categorize dry eye 
patients.15, 20, 21 Hence, symptoms of dry eye are a key factor in the diagnosis and 
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treatment of dry eye. It has been reported that the incidence and prevalence of dry eye 
increases with aging.14, 22-24 Studies have shown that the number of women affected with 
dry eye disease is higher than that found in men.25-28  Menopause can play an important 
role in causing dry eye symptoms.1, 29, 30 The Women’s Health Study 8 estimated that 3.2 
million women aged over 50 suffer from moderate to severe forms of dry eye.1 
A variety of questionnaires are available for the evaluation of symptoms, which 
can aid in the diagnosis of dry eye.1-14, 31 Of these, the Allergan Ocular Surface Disease 
Index (OSDI) © questionnaire (appendix A)  is a validated questionnaire,7 which includes 
relatively few questions and is more easily applied than many of the other longer, more 
complex questionnaires that are available. The questionnaire originally had 40 items, 
which was later reduced to a simpler 12 item questionnaire, to provide a rapid assessment 
of symptoms.7  
End of day ocular surface dryness is a frequently reported complaint from both 
those subjects who exhibit signs and symptoms of dry eye and contact lens wearers.9 
Many of these patients use ocular lubricants to alleviate their symptoms, particularly at 
the end of the day. One of the questionnaires that has been reported to assess ocular 
surface symptoms of dryness and diurnal fluctuations in symptoms, especially in mild to 
moderate dry eye patients, is the Indiana Dry Eye Questionnaire (DEQ).9, 32  The DEQ 
consists of a total of 23 questions (appendix C). It includes questions about frequency and 
the diurnal severity of common ocular surface symptoms reported by symptomatic dry 
eye individuals. In addition to questions related to ocular symptoms, questions on how 
much these symptoms interfere with day to day activities are also present. 
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The purpose of this study was to characterize symptoms of dry eye in a group of 
postmenopausal women (PMW) using two different dry eye questionnaires, namely the 
Allergan OSDI questionnaire and the Indiana DEQ. 
 
4.3 Materials and Methods 
The protocol for this study was approved by the Office of Research Ethics at the 
University of Waterloo. Study participants were recruited at the Centre for Contact Lens 
Research, within the School of Optometry. A case history and complete ocular surface 
examination was performed to determine participant eligibility. Informed consent was 
obtained from all participants, after all the procedures had been explained. Participants 
who were on Hormone Replacement Therapy (HRT) were excluded, due to the 
confounding results present in the literature on whether HRT is protective or exacerbates 
dry eye symptoms and signs.33, 34 Non-contact lens wearers (ceased lens wear at least 1 
year before participating in the study) and candidates with systemic disease, or using any 
systemic or topical medications that may have affected ocular health, were also excluded 
from the study. For the purpose of this study, “postmenopausal” was defined as no 
menses for at least one year, not associated with hysterectomy. This research study 
adhered to the tenets of the Declaration of Helsinki. 
Eighty two healthy PMW greater than 50 years of age were recruited. Participants 
completed the Allergan Ocular Surface Disease Index© (OSDI)7  questionnaire and the 
Indiana Dry Eye Questionnaire (DEQ)9, 32 and were categorized as being symptomatic or 
asymptomatic of dry eye based on their response to the OSDI questionnaire. The 
administration and scoring system for the OSDI has been described in detail elsewhere7 
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Broadly, the OSDI is a questionnaire that includes 12 questions, which are subdivided 
into three groups: ocular symptoms, vision related functions and environmental factors. 
The OSDI scoring is based on a 0-100 scale, with the highest score representing greater 
disability. The OSDI questionnaire is graded on a scale from 0 to 4, where 0 indicates 
“none of the time”; 1, “some of the time”; 2, “half of the time”; 3, “most of the time”; 4, 
“all of the time”. The following formula is used to find the total OSDI score:  OSDI = 
[(sum of scores for all questions answered) × 100] / [(total number of questions 
answered) × 4]. An OSDI score of 0-12 represents NDE; an OSDI score of 13-22 is 
categorized as mild DE and an OSDI score of 23-32 represents moderate dry eye.7, 35 
The questions in the Indiana DEQ related to ocular symptoms included 
discomfort, dryness, visual changes, soreness and irritation, grittiness and scratchiness, 
foreign body sensation, burning and stinging, light sensitivity, and itching. The 
questionnaire also included questions about age, how much ocular symptoms affected 
daily activities, questions concerning computer use, history of contact lens wear, use of 
systemic and ocular medications, allergies, self-assessment of whether subjects thought 
they had dry eye, and whether subjects had been previously diagnosed as having dry eye. 
However, this questionnaire does not have a specific formula to compute the scores, as 
described above for the OSDI questionnaire. 
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4.4 Statistical analysis 
Statistical analysis was performed using Statistica Ver7.1 (StatSoft Inc., Tulsa, 
OK, USA). Graphs were plotted using GraphPad Prism 5 (GraphPad Software Inc, San 
Diego, CA, USA). OSDI scores and sub-scores between the two groups were compared 
using a Mann Whitney U test.  
DEQ analysis: A Mann Whitney U test was performed to compare the frequency 
of scores (Questions 4 to 12), issues relating to the frequency of the subjects’ eyes feeling 
“bothered” (Question 13a), the number of hours of computer use (Questions 14a and b), 
and dryness elsewhere in the body (Question 17). Diurnal shifts (morning to evening) of 
the scores within each group was compared using Friedman analysis of variance and 
across the groups (non dry eyed group vs dry eyed group) were compared using a Mann 
Whitney U test.  
A Chi-square test was performed to compare DEQ allergy, medication use and 
artificial tear use (Questions 15 and 16a and 20). A Chi-square test was also performed 
for questions pertaining to self diagnosis and doctor’s diagnosis of dry eye (Questions 
18a and 19). Correlations between OSDI and DEQ were undertaken using a Spearman 






4.5.1 OSDI classification 
The mean age (mean ± SD) of the NDE subjects (n=39) was 59.7 ± 6.6 years and 
64.1 ± 9.2 years for the DE participants (n=43). The OSDI total score was significantly 
different between the two groups (NDE = 7.43 ± 7.71 vs DE = 24.87 ± 13.89; p<0.001). 
The symptomatic group of participants consisted of 16 mild and 27 moderate dry-eyed 
patients (there were no subjects who were categorized as being “severe”). All three OSDI 
sub-scores were also significantly different between the symptomatic and asymptomatic 
groups, with higher scores for all three subcategories for the dry-eyed subjects (p<0.001; 
summarized in Table 4-1).  
Due to the length and number of questions (23 questions) in the DEQ, the mild 
and moderate dry eye groups were combined together as the “dry eyed” group in the rest 


















































































27.21 <0.001* <0.001* 0.43 
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4.5.2 DEQ responses 
4.5.2.1 Frequency and intensity of ocular symptoms  
Figures 4-1and 4-2 demonstrate the responses to questions related to the 
frequency of nine ocular symptoms by NDE and DE PMW. Over 55% of the dry eyed 
PMW demonstrated symptoms of frequent to constant discomfort. 47% complained of 
frequent to constant dryness symptoms. Other symptoms such as blurry vision, soreness 
and irritation, grittiness and scratchiness, foreign body sensation, burning and stinging, 
light sensitivity, and itching ranged from 11 to 37%. This is markedly different to the 
control subjects, who reported frequent to constant discomfort and dryness at only 5% 
and 0%, respectively. There was a significant difference between the asymptomatic and 




Figure 4-1: Frequency of symptoms in NDE participants using DEQ 
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Figure 4-2: Frequency of symptoms in DE participants using DEQ  
 
4.5.2.2 Diurnal variation of ocular symptoms  
Figures 4-3 and 4-4 demonstrate the diurnal variation in symptoms in the non dry 
eyed and the dry eyed group respectively. When morning and evening scores were 
compared within each group (with the exception of “soreness”; p=0.02), no change in 
symptoms were reported over the course of the day (p>0.05) within the non dry eyed 
group. However, the dry eyed group showed significant differences, with increasing 
symptoms of dryness towards the end of the day for all the symptoms evaluated 
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(p<0.005), except for “light sensitivity” (p=0.052). When symptoms at the various points 
in time were compared between groups, Mann-Whitney U test showed significant 
differences between the two groups for the majority of symptoms, including comfort, 
dryness, soreness and irritation, grittiness and scratchiness, burning and stinging 
symptoms (p<0.001). The dry eyed group showed higher scores than the non dry eyed 
group throughout the day as shown in Figures 4-5 and 4-6. The rest of the symptoms 
(blurry vision, foreign body sensation and itching) showed significant differences only in 
the evening. Light sensitivity was significantly different between the two groups only for 
























Figure 4-5: Morning (am) middle of the day (mid day) and evening (pm) symptom 
mean intensity score reported by dry eyed and non dry eyed PMW 
● represents dry eyed participants and ▲ represents non dry eyed participants. * represents 









Figure 4-6: Morning (am) middle of the day (mid day) and evening (pm) symptom 
mean intensity score reported by dry eyed and non dry eyed PMW 
● represents dry eyed participants and ▲ represents non dry eyed participants. * represents 
statistically significant difference between groups over time. 
 
The participants were also asked to comment on the frequency at which their eyes 
felt bothered during the previous week that made them stop their work. Over 32% of the 
symptomatic PMW reported “frequently” and 30% of the women complained of only 
Grittiness Foreign body sensation 
Burning Light sensitivity 
Itching 
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“infrequent” symptoms. About 19% of the subjects complained of their eyes being 
bothered several times during the week. The percentage of participants who reported their 
“eyes being bothered daily” and “several times daily” were 14% and 12% respectively. 
92% of the asymptomatic women reported that their eyes were not bothered. 
 
Figure 4-7: Frequency of self diagnosis of dry eye vs doctors diagnosis of dry eye 
 
When the participants were asked about how often they experienced dryness of 
the mouth, nose or vagina in the past month, 44% of the DE PMW reported dryness that 
was present “daily.” In contrast, the percentage of NDE PMW who reported dryness was 
15%. This was statistically significantly different (p>0.001). About 80% of the DE 
participants and 5% of the NDE participants reported that they had previously been told 
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that they had dry eyes by their clinician (Figures 4-7). Three percent of the DE group did 
not know if they had been diagnosed. When participants were asked “do you think you 
have dry eye(s)?”, 89% of the DE women and 2% of the NDE group reported “yes.” 
Seven percent of the DE and 5% of the NDE participants were not sure (Figures 4-7). 
4.5.2.3 Computer usage 
In this study, computer usage was slightly greater among the asymptomatic 
controls, but the difference was not significant among groups (p = 0.145, Mann Whitney 
U test). About 38% of the NDE and 53% of the DE post menopausal women did not use 
computers for work related reasons. On average, NDE subjects reported 2.6 hours of 
computer use on normal working day and 1.2 hours on a nonworking day, DE subjects 
reported 1.7 hours of workday computer 1.4 hours on a leisure basis.  
4.5.2.4 Medication and allergies 
Allergies and medication usage is listed in Tables 4-2 and 4-3. The percentage of 
subjects reporting allergies was very similar among the two groups. Current usage of 
medication and allergy medication (if any) was also similar among both groups (p>0.05, 








Table 4-2: Response to questions on medication usage in DEQ  
NDE DE 
Medications 
YES (%) NO (%) YES %) NO (%) 
Thyroid 13 87 19 81 
Blood pressure 28 72 23 77 
Diabetes 0 100 0 100 
Diuretic 18 82 7 93 
Acutane 0 100 0 100 
Heart condition 3 97 5 95 
Depression 5 95 12 88 
Ulcer 0 100 7 93 
Oral contraceptives 0 100 0 100 
 
 
Table 4-3: Response to questions related to allergies in DEQ  
NDE DE 
Allergies 









Seasonal 33 64 3 33 60 7 
Skin 5 95 0 9 86 5 
Asthma 5 95 0 14 81 5 
Animals 15 85 0 23 68 9 
Pollen and mold 21 77 2 19 67 14 
food 5 92 3 21 74 5 
Affecting your eyes 23 74 3 19 58 23 
Allergies to Contact 
lens solutions 0 90 10 2 74 24 




4.5.2.5 Dry eye treatments 
Question 18b in the questionnaire targeted the effectiveness of dry eye treatments, 
such as artificial tears, warm compresses, lid scrubs and punctal plugs. About 30% of the 
dry eyed participants reported responses midway between “no help at all” and a 
“complete cure,” as shown in Table 4-4. Fewer subjects reported using lid scrubs, warm 
compresses and punctal plugs, with similar relief reported.  Sixty two percent of DE 
women on an average instilled artificial tears four times a day (range = 0 to 8 times) and 
spent $9 (range = $0 to $30) a month on the purchase of artificial tears. Few of the 
participants used samples of artificial tear drops, if available. 







at all (% 
subjects) 
Mid way between no help 








Artificial tears 2 23 30 16 5 23 
Warm compress 
or lid cleaning 2 2 9 5 0 81 
Punctal plugs or 
cauterization 0 0 2 0 0 98 
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4.5.2.6 Correlations 
Spearman correlation analysis between OSDI total score and DEQ for symptom 
comparison showed weak but significant associations (R=0.45 to 0.65; p<0.001) as 
shown in table 4-5. Similar results were observed for Spearman correlation analysis 
between OSDI sub scores and DEQ showing significant correlations (Ocular symptom: 
R=0.49 to0.72; p<0.001; Vision related functions: R=0.24 to 0.52; p<0.05; 
Environmental triggers: R=0.33 to 0.50; p<0.001). 
 
Table 4-5: Correlation between OSDI total score and frequency of symptoms of dry 
eye (Questions 4 to 12 from DEQ) 
 
OSDI  Spearman R p value 
Discomfort 0.65 <0.0001 
Dryness 0.59 <0.0001 
Blurry vision 0.46 <0.0001 
Soreness 0.58 <0.0001 
Grittiness & scratchiness 0.53 <0.0001 
Foreign body sensation 0.45 <0.0001 
Burning and stinging 0.57 <0.0001 
Light sensitivity 0.52 <0.0001 




In this study the symptoms of dry eye were characterised in a group of PMW 
using validated questionnaires, namely the Allergan Ocular Surface Disease Index© 
(OSDI) Questionnaire and the Indiana Dry Eye Questionnaire (DEQ). 
As pointed out by Begley et al,9 clinicians often rely on symptoms alone to arrive 
at a diagnosis and treatment plan for dry eyed patients, without any sign of visible tissue 
damage.9 Population-based studies of the elderly have shown that the proportion 
identified by any clinical tests that reveal visible signs of tissue damage is far less than 
that revealed by patient reported dry eye symptoms.23  
Our attempt to classify participants as being symptomatic or asymptomatic of dry 
eye using an OSDI questionnaire was demonstrable, with statistically significant 
differences between the OSDI total score and sub scores (NDE =7.43 ± 7.71 vs DE = 
24.87 ± 13.89; p<0.001). Following grouping of the subjects based on the results from the 
OSDI questionnaire, subsequent completion and analysis of the DEQ revealed that >55% 
of the dry eyed PMW demonstrated symptoms of frequent to constant discomfort and 
47% complained of frequent to constant dryness symptoms. This is consistent with other 
studies performed previously using the DEQ in a non-Sjogren’s dry eyed group.9, 10, 36 
Other symptoms experienced by the dry eyed group, such as soreness, grittiness, visual 
changes and itchy eyes, showed a range of 11- 37% for frequent to constant symptoms. 
The diurnal shift in the intensity of symptoms in the dry eyed PMW was towards the 
higher side in the evening, as seen in Figures 4-4, 4-5 and 4-6. This is in agreement with 
previous studies using the DEQ, with a similar diurnal variation in Sjogren’s-related dry 
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eye, as well as contact lens wearers and non-Sjogren’s dry eye, with Sjogren’s related dry 
eye showing the maximum increase at the end of the day.9, 10, 36 
Many non dry-eyed PMW reported “never or infrequent” symptoms, but they 
rarely reported “frequent to constant” symptoms (Figure 4-1), nor did they report very 
“intense symptoms” (Figure 4-3). Some of the non dry-eyed PMW showed a trend of 
increasing symptoms of burning and itching towards the end of the day, but this was still 
not significant. This emphasizes the effect that the environment,36 workplace, and 
humidity may have on the tear film.37  
Over 32% of the symptomatic PMW reported the presence of symptoms 
“frequently”, which caused them to cease their activities. About 19% of the subjects 
complained that their eyes were bothered significantly several times during the week. The 
percentage of participants who reported their “eyes being bothered daily” and “several 
times daily” were 14% and 12% respectively. Even though 60% of the dry-eyed PMW 
used artificial tears regularly, only 5% of them reported that the drops provided a 
“complete cure”, suggesting that the 95% of PMW who use artificial tears experience 
only partial relief.  
The DEQ comprises a variety of symptom-based questions for a variety of ocular 
surface symptoms and their changing intensity over the course of the day. The Contact 
Lens DEQ, that was developed to study the dryness responses in contact lens wearers,38 
has a method/formula to obtain a total symptom score. Even though the DEQ is a long 
and extensive questionnaire and is one of the very few that can target any potential 
diurnal variation in symptoms, it lacks a scoring method to compute a final symptom 
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score, unlike the McMonnies4 or OSDI7 questionnaires. This remains one of the major 
disadvantages of using the DEQ in a clinical environment.  
Schiffman et al7 studied 109 cases with dry eye disease and 30 control subjects. 
The scores on both the OSDI and two other questionnaires (McMonnies Dry Eye 
Questionnaire and National Eye Institute Visual Functioning Questionnaire-NEI-VFQ) 
were compared, and a significant correlation was observed.7  Nichols et al have also 
shown significant correlations between the OSDI and NEI-VFQ.31 Similar results were 
demonstrated by Vitale et al.39  
In this study, when an attempt to correlate the OSDI (total score) versus the DEQ 
frequency scores was made, there was a significant correlation (R values 0.45 to 0.65; 
p<0.001).  The range of R values noticed in Table 4-5 may be due to the fact that the 
OSDI total score is a combination of questions related to ocular symptoms, vision related 
functions and environmental triggers. The end point is a combination of scores from 
different symptoms. This compares with the DEQ, which has 9 individual questions on 
symptoms targeted on dryness symptoms on a categorical scale. This emphasizes the fact 
that both surveys can be used for grouping individuals as dry eyed and non-dry eyed. 
They have certain questions in common; however, each questionnaire has its uniqueness.  
OSDI can be used to separate PMW who demonstrate symptoms of ocular dryness. In 
addition to a variety of dry eye symptom questions, the DEQ is a useful tool to study the 
diurnal variations in dry eye symptoms. 
Currently there is no internationally accepted criterion for the diagnosis of dry eye 
disease, but the OSDI is a standardized tool to evaluate symptoms, and can easily be 
performed and used to symptomatically diagnose dry eye.  It is suggested that symptoms 
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assessment should be included as an important part of the diagnostic assessment and 
management of dry eye patients, to determine their response to treatment.9  
4.7 Conclusion 
Participants categorized as being symptomatic of dry eye using OSDI also 
demonstrated higher frequency and worsening dry eye symptoms towards the end of the 
day.  Although dry eye disease lacks a strong correlation between objective tests and 
subjective symptoms, symptoms are an important aspect of dry eye disease. The need to 
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5 Clinical signs and symptoms in postmenopausal females 
with symptoms of dry eye 
Srinivasan S, Joyce E, Jones LW. Clinical signs and symptoms in postmenopausal 
females with symptoms of dry eye. Ophthalmic and Physiological Optics. In press. 
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5.1 Abstract 
Aim: To characterize clinical signs and symptoms in a group of postmenopausal women 
(PMW) who present with and without symptoms of dry eye. 
 
Methods: Eighty three healthy PMW were categorized as being symptomatic or 
asymptomatic of dry eye based on their response to the Allergan Ocular Surface Disease 
Index© (OSDI) questionnaire. Non invasive tear breakup time (NITBUT) was evaluated 
using the ALCON Eyemap®. Tear volume was assessed using the Phenol Red Thread 
(PRT) test and bulbar conjunctival hyperemia was measured using objective and 
subjective methods.      
      
Results: The total OSDI score (TOS) and sub scores for the (n= 39) Non Dry Eye (NDE) 
and (n= 44) Dry Eye (DE) groups were significantly different (TOS: NDE = 7.43 ± 7.71 
vs DE = 24.87 ± 13.89; p<0.001). The DE group exhibited a shorter NITBUT (5.3 ± 1.7 
vs 7.0 ± 2.7 secs; p=0.0012). Tear volume was lower for the DE group (19.3 ± 5.1mm vs. 
16.3 ± 5.6mm; p=0.031). Bulbar hyperemia was higher in the DE group for both 
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subjective techniques (48.4 ± 10.0 vs 40.6 ± 10.4; p=0.0011) and objective (u’ = 0.285 ± 
0.006 vs. 0.282 ± 0.006; p=0.005). 
 
Conclusions: OSDI can be used to separate PMW who demonstrate clinical signs of 
ocular dryness. PMW with dry eye symptoms demonstrate shorter NITBUT, lower tear 
volume and increased bulbar conjunctival hyperemia than those who have no symptoms.  
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5.2 Introduction 
The incidence and prevalence of dry eye increases with increasing age1 and the 
number of women affected with dry eye disease is higher than that found in men.1-3 The 
Women’s Health Study1 estimated that 3.2 million women aged over 50 suffer from 
moderate to severe forms of dry eye.4 
A reduction in sex hormones, such as androgens, occurs in both males and 
females with increasing age.5 The hormonal changes that accompany menopause can play 
an important role in the production of dry eye symptoms,4, 6, 7 and these symptoms may 
precede clinically observed ocular surface changes.8 In contrast, clinical signs may be 
observed by practitioners in the absence of patient reported symptoms of ocular dryness,8, 
9 and several studies have reported this clear lack of agreement between the signs and 
symptoms that occur in patients with dry eye disease.9-12 
The most recent definition proposed by the Dry Eye Workshop13 defines dry eye 
as a “multifactorial ocular surface disease diagnosed by symptoms of discomfort and 
signs of visual disturbance, tear film instability and ocular surface damage, accompanied 
by increased osmolarity of the tear film and ocular surface inflammation”.13 
When clinicians attempt to classify patients with signs and symptoms of dry eye, 
a wide battery of tests are available.14 Of these, a careful patient history and the use of 
validated dry eye questionnaires have been shown to be very useful in the diagnosis of 
dry eye.10, 15-20 In addition, assessments of tear stability and tear volume have also shown 
differences between those patients presenting with and without dryness symptoms.11, 14, 21-
24 Given that the most recent definition of dry eye suggests that ocular surface 
inflammation is also involved,13 then assessment of ocular surface hyperemia (redness), 
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which may act as a surrogate of mild inflammation, is also a variable worthy of study. 
However, to-date this latter issue of ocular surface hyperemia has not attracted much 
attention in the diagnosis of dry eye, despite the fact that it is a common complaint of 
those with irritated and uncomfortable eyes.10, 17, 25, 26 
To-date, the majority of studies investigating ocular dryness symptoms and/or 
signs in postmenopausal women (PMW) have focused on the impact of hormone 
replacement therapy (HRT) or other drugs associated with controlling complications 
associated with cessation of menses.27-35  The purpose of this study was to characterize a 
variety of clinical signs and symptoms in asymptomatic and symptomatic dry eyed PMW 
not on HRT, and to attempt to correlate these symptoms and signs.  
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5.3 Materials and Methods 
The protocol for this study was approved by the Office of Research Ethics at the 
University of Waterloo. Study participants were recruited at the Centre for Contact Lens 
Research at the School of Optometry. Informed consent was obtained from all 
participants after all the procedures had been explained. A case history and complete 
ocular surface examination was performed to determine participant eligibility. 
Participants who were currently taking HRT were excluded, due to the confounding 
results present in the literature on whether HRT is protective or exacerbates dry eye 
symptoms and signs.30, 31 Non-contact lens wearers and candidates with any form of 
systemic disease or those who were taking any systemic or topical medications were also 
excluded from the study. For the purpose of this study, “postmenopausal” was defined as 
no menses for at least one year, not associated with hysterectomy. This research study 
adhered to the tenets of the Declaration of Helsinki. 
Eighty three healthy PMW who were greater than 50 years of age were recruited 
in this study. Participants completed the Allergan Ocular Surface Disease Index© 
(OSDI)36, 37 and were categorized as being symptomatic or asymptomatic of dry eye 
based on their response to OSDI. The administration and scoring system for the OSDI 
has been described in detail elsewhere.36, 37  Broadly, the OSDI is a questionnaire that 
includes 12 questions, which are subdivided into three groups: ocular symptoms, vision 
related functions and environmental factors. The OSDI scoring is based on a 0-100 scale, 
with the highest score representing greater disability. The OSDI questionnaire is graded 
on a scale from 0 to 4, where 0 indicates none of the time; 1, some of the time; 2, half of 
the time; 3, most of the time; and 4, all of the time. The following formula is used to find 
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the total OSDI score:  OSDI = [(sum of scores for all questions answered) × 100] / [(total 
number of questions answered) × 4]. The OSDI scores and sub-scores for the two groups 
were then recorded and compared.  An OSDI score of 0-12 represents NDE; an OSDI 
score of 13-22 is categorized as mild DE and an OSDI score of 23-32 represents 
moderate dry eye.36, 37 
One observer, who was masked with respect to whether the subjects were 
considered dry-eyed or not, was responsible for collecting all the data. Clinical tests were 
undertaken in the following order. Tear stability was assessed by performing a non 
invasive tear breakup time (NITBUT) evaluation using the ALCON Eyemap® model 
EH-290 topography system (ALCON, Inc., Forth Worth, Texas, USA). The keratoscope 
unit produces concentric rings of light, which are reflected off the cornea and imaged in 
the CCD camera. Participants were comfortably seated with their head supported by a 
forehead and chin rest and looked at a fixation light at the centre of the concentric rings 
of light. Participants were asked to blink 3 times before each measurement was taken. 
NITBUT was measured by measuring the time taken for distortions or discontinuities to 
appear in the reflected image of the concentric ring pattern. The time (in seconds) for the 
tear-film to rupture (and thus distort the rings) was measured using a stopwatch, to the 
nearest 0.1 of a second.  Three measurements were taken in each eye and the average of 
these was used for analysis purposes. 
Tear volume was assessed using the Phenol Red Thread (PRT) test (ZONE-
QUICK, Showa Yakuhin Kako Co., Ltd. Tokyo, Japan). The PRT was placed at a point 
approximately 1/3 of the distance from the lateral canthus of the lower eyelid with the 
eye in primary position, as previously reported.38 The lower lid was pulled down gently, 
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and the folded 3mm portion of the thread was placed on the palpebral conjunctiva at the 
position specified. Each eye was tested with the subjects’ eyes open for 15 seconds. 
During the test the patients were instructed to look straight ahead and blink normally. 
After 15 seconds, the lower lid was gently pulled down, and the thread was gently 
removed with an upward motion. Care was taken to pull the eyelid down before removal 
of the thread to avoid discomfort. The length of the color change on the thread, which 
indicates the wetting length, was measured immediately in millimeters from the very tip 
regardless of the fold. No topical anesthetic was used. A stop watch was used to measure 
the time.  
 Bulbar conjunctival hyperemia was assessed using both subjective and objective 
methods. The slit lamp was used to subjectively grade the level of temporal bulbar 
conjunctival hyperemia using a modified CCLRU scale, which uses a 0-100 scale (0 – 
negligible, 25 - trace 50 - mild 75 – moderate, 100 – severe).39-41  The subjects were 
comfortably seated at the slit lamp and the position of gaze was directed to allow grading 
of hyperemia on the temporal bulbar conjunctiva of both eyes. Hyperemia was assessed 
under diffuse white light with 16X magnification. Mean value (left and right eye) was 
recorded for use in subsequent analysis.  
 Objective bulbar redness was undertaken using a SpectraScan PR650© 
Spectrophotometer (Photo Research Inc, Chatsworth, CA) under controlled illumination. 
It is a table top device that determines measurements of luminance and chromaticity by 
measuring the absolute intensity at each wavelength and then calculating the equivalent 
CIE u’ value.39, 42 The subject sat at the photometer and looked at a fixation light to their 
left or to the right, such that the temporal conjunctiva was aligned with the instrument. 
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The examiner looked through the eye piece and positioned the black measuring spot 
(approximately 19.63 mm2) of the photometer approximately 2 mm from the temporal 
limbus on the temporal bulbar conjunctiva. The spectrophotometer was turned on just 
before the measurement and turned off immediately after, to ensure that the ocular 
surface temperature did not increase and changes in ocular surface hyperemia were 
minimized. Redness was measured three times on both eyes. Mean value (left and right 
eye) was recorded for use in subsequent analysis.  
Corneal and conjunctival staining could not be performed as a part of this study 
due to the nature of the study design, which included collection of tears and conjunctival 
impression cytology samples for subsequent biomarker analysis (reported in later 
chapters). The addition of fluorescein and/or other vital dyes would affect the subsequent 
analysis of the biomarkers and was thus not undertaken.  
5.4 Statistical analysis 
 Statistical analysis was performed using Statistica Ver7.1 (StatSoft Inc., Tulsa, 
OK, USA). NITBUT, PRT values, subjective and objective bulbar hyperemia and OSDI 
scores were compared using Mann Whitney U test. Correlations were undertaken using a 




All data are expressed as means ± standard deviation. The mean age of the 
participants was 63.6 ± 9.4 yrs in the symptomatic group (n=44) and 59.5 ± 6.6 yrs in the 
asymptomatic group (n=39). Of the 83 participants enrolled, only one participant reported 
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severe dry eye symptoms and was thus excluded from this analysis, resulting in 43 
participants in the dry eye group (mild = 16, moderate = 27).  
 
Table 5-1 details the OSDI total score and sub scores for both groups, with the 
symptomatic dry eye (DE) group being subdivided by their severity of symptoms. The 
total and sub-scores for the DE group overall were significantly greater than the 
asymptomatic non dry eye (NDE) group (p<0.001).  
 
 




























Total Score 7.43 ± 7.71 24.87 ± 13.89 <0.001* 18.37 ± 9.29 
28.31 ± 
13.02 <0.001* <0.001* 0.01* 
Ocular  Symptoms 7.56 ± 8.42 23.98 ± 19.21 <0.001* 17.35 ± 13.59 
26.73 ± 
24.49 0.002* <0.001* 0.10 
Vision Related 
Functions 7.05 ± 12.18 
17.19 ± 
16.42 0.002* 8.33 ± 7.21 
22.20 ± 
21.42 0.11 <0.001* 0.003* 
Environmental 
Triggers 8.22 ± 12.29 
34.09 ± 
25.97 <0.001* 30.39 ± 21.02 
36.86 ± 
27.21 <0.001* <0.001* 0.68 
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 A summary of the clinical measures is reported in Table 5-2. The DE group 
exhibited a shorter NITBUT and lower tear volume than the NDE group. The DE group 
had slightly increased levels of bulbar hyperemia assessed both subjectively and 
objectively, when compared with the NDE group. When the DE group was broken down 
into mild and moderate subgroups, no significant differences were found in the NITBUT, 
PRT and conjunctival bulbar redness between NDE and the mild DE group. Comparison 
of clinical data between mild and moderate sub groups also showed no statistically 
significant differences. However, all the clinical measures showed a significant difference 
between the NDE and moderate DE group (p<0.05), as described in Table 5-2.  
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P (α =0.05) 
(NDE vs DE) 
Mild DE Moderate DE 
p (α =0.05) 
(NDE vs Mild) 
p (α =0.05) 
(NDE vs 
Moderate) 
p (α =0.05) 
(Mild vs 
Moderate) 
NITBUT (seconds) 7.0 ± 2.7 5.3 ± 1.7 0.0012* 5.7 ± 1.9 5.1 ± 1.2 0.105 0.002* 0.31 








0.282 ± .006 0.285 ± 0.006 0.005* 0.284 ± 0.005 0.286 ± 0.005 0.126 0.013* 0.221 
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 Spearman correlations between the clinical signs and total OSDI scores were 
weak (0.341 to -0.293). Statistically significant correlations (p<0.05) were found for three 
of the clinical measures (NITBUT r = -0.293; subjective redness r = 0.341; objective 
redness r = 0.278). The exception to this was PRT, which showed no statistically 
significant correlation (r = -0.117; p>0.05). Correlations between subjective and objective 
redness were also significant (r = 0.660; p< 0.001). Correlations between clinical signs 
with OSDI sub scores were also weak (0.10 to 0.282). 
 
5.6 Discussion  
In this study, we attempted to characterize and compare clinical signs and 
symptoms in two groups of PMW. A validated questionnaire was used as a tool to 
categorize these females into dry eyed and non dry eyed individuals and NITBUT, PRT 
and bulbar conjunctival redness measurements were undertaken and compared in these 
two groups.  
A very recent study34 has evaluated the effect of HRT on dry eye in PMW, 
comparing the results to forty age-matched untreated women, who acted as controls. To 
our knowledge, the study we are reporting here is the first that has studied clinical signs 
(including subjective and objective redness measurements) and symptoms in PMW who 
are not on HRT.  HRT usage has shown confounding results29, 32 in terms of exacerbation 
of dry eye disease.34 Use of estrogen alone has shown an increase in the prevalence of dry 
eye,28 as opposed to estrogen combined with progesterone.28, 31, 33 This is a major reason 
why we decided to exclude subjects who were taking HRT from this study.   
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The OSDI questionnaire measures the severity of dry eye disease based on 
symptoms, functional changes and environmental triggers.36, 37  Analysis of Table 5-1 
shows the utility of using OSDI to categorise PMW with and without symptoms of dry 
eye and the ability of OSDI to subcategorise those with mild and moderate symptoms. 
Using this questionnaire, the majority of the symptomatic group was categorized as 
having “moderate” symptoms. Based on severity of symptoms, the symptomatic group 
with moderate dry eye symptoms showed significantly higher total scores and sub-scores 
in relation to NDE participants. The participants who had mild dry eye symptoms also 
showed higher scores when compared to NDE. The exception to this trend was vision 
related functions, which showed no statistically significant difference. 
A stable and structurally intact tear film is essential for a smooth ocular surface. 
One of the tear stability tests suggested in the DEWS diagnostic methodology14 and 
earlier studies43-45 is non invasive tear film break up time (NITBUT). This test is 
repeatable,43-45 sensitive14, 46 and provides an accurate measurement to differentiate 
between symptomatic and asymptomatic dry eyed individuals.21, 26 14 Our data supports 
the fact that NITBUT is a clinical test that can differentiate between two populations with 
and without symptoms of dry eye, as shown in Table 5-2.  The results from our study 
clearly demonstrate that the dry eye group had poor tear film stability. This could be due 
to multiple factors, including a deficiency or abnormality of any of the components of the 
tear film.47 Aging is associated with significant sex-related alterations in the polar and 
neutral lipid profiles of human meibomian gland secretions.5 Studies have shown that the 
meibomian gland is an androgen target organ and deficiency of androgen may promote 
meibomian gland dysfunction and tear film instability and dry eye, and androgen 
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deficiency may be an important etiologic factor in the pathogenesis of evaporative dry 
eye in women with Sjogrens syndrome.5, 48-51  Our values are comparable to a recently 
published study.34 
The Schirmer Test has long been considered the “gold standard” method to 
evaluate tear film volume and production. However, it has some significant 
disadvantages due to its ability to stimulate tear production. In order to overcome the 
inherent difficulties and disadvantages of the Schirmer test21, 52, the less “invasive” 
phenol red thread (PRT) test was developed.53 The PRT test time is significantly lower 
than that required for the Schirmer test, at only 15 seconds, and the discomfort level is 
minimal, resulting in less reflex tear production54 and this was the test used in our study. 
The exact parameter of the tears that is measured by the PRT test is open to debate. 
Sakamoto and co-workers suggested that PRT measures the volume of the residual tear 
film in the inferior conjunctival sac.55 Other studies have shown that the PRT test 
estimates the presence and magnitude of the tear volume, rather than production rate 
itself.56 A recent study by Tomlinson and colleagues57 reported that the PRT test 
demonstrates different absorption characteristics of the thread, based on the biophysics or 
composition of tears, which allows the differentiation between dry eye and normal 
subjects. Studies that have compared the Schirmers test and PRT have shown a weak 
agreement between the tests.11, 24, 43, 54 This is possibly because each test measures 
different aspects of the tear film.54 Studies have also shown that the agreement between 
the symptoms as measured by the validated questionnaire and either test were poor for all 
the cutoff values used.54, 58, 59 Regardless of what PRT test measure, the results from this 
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study demonstrated significantly lower PRT values in the DE group in comparison with 
the NDE group, as shown in Table 5-2.  
Recently, we have reported poor tear ferning patterns and increased osmolality in 
tears collected from PMW with mild to moderate forms of dry eye (chapter 6),12 
emphasizing the fact that the composition of the tear film does appear to be different in 
DE and NDE PMW. An evaluation of our PRT data does indicate that the values reported 
are higher than those anticipated, with the values for DE group being higher than the cut 
off 9mm53 and 10mm43 that have been proposed by previous authors. However, the 
suggestion of a cut off value comes from a study that included a population with a wide 
age range and both genders,53, 55 which is quite different to this study, which includes 
only older female subjects.  To our knowledge, no PRT cut off value has been proposed 
for older age groups alone. As one would expect, age typically results in reduced tear 
volume.60, 61  However, a recent study has shown that older individuals tend to exhibit a 
higher tear meniscus height (and hence tear volume), due to age-related constriction of 
the puncta, resulting in limited drainage of tears from the ocular surface.62 Thus, it is 
entirely feasible that our PRT data for our older group of PMW is appropriate, potentially 
due, in part, to punctal stenosis. However, this requires further investigation. 
The recent acceptance of the fact that many dry eye conditions are related to 
increased inflammation13 led us to measure the levels of bulbar conjunctival redness of 
our subjects, which is one of the most common symptoms reported by individuals who 
are symptomatic of dry eye25, 43 and could be considered to be a potential surrogate of 
ocular inflammation. The results from this study show increased levels of bulbar 
conjunctival hyperemia in the symptomatic group, by both objective and subjective 
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methods (Table 5-2). The two methods of assessing bulbar redness were strongly 
correlated (r = 0.660; p< 0.001), demonstrating the utility of using objective redness 
assessments. These results corroborate others from our group from a different patient 
population39 and show that objective redness assessments could be useful in multi-site 
clinical studies, where subjective redness assessments could exhibit significant inter-
observer variability. One potential reason for increased bulbar hyperemia could be sub-
clinical inflammation. This could be driven by multiple factors, including hormones, 
changes to the composition or quality of the tear film, environmental effects or 
inflammatory mediators (for example, cytokines) in the tear film. Further study is 
required to investigate and understand the physiology and mechanisms driving the 
increased hyperemia in dry eyed PMW. 
5.7 Conclusion 
PMW who are categorized as being symptomatic of dry eye show variable 
symptoms of ocular irritation when compared with a group of asymptomatic subjects. 
Participants symptomatic of dry eye exhibited shorter NITBUT and PRT values than an 
asymptomatic control group. In addition, greater levels of bulbar conjunctival hyperemia 
were observed (when measured both objectively and subjectively) in the symptomatic 
PMW, emphasizing the link between ocular surface redness and dryness. Correlations 
between most of the clinical signs measured and symptoms were weak, yet statistically 
significant.   
Dry eye questionnaires such as OSDI can be used as an effective tool in 
categorizing subjects based on their severity of symptoms. PMW present a significant 
group of subjects with symptoms and signs of dry eye. They represent an ideal group of 
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individuals to study dry eye treatment and new therapies, including anti-inflammatory 
and decongestive agents. The majority of the subjects in the dry eyed group reported 
moderate symptoms of dryness and further studies are required to investigate more severe 
dry eye groups and also understand the changes to the ocular surface at the cellular level.  
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6 Tear osmolality and ferning patterns in postmenopausal 
women 
Originally published as: Srinivasan S, Joyce E, Jones LW. Tear osmolality 
and ferning patterns in postmenopausal women. Optom Vis Sci 2007;84:588-92. 
(c) The American Academy of Optometry, 2007. 
 
6.1 Abstract 
Purpose: To compare tear osmolality and ferning patterns in postmenopausal women 
(PMW) with and without dry eye symptoms.  
 
Methods: Thirty-seven healthy PMW (>50 years of age), not on hormone replacement 
therapy, were categorized as being symptomatic or asymptomatic of dry eye based on 
their responses to an Allergan "Single-Item Score Dry Eye Questionnaire" (SIDEQ). 
They subsequently completed the Allergan "Ocular Surface Disease Index" (OSDI) 
questionnaire. Tear samples were collected from participants to evaluate osmolality and 
ferning patterns. A novel freezing point depression osmometer (Advanced Instruments 
Inc., Model 3100 Tear Osmometer), was used to measure the osmolality of the tear film. 
The tear ferning test was performed and evaluated for the quality of ferning based on the 
Rolando grading system.  
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Results: SIDEQ responses revealed 21 symptomatic and 16 asymptomatic participants. 
The OSDI total score was 6.5 +/- 5.9 for the non-dry-eyed (NDE) group and 25.7 +/- 12.4 
for the dry-eyed (DE) group. The subscores for the DE group were significantly greater 
than the NDE group (p < 0.001). Osmolality values in DE individuals were significantly 
different from NDE (328.1 +/- 20.8 vs. 315.1 +/- 11.3 mOsm/kg; p = 0.02). Fifty percent 
of the DE participants showed type II ferning patterns and 29% of the DE participants 
showed type III ferning patterns, whereas the NDE participants showed either type I 
(44%) or II (66%) ferning patterns. There was a significant difference between the DE 
and NDE participants for the ferning patterns (p = 0.019). There was no significant 
correlation between tear osmolality and tear ferning (DE: r = 0.12; p > 0.05, NDE: r = -
0.17; p > 0.05).  
 
Conclusions: Osmolality in mild and moderately DE PMW is higher than in NDE PMW 
and tear ferning is a rapid, simple, noninvasive laboratory procedure that indicates altered 
tear quality in PMW with symptoms of dry eye. 
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6.2 Introduction 
Dry eye can be broadly defined as any tear film anomaly that can interfere with 
normal ocular surface physiology.1 There is an increased incidence and prevalence of dry 
eye among the elderly,2 especially women aged 50 years and over,3 which may affect 
their quality of life.4 Menopause plays an important role in causing symptoms of dry eye 
syndrome (DES).5, 6 To accurately diagnose patients with DES requires a suitable 
combination of patient symptoms and clinical signs.7 The use of different dry eye 
questionnaires and a careful patient history have proved to be very useful in the 
assessment of dry eye.8 However, several reports show that a poor correlation exists 
between the symptoms and signs of dry eye.9-13  
A clinical test that has been suggested as being highly diagnostic involves 
measuring tear film osmolality.14 This is often considered a “gold standard” in the 
evaluation of subjects with dry eye,14-16 due to the hypertonic tear film found in dry eyed 
individuals. 1, 17-20 A hypertonic tear film causes ocular surface damage and may lead to 
discomfort.1, 18, 19 Osmolality is a function of tear secretion, drainage, absorption and 
evaporation and can be regarded as a single parameter of tear film dynamics.14 Even 
though tear osmolality has been considered the “gold standard” for diagnosing DES, it is 
not widely used clinically due to the lack of available equipment and the fact that most 
osmometers require a large volume of tears (typically 5-10µl),8, 21 which limits its use in 
many dry eye subjects, particularly those with severe disease.21, 22  
Measuring tear film osmolality is often undertaken using a freezing point 
depression method,14 typically using the Clifton instrument.16-20, 23, 24 However, this 
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instrument requires considerable expertise, is time consuming and the equipment is 
difficult to maintain.16, 21, 22  Recently, two new osmometers have become available that 
use micro-volumes (<1µl) that make them ideally suited for use in dry eye research.25, 26  
We have recently reported on the use of a micro-volume freezing point depression 
instrument (Model 3100 Tear Osmometer; Advanced Instruments, Inc. Norwood, MA, 
USA), which is rapid and easy to use.26 
Another test that has been reported to differ between dry-eyed and non dry-eyed 
individuals is the Tear Ferning Test (TFT). Tear fluid, when dried on a microscope slide, 
produces a specific “ferning pattern”, which is believed to be due to an interaction 
between various electrolytes in the tears and macro-molecules such as proteins.27 An 
increased salt concentration in tears (as occurs in hyperosmotic tears) and other changes 
in tear composition may cause an alteration in the ferning patterns observed.28 Studies 
have shown that an alteration in tear ferning patterns occurs in dry eyed individuals and 
subjects aged over 40,29 with a tendency for “less” ferning to be observed. 
The purpose of this study was to determine tear osmolality and tear ferning patterns 
in a group of postmenopausal women (PMW) with and without symptoms of dry eye and 






6.3 Materials and Methods 
The protocol for this study was approved by the Office of Research Ethics at the 
University of Waterloo. Study participants were recruited at the Centre for Contact Lens 
Research, School of Optometry. A case history and complete ocular surface examination 
was performed to determine participant eligibility. Informed consent was obtained from 
all participants after all the procedures had been explained. We excluded participants who 
were on Hormone Replacement Therapy (HRT) due to the confounding results present in 
the literature on whether HRT is protective or exacerbates dry eye symptoms and signs.30, 
31 Contact lens wearers and candidates with any major systemic disease or using any 
systemic or topical medications that may affect ocular health were also excluded from the 
study. 
Thirty seven healthy PMW over 50 years of age were recruited in this study. 
Participants were categorized as being symptomatic or asymptomatic of dry eye based on 
their responses to a Single-Item Score Dry Eye Questionnaire (SIDEQ).32 The SIDEQ 
self assessment questionnaire32 assessed the subjects’ ocular discomfort due to symptom 
of dryness on a 0-4 scale, ranging from “none” to “severe”. Participants who reported 
“none” or “trace” symptoms were grouped in the non-dry eyed (NDE) group and the 
remainder were grouped into the dry eyed (DE) group. They subsequently completed the 
Allergan Ocular Surface Disease Index©33 (OSDI) questionnaire. The administration and 
scoring system for the OSDI questionnaire has been described in detail elsewhere.33 
Broadly, the OSDI scoring is based on a 0-100 scale, with the highest score representing 
greater disability.33 The OSDI scores for the two groups (which were derived using the 
SIDEQ questionnaire) were then recorded and compared.   
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6.3.1 Osmometry 
Tear samples were collected from all participants between 9 AM and 11 AM to 
evaluate osmolality and ferning patterns. Approximately 2 µl of tears were collected from 
the inferior tear meniscus of the right eye of each subject using a single-use, graduated, 
disposable, sterile, smoothly polished, fine glass capillary tube (Wiretol-Micropipettes, 
Drummond Scientific Co., Broomall, PA, USA), as carefully as possible to reduce reflex 
tearing, at a slit lamp biomicroscope. The time taken to collect the sample was less than 
one minute, with most dry-eyed participants typically taking longer than the non dry-eyed 
subjects. This sample was then carefully transferred to an eppendorf tube for use in both 
the osmometer and the ferning test.  Firstly, approximately 0.5 µl of these tears were 
transferred to a single-use, disposable polycarbonate capillary tube to load the sample 
into a novel freezing point depression osmometer (Model 3100 Tear Osmometer; 
Advanced Instruments, Inc. Norwood, MA, USA). Figure 6-1 represents typical crystal 
patterns before and during the freezing procedure. Tear samples varied in their time to 






Figure 6-1: Tear film samples in the Model 3100 Tear Osmometer 
 The image on the left represents tear samples before freezing and the image on the right 
represents tear samples during the melting phase 
 
6.3.2 Tear ferning 
 This method of collection allows a standard volume of tears to be collected and 
has also shown to result in reproducible ferning patterns.34 Approximately 0.5 ul of tears 
was carefully pipetted out from the eppendorf and TFT was performed by dropping 0.5µl 
of the tear sample onto a clean glass microscope slide, which was allowed to dry at room 
temperature and evaluated at 10X magnification on a light microscope. The quality of 
ferning observed was based on the Rolando grading system,35 which grades the ferning 
patterns from grades 1 (abundant ferning) through to grade 4 (no ferns). Photographs 
were taken immediately after drying to avoid misinterpretation in grading due to 
alterations in the ferning patterns, which may arise due to humidity and temperature 
changes in the environment.27  
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6.3.3 Statistical analysis 
Statistical analysis was performed using Statistica Ver7.1 (StatSoft Inc., Tulsa, OK, 
USA). Differences in ferning patterns between the groups were determined using the 
Mann Whitney U test and osmolality values and OSDI scores were compared using a 
unpaired Student-t test. Correlations were undertaken using a Spearman rank correlation. 
A p value of less than 0.05 was considered to be statistically significant.  
 
6.4 Results 
The SIDEQ responses revealed 21 symptomatic (66.3 ± 9.8 yrs) and 16 
asymptomatic (58.7 ± 5.7 yrs) participants. Figure 6-2 reports the total and sub-scores for 
the OSDI questionnaire. The OSDI total score was significantly different between the two 
groups (NDE 6.5 ± 5.9 vs DE 25.7 ± 12.4; p<0.001). All three OSDI sub-scores were also 
significantly different between the symptomatic and asymptomatic groups, with higher 





Figure 6-2: OSDI Questionnaire: Graph representing the total score, ocular 
symptoms, vision related, and environmental factors 
The OSDI total score was significantly different between the two groups (NDE 6.5 ± 5.9 vs DE 
25.7 ± 12.4; p<0.001. The error bars represents standard deviation) All three OSDI sub-scores 
were also significantly different between the symptomatic and asymptomatic groups, with higher 
scores for all three subcategories for the dry-eyed subjects (p<0.001).  
 
Figure 6-3: Osmolality in dry eyed (DE) and non dry eyed (NDE) participants 
 The mean osmolality values in the DE group was higher than that in the NDE group (328.1 ± 
20.8 vs 315.1 ± 11.3 mOsm; p=0.02. The error bars represents standard deviation) 
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When ferning patterns were graded using the Rolando grading system, the 
majority of the symptomatic candidates showed type II ferning patterns (50%), while all 
of the asymptomatic participants showed either type I (44%) or type II (56%) ferning 
patterns (p=0.019) (Table 6-1). Typical ferning patterns seen are shown in Figures 6-4a-
d.  
Table 6-1: Represents the percentage distribution of dry eyed and non dry eyed 
participants showing ferning patterns (grade I to IV) 
 
Ferning Grade % of dry eyed participants showing ferning pattern 
% of non-dry eyed participants 
showing  ferning pattern 
I 14 44 
II 50 56 
III 29 0 







       
       
Figure 6-4: Tear ferning patterns in postmenopausal women  
a) grade1 (uniform, abundant ferning, with no spaces between ferning); b) grade 2 (abundant 
ferning, with some empty spaces between ferning; c) grade 3 (partial ferning, with large empty 
spaces between ferning); d) grade 4 (absence of ferning) 
 
 
When an attempt was made to correlate osmolality with ferning patterns, no 
significant correlation was found (DE: r=0.12; p>0.05, NDE: r=-0.17; p>0.05). There was 
also no significant correlation found between OSDI scores with osmolality (DE: r=0.40; 








In this study, two groups of PMW were evaluated for tear osmolality using a new 
nanolitre osmometer that employs the freezing point depression technique. Tear ferning 
patterns of these individuals were also evaluated and classified based on the Rolando 
grading system. 
Our results for tear osmolality are in accordance with studies previously 
undertaken. Reports have suggested that the average tear film osmolality values for non 
dry-eyed individuals assessed using the freezing point depression osmometry and vapor 
pressure osmolality is 302 ± 9.7 mOsm/Kg, with a range of 283 – 318 mOsm/Kg.36 Large 
variations have been recorded in the osmolality values for dry-eyed individuals, with a 
mean value of 326 ± 22.1 mOsm/Kg and a range from 314 – 365 mOsm/Kg.36 This same 
study, based on a meta analysis on published data in determining referent values for 
diagnosis of dry eye, has shown the cut off value to be 315.6 mOsm/Kg.36 Our results 
showed a similar trend, with higher values for the dry-eyed participants (328.1 vs 315.1), 
with our mean for non dry-eyed osmolality being slightly higher than the mean reported 
by Tomlinson et al.36 This could be due to the fact that the tear production, flow and 
volume reduce with older age,37, 38 hence causing an increase in the solutes present in the 
tears and thereby increasing tear osmolality. In this study, all participants were older than 
50 years of age and thus a slightly higher than normal osmolality would be expected. 
However, to-date normal referent values for varying age groups does not exist and this 
warrants further study.  
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 Most of the asymptomatic candidates in this study did not only fall into the 
ferning grade I category, which re-emphasizes the fact that there is a tendency towards 
less ferning in people aged over 40 years of age, regardless of their symptoms.29 There 
was no significant correlation between OSDI score and ferning grade, indicating that 
mild to moderate forms of dry eye show varying ferning grades. However, we were able 
to demonstrate a significant overall difference between the two groups, suggesting that 
“extremes” do show differences, with a general movement from grade I to grade IV as 
the symptoms increase. Tear ferning is a non-invasive laboratory technique that can be 
performed in a clinical as well as research set up. However, care must be taken to 
maintain the room temperature and humidity levels while drying the tear drop on the 
glass slide, as this process can be greatly affected by environmental factors.27 This must 
be ensured, especially when diurnal variation studies to study ferning patterns are being 
undertaken.  
 A previous study39 was not able to show any significant correlation between 
dryness symptoms and tear ferning patterns, whereas they were able to show a correlation 
between impression cytology and symptoms. Previous studies have shown that dryness 
and ferning patterns are related,29, 40 which is supportive of our findings, which indicate 
that subjects with symptoms of dry eye show poorer ferning patterns. 
 Our data were unable to show a significant correlation between tear osmolality 
and ferning patterns. The spread of the data clearly shows that not all the participants who 
reported with higher osmolality values had poor ferning patterns. This is the first paper 
that we are aware of that has addressed this issue in human subjects, particularly PMW 
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and these data suggest that the factors that produce alterations in osmolality and ferning 
are independent of each other. 
6.6 Conclusion 
  Dry eye is a common ocular surface disorder with diverse etiology.41 A novel 
nanolitre osmometer, which requires <1 µl of tears, is a useful tool to determine tear film 
osmolality. Tremendous improvements and refinements have been made to measure 
osmolality in a very quick and reliable manner, which can be used as a simple clinical 
test for assessment of DES. Tear ferning is a rapid, simple, non-invasive laboratory 
procedure that indicates the altered tear quality in dry eye conditions and can provide 
valuable additional data in the diagnosis of subjects with DES. Further research is 
required to study the tear film osmolality and ferning patterns on severe dry eyed groups 
and the effects of diurnal variation, in addition to studies to determine appropriate 
referent osmolality values for differing age groups. 
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7 Tear Lipocalin and Lysozyme Concentrations in 
Postmenopausal Women 
Srinivasan S, Joyce E, Boone A, Simpson T, Jones L, Senchyna M. Tear lipocalin and 




Purpose: To investigate the potential relationship between subjective symptoms, tear 
volume, and tear break up time with tear film lipocalin and lysozyme concentrations in a 
group of symptomatic dry-eyed postmenopausal women (PMW), compared to 
asymptomatic controls. 
 
Methods: Eighty five healthy PMW (>50 years of age) were categorized as mild or 
moderate dry eye (DE), or asymptomatic (no symptoms of dry eye (NDE) based on their 
responses to the OSDI© questionnaire. Non invasive tear breakup time (NITBUT) and 
tear secretion were measured. Tears were collected via capillary tube and an eye wash 
method. Tear lysozyme and lipocalin concentrations were determined via Western 
blotting.    
 
Results: OSDI responses revealed 16 mild DE, 30 moderate DE, and 39 NDE. The OSDI 
total score as well as the sub scores for the DE groups were significantly greater than the 
NDE group (p<0.001). The mild and moderate DE groups exhibited significantly shorter 
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NITBUTs compared to NDE (p<0.004). Tear secretion using PRT test was found to be 
significantly lower in the moderate DE group compared to NDE (p <0.001). No 
difference in tear lysozyme or lipocalin concentration was found between DE and NDE 
groups, irrespective of tear collection method, although method of collection significantly 
influenced absolute concentrations (p<0.008). Significant correlations were not found 
between symptoms or signs of dry eye compared to either lipocalin or lysozyme 
concentration. 
 
Conclusion: Our data clearly demonstrated a lower NITBUT and tear secretion in DE 
individuals compared to NDE. No difference was found in tear film lipocalin or lysozyme 
concentration between DE and NDE individuals, irrespective of tear collection method. 
Comparison of clinical data with lipocalin and lysozyme concentrations failed to reveal 
statistically significant correlations.  
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7.2 Introduction 
Due to the efforts of the 2007 Report of the International Dry Eye Workshop 
(DEWS), dry eye is defined as “a multifactorial disease of the tears and ocular surface 
that results in symptoms of discomfort, visual disturbance, and tear film instability with 
potential damage to the ocular surface”.1 It is estimated that 5% to over 35% of the 
population at various ages are affected by dry eye.2 Data from large epidemiological 
studies of dry eye (the Women’s Health Study3 and the Physicians Health Study4), clearly 
suggest that the prevalence of dry eye is greater in women than in men, and that 
approximately 3.2 million women and 1.6 million men aged 50 years or older suffer from 
moderate to severe dry eye. Identifying risk factors for dry eye is complicated, in part, 
due to the multi-etiological nature of dry eye. Evidence does suggest that hormonal 
status, and in particular sex steroids, play a role in ocular surface homeostasis and 
function. Not only is dry eye associated with menopause but also menopausal hormone 
therapy increases the prevalence of dry eye over menopausal women not receiving 
therapy.1 
Diagnosis of dry eye is currently based on clinical findings, in particular tear-film 
break-up time, tear secretion or volume, ocular surface staining and patient symptoms.5-7 
However, several studies have reported very poor correlations between the classical signs 
and symptoms of dry eye,8-12 in addition to poor test reproducibility.13 This poor 
correlation may in part be due to the lack of understanding of symptoms and how they 
relate to test results.13-15 However, other contributing factors may be the multi-etiological 
nature of dry eye, as well as a lack of standardization of diagnostic tests and symptom 
questionnaires.6 Due to these issues, an enhanced biochemical understanding of the 
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pathophysiological / biochemical processes underlying dry eye would enable both the 
proper utilization and continued development of specific and sensitive diagnostic tests to 
facilitate objective reproducible and standardized diagnostic tests and methods to 
evaluate treatment efficacy. 
The tear film, which is a critical component of the ocular surface function unit, is a 
dynamic entity. The production and turnover of tears complete in mucins, proteins, lipids, 
lipoproteins, glycolipids and aqueous is essential to providing the ocular surface with 
microbiological protection, nutrition, lubrication and cleansing as well as maintenance of 
visual acuity. Based on our current understanding, alterations in volume and/or 
composition of the tear film can lead to reduced stability and function and as a 
consequence manifest as dry eye disease.16  
Alteration in expression of numerous proteins, lipids, mucins, inflammatory 
cytokines, matrix metalloproteases and growth factors have been implicated in dry eye.16-
24 However, there is little information characterizing changes in tear film composition 
and how such putative biochemical changes relate to tear function and/or signs and 
symptoms of dry eye. Of the data that does exist, reductions in tear film proteins such as 
lysozyme, lipocalin and lactoferrin have been described as markers of ocular surface 
disorders such as dry eye, conjunctivitis and blepharitis.25-30 Lipocalin and lysozyme are 
particularly abundant in the complete tear film, where they assume numerous key 
functional and protective roles. Approximately one third of the protein content of the 
tears is made up of lipocalins,31-35 which are members of the lipid binding protein super-
family. Tear lipocalins bind and transport phospholipids, fatty acids, cholesterol, retinol 
and tocopherol, scavenge  lipid products of inflammation and possess antimicrobial 
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activity.31, 36-38 Lysozyme, which accounts for 20-40%33, 39, 40 of total tear protein is best  
known for its anti-microbial activity.35, 39, 41  
To date, no comprehensive study has been performed to assess tear film lysozyme 
or lipocalin concentration in postmenopausal women (PMW). Thus, the purpose of this 
study was to investigate the potential relationship between subjective symptoms, tear 
secretion and tear break up time with tear film lipocalin and lysozyme concentrations in a 
group of symptomatic dry-eyed PMW, compared to asymptomatic controls to gain 
insight into potential clinical – biochemical relationships and gauge the utility of these 




Approval of this project was granted through the Office of Research Ethics at the 
University of Waterloo and all procedures adhered to the tenets of the Declaration of 
Helsinki. Participants were recruited at the Centre for Contact Lens Research, University 
of Waterloo, School of Optometry. Informed consent was obtained from all participants 
following explanation of purpose and procedures. A case history and complete ocular 
surface examination was performed to determine participant eligibility. Participants on 
hormone replacement therapy (HRT) were excluded, as were contact lens wearers and 
participants receiving any topical ocular medication or systemic medication known to 
exacerbate dry eye. Participants with history of blepharitis and/or active blepharitis were 
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also excluded from the study. For the purpose of this study, “postmenopausal” was 
defined as no menses for at least one year, not associated with hysterectomy.  
7.3.2 Subjective symptoms 
Eighty five healthy PMW (>50 years of age) were recruited. Participants 
completed the Allergan Ocular Surface Disease Index© (OSDI)42 and were categorized as 
being symptomatic (46 individuals; age=63.2±9.5 yrs) or asymptomatic (39 individuals; 
age=59.9±7.3 yrs) of dry eye, based on their response to OSDI, as described in detail 
elsewhere42   and in chapter 4. 
7.3.3 Objective measurements 
Tear stability was assessed by performing non invasive tear breakup time 
(NITBUT) using the ALCON Eyemap® model EH-290 topography system (ALCON, 
Inc., Forth Worth, Texas, USA) (explained in chapter 3 section 3.4).  
Tear secretion was assessed using the Phenol Red Thread (PRT) test. The PRT 
(ZONE-QUICK, Showa Yakuhin Kako Co., Ltd. Tokyo, Japan) was left in the lower 
conjunctival fornix for 15 seconds. The length of colour change from yellow to red on the 
thread was measured in millimeters (explained in chapter 3 section 3.5).  
Corneal and conjunctival staining could not be performed as a part of this study 
due to the nature of the study design, which included collection of tears and conjunctival 
impression cytology samples. The addition of fluorescein and/or other vital dyes would 
affect the subsequent analysis of various biomarkers and was thus not undertaken. 
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7.3.4 Analytical techniques 
Reagents and Materials: All PhastSystem™ pre-cast gels, buffer strips, well 
combs, filter paper and ECL-Plus™ kits were purchased from GE Healthcare (Baie 
d'Urfe, QC, Canada).   Immuno-Blot® PVDF (polyvinylidene difluoride) membrane and 
DC Protein Assay Kit®  were purchased from BioRad Laboratories (Mississauga, ON, 
Canada). Polyclonal rabbit anti-human lysozyme  from Nordic Immunological 
Laboratories (Tilburg, the Netherlands), monoclonal mouse anti-human lipocalin  from 
R&D Systems (Minneapolis, MN, USA),  goat anti-mouse IgG-HRP from Jackson 
ImmunoResearch (West Grove, PA, USA),  and human lysozyme (neutrophil)  from 
Calbiochem (La Jolla, CA, USA) were purchased from the  distributor Cedarlane 
Laboratories (Hornby, ON, Canada). Goat anti-rabbit IgG-HRP and all other analytical 
grade reagents were purchased from Sigma –Aldrich (Oakville, ON, Canada).  
7.3.5 Tear collection  
Tears were collected using a capillary tube from all subjects. In addition, to 
explore the utility of an alternative means of tear collection, 46 subjects (20 controls and 
26 DE) also underwent a second collection by way of an eye wash. The two collections 
were separated by 15 – 25 minutes to allow for tear film regeneration.  
Capillary Tear Collection: Using a graduated disposable 5 μl microcapillary tube 
(Wiretol-Micropipettes, Drummond Scientific Co., Broomall, PA, USA) up to 5 μl of 
tears / eye were collected from the inferior temporal tear meniscus of each participant as 
explained in chapter 3 section 3.6. A maximum of 5 min was allowed / eye for tear 
collection. Tears from both eyes were pooled and stored at -80oC until use. 0.5 µL of 
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tears diluted in 9.5 µL of distilled water and the DC Protein Assay Kit®  (BioRad, 
Mississauga, ON, Canada) were used to determine total tear film protein. Duplicate 
samples were analyzed and data was read at 750 nm on a Multiskan Microplate 
spectrphotometer (Thermo Labsystems, Franklin, MA, USA) (explained in chapter 3 
section 3.13.1).  
 
Eye Wash Tear Collection:  Tears were collected using a wash method as 
described elsewhere24 and explained in chapter 3 section 3.10). Washes were pooled 
together and stored at -80oC until use. Total protein was determined as described above 
using 5 µL of eye wash.  
Both tear sampling methods were conducted as carefully as possible to avoid 
reflex tearing. The time taken to collect the sample via capillary tube was less than three 
minutes, with most dry-eyed participants typically taking longer than the non dry-eyed 
subjects. Time taken for collection of eyewash samples were the same for both the 
groups. It approximately took one minute per eye to perform the eye wash collection. 
7.3.6 Electrophoresis and immunoblotting 
Quantification of tear lipocalin and lysozyme are explained in chapter 3 section 
3.13.3 and appendix F.  
7.4 Statistical analysis 
Statistical analysis was performed using Microsoft Excel™ XLfit© software. All 
data are reported as mean ± standard deviation. Statistical differences between groups 
were identified by one-way ANOVA, and when necessary, Dunnett’s comparison of 
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means and by Tukey’s test. Significance was identified at p<0.05 (α = 0.05). Pearson 
correlations between subjective and objective clinical measurements and concentration of 
lipocalin or lysozyme were calculated in Excel™.    
  
7.5 Results 
7.5.1 Subjective symptoms 
In this study, the presence and severity of dry eye was determined based on 
symptoms only, as quantified by total OSDI score, using the following criteria: control 
(non-dry eye, NDE) OSDI score = 0-12; mild dry eye OSDI score = 13-22 and moderate 
dry eye OSDI score= 23-32 (Table 7-1). Based on this criterion, 39 subjects were defined 
as controls. Sixteen subjects presented with mild dry eye and the remainder (n=30) were 
classified as moderate. Mean ages (mean ± SD) of the control, mild and moderate groups 
were 59.5 ± 6.5, 63.1 ± 10.0 and 64.2 ± 8.9 years respectively. There was no significant 
difference between the ages of the three groups (p=0.07). The total OSDI scores for the 
two dry eyed groups were significantly higher compared to the NDE group (p<0.0001), 
as was the total score of the moderate group compared to the mild group (p=0.03). 
Analysis of the individual OSDI sub scores revealed a significantly elevated score for the 
mild and moderate DE groups in each category compared to the NDE group, with the 
exception of the Vision Related Function score, where there was no distinction between 
NDE and mild dry eye. Mild and moderate dry eye sub scores were statistically similar, 
with the exception of the Vision Related Function score, which was significantly elevated 
in the moderate group (p<0.01).  
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(n = 39) 
Mild Dry Eye 
(n = 16) 
Moderate Dry 
Eye 













Total OSDI Score 7.4±7.7 18.9±9.2 27.2±14.4 <0.001 <0.001 0.03 
Ocular  Symptoms 7.6±8.4 18.1±13.5 25.3±19.5 <0.006 <0.001 0.17 
Vision Related 
Functions 7.1±12.2 8.6±7.1 20.8±17.7 0.6 <0.001 0.005 
Environmental 
Triggers 8.2±12.3 31.0±20.6 36.9±28.7 <0.001 <0.001 0.45 
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7.5.2 Objective measurements 
Figure 7-1 reports the tear secretion values determined by the PRT test. Tear 
secretion in moderate DE subjects was significantly reduced compared to NDE subjects 
(p<0.0001). Tear secretion in mild DE subjects was slightly lower when compared to 
NDE, however statistical significance was not achieved (p=0.15). Figure 7-2 reports the 
NITBUT determined by the corneal topographer. NITBUT was significantly reduced in 
both mild (p=0.04) and moderate (p<0.001) DE subjects compared to the NDE group, 
and no difference was found between the two dry-eyed groups (p=0.73).     
 
 
Figure 7-1: Box plots of tear secretion as measured by phenol red thread test 
Inner boxes represent mean, dotted boxes represent standard error and whiskers represent 
standard deviation of phenol red thread test measurements from non dry-eyed subjects (NDE), 




Figure 7-2: Box plots of non invasive tear film break-up measurements 
 Inner boxes represent mean, dotted boxes represent standard error and whiskers represent 
standard deviation of NITBUT measurements from non dry-eyed (NDE), mild dry eye and 
moderate dry eye subjects.  * represent statistically significant difference relative to NDE. 
 
7.5.3 Tear total protein 
Figure 7-3 reports the total tear protein data in the tears collected by glass 
capillary tube. No difference in protein concentration was found comparing mild 
(p=0.057) or moderate (p=0.895) dry eyed tears to NDE tears, nor was a difference found 
between the two DE groups (p=0.056). Although protein concentration was lower in tears 
collected using the eye wash method due to dilution with saline, no difference (p=0.26) 
was found in protein concentration between the NDE (1.91 ± 0.94 µg/µL) and pooled DE 
groups (1.61 ± 0.91 µg/µL). Stratification of total protein values based on dry eye 
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symptom severity was not performed with eye wash data due to relatively small sample 
size of both DE groups.  
 
Figure 7-3: Box plots of tear film protein concentration 
 Inner boxes represent mean, dotted boxes represent standard error and whiskers represent 
standard deviation of tear film protein concentration from non dry-eyed (NDE), mild dry eye and 
moderate dry eye subjects. Tears were collected using a glass capillary tube. 
7.5.4 Tear film lipocalin concentration 
Figure 7-4 reports the tear film lipocalin concentration collected via glass 
capillary tube (n=74) and eyewash methods (n=46). No difference in lipocalin 
concentration was found between DE and NDE groups using tears collected via capillary 
tube (p=0.26) or eye wash (p=0.42). Paired comparison of the two tear collection 
techniques (n=43) revealed a significant difference in calculated tear lipocalin 
concentration (p=0.0004), where mean capillary concentration was 0.22 ± 0.12 AU and 
mean eye wash concentration was 0.15 ± 0.06 AU. Lipocalin concentration in relation to 
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symptom severity of dry eye was not examined with eye wash tear samples due to 
relatively small sample size of the two DE groups. A trend towards reduction in lipocalin 
concentration as symptom severity of dry eye increased was noted with tear samples 
collected with capillary tubes, as shown in Figure 7-5. No significant correlations were 
found between tear film lipocalin concentration and tear secretion, tear break up time or 
OSDI questionnaire response data (Table 7-2). 
 
Figure 7-4: Box plots of mean tear film lipocalin concentration 
Inner boxes represent mean, dotted boxes represent standard error and whiskers represent 
standard deviation of lipocalin measurements from non dry-eyed (NDE) dry-eyed (DE) 
subjects (participants with mild & moderate symptoms combined). Data from tears 





Figure 7-5: Box plots of mean tear film lipocalin concentration as a function of dry 
eye symptom severity 
Inner boxes represent mean, dotted boxes represent standard error and whiskers represent 
standard deviation of lipocalin measurements from non dry-eyed (NDE), mild dry-eyed and 
moderate dry-eyed subjects. Tears were collected with capillary tubes. 
 
7.5.5 Tear film lysozyme concentration 
Figure 7-6 reports the tear film lysozyme concentration collected via glass 
capillary tube (n=43) and eyewash methods (n=38). No difference in lysozyme 
concentration was found between DE and NDE groups using tears collected via capillary 
tube (p=0.20) or eye wash (p=0.59). Lysozyme concentration in relation to symptom 
severity of dry eye was not examined due to relatively small sample size for both 
methods of tear collection. Paired comparison of the two tear collection techniques 
(n=37) revealed a significant difference in calculated tear lysozyme concentration 
(p=0.008), where mean capillary concentration was 0.30 ± 0.09 µg/µg total tear protein 
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and mean eye wash concentration was 0.25 ± 0.08 µg/µg total tear protein. No significant 
correlations were found between tear film lysozyme concentration and tear secretion, tear 
break up time or OSDI questionnaire response data (Table 7-2). Correlation analysis 
between OSDI total scores for the three groups (normal, mildly symptomatic and 
moderately symptomatic dry eye) and tear secretion, tear break up time or lipocalin via 
capillary tube showed weak and insignificant correlation. Similar results were found for 
the correlation analysis between OSDI sub scores and tear function test. 
 
 
Figure 7-6: Box plots of mean tear film lysozyme concentration 
Inner boxes represent mean, dotted boxes represent standard error and whiskers represent 
standard deviation of lysozyme measurements from non dry-eyed (NDE) and dry-eyed (DE) 
subjects (participants with mild & moderate symptoms combined). Data from tears collected via 
capillary and eye wash methods are displayed for comparison. 
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Tears Collected via 








Tears Collected via 
Eye Wash (n=38) 
PRT Test 0.181 0.032 -0.094 -0.184 
NITBUT 0.072 0.002 0.241 0.058 
Total OSDI Score -0.174 0.175 -0.347 0.150 
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7.6 Discussion  
Several studies have suggested that various tear film proteins may serve as 
surrogate endpoints for evaluation of ocular surface disorders, and the quantitation of tear 
lysozyme has recently been proposed as one of many potential clinical tests used in the 
assessment of dry eye.5  In this study, we quantified the concentration of tear film 
lysozyme and lipocalin in two groups of PMW, with and without symptoms of dry eye, to 
gain insight into the diagnostic sensitivity and selectivity of these biomarkers and to 
investigate potential relationships between protein concentrations and clinical signs and 
symptoms of dry eye.  
We chose to stratify subjects solely on symptoms as quantified by the OSDI 
questionnaire. It is a validated questionnaire recommended by the DEWS 2007 report and 
it is one way of potentially classifying participants based on the symptom scores. Based 
on the OSDI criteria, we enrolled three statistically distinct groups: those without 
symptoms of dry eye and those with either mild or moderate dry eye.  Review of 
objective measurements suggested that both tear secretion and NITBUT were 
significantly reduced in moderately symptomatic dry-eyed subjects relative to controls. 
Additionally, mildly symptomatic dry-eyed subjects presented significantly reduced 
NITBUT relative to controls.  An evaluation of our PRT data does indicate that the values 
reported are higher than those anticipated, with the values for DE group being higher than 
the cut-off that have been proposed by previous authors.13, 43, 44, The suggestion of a cut-
off value comes from a study that included a population with a wide age range and both 
genders43, 44, which is quite different to this study, which includes only older female 
subjects. As one would expect, age typically results in reduced tear volume.45, 46  
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However, a recent study has shown that older individuals tend to exhibit a higher tear 
meniscus height (and hence tear volume), due to age-related constriction of the puncta, 
resulting in limited drainage of tears from the ocular surface.47 Thus, it is entirely feasible 
that our PRT data for our older group of PMW is appropriate, potentially due, in part, to 
punctal stenosis. However, this requires further investigation. Taken together, it appears 
that alterations in tear stability and secretion are involved in the pathophysiology of dry 
eye within the PMW population. Further research is currently underway to explore 
correlations within this data set.     
With respect to protein biomarkers, Dougherty and McCulley48 reported that 
blepharitis patients with clinically diagnosed KCS had a lower mean tear film lysozyme 
concentration compared to either blepharitis patients with no KCS or control subjects. In 
chronic smokers, Satici et al49 reported that tear film break time, mean Schirmer I scores 
and tear lysozyme concentration were statistically lower compared to a group of non-
smokers and thus concluded that each measurement was an assessment of ocular surface 
damage.  Whether a dilution effect was present due to excessive tearing associated with 
smoking was not ruled out. deLuise and Tabbara27 described a trend favoring reduced 
tear lysozyme concentration in dry eyed individuals compared to a control population 
although statistical significance was not achieved due to considerable data overlap 
between the two groups. Markusse et al50 also found that despite a trend of reduced 
lysozyme concentration in primary Sjögren’ subjects compared to controls, data overlap 
suggested that lysozyme quantitation lacked the required specificity for diagnostic use. 
Data reported in this study are in agreement with these latter two studies, as our results 
suggest that no difference in tear lysozyme concentration exists in dry-eyed PMW 
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compared to asymptomatic controls, irrespective of method of tear collection. Few 
studies have shown a difference in the lysozyme levels in tears.21, 51 These differences in 
results could be due to the population studied, age, tear collection method, classification 
system for what constitutes “dry eye”, or the analytical method used. 
Tear lipocalin has been proposed as a marker of lacrimal function,52, 53 as well as 
playing a key role in maintaining tear stability.29, 53, 54   In a study of intolerant contact 
lens wearers,29 it was found that tear lipocalin concentration was significantly elevated 
compared to a control group of tolerant wearers. The authors suggested that the increase 
in lipocalin may be in response to lipid by-products circulating in the tear film. That tear 
film instability may result from the altered tear biochemistry was supported by the 
finding that lipocalin concentration was significantly correlated with NITBUT (r=0.440; 
0.036). Evans et al53 reported that tear film lipocalin concentration in a group of PMW 
not using HRT was not significantly different to a post menopausal control group,  as 
well as a group of hysterectomized women receiving HRT and a group of age-matched 
men. The authors also reported that the range of lipocalin concentrations was greatest in 
the post menopausal group not using HRT and suggest that HRT may smooth out 
fluctuating hormone levels associated with menopause and that estrogen may have an 
ability to regulate the secretion of lipocalin from the lacrimal gland. Our data are 
consistent with the work of Evans et al,53 in that we found no difference in tear lipocalin 
concentration in postmenopausal dry-eyed women compared to asymptomatic controls, 
irrespective of method of tear collection.  
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We compared both lysozyme and lipocalin data with clinical results and found no 
correlation with OSDI response data, NITBUT or tear secretion. Although our work 
demonstrates that PMW with symptoms of dry eye had reduced tear stability and capacity 
to secrete tears, tears that were produced were biochemically normal with respect to two 
major lacrimal gland proteins (lysozyme and lipocalin), as well as total protein content.   
As a secondary objective we sought to investigate the utility of two different tear 
collection methods. Although the use of glass capillary tubes is perhaps the most 
common technique, an eye wash method provides a user friendly, safe, rapid and - in the 
case of severe aqueous deficient dry eye - more realistic means of collecting tears. We 
found that although both tear collection methods provided the same conclusion of no 
difference in tear lysozyme or lipocalin concentration between study groups, the absolute 
concentrations calculated were statistically different, with higher values associated with 
capillary collection in both cases. Studies comparing capillary collection to Schirmer I or 
polyester rod collection have found that tear protein concentrations are greater with the 
latter techniques, potentially due to contributions from intercellular constituents and/or 
absorption characteristics.55-57  We can speculate that an eye wash technique may add a 
minimal dilution variable to overall protein yield, thus resulting in slightly lower absolute 
values when data is normalized to total protein, as was done in this study. Our work, as 
well as that reported in the literature, highlights the importance of specifying collection 
technique in the comparison of data sets. Furthermore, variables such as the biomarker 
under study, the subject population and post-collection analytical methods may all 
influence or be affected by a given tear collection technique. Thus, prior to adopting a 
method of tear collection, all such variables should be considered.  
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7.7 Conclusion 
The quantitation of tear biomarkers offers potential advantages of specificity and 
reproducibility that could provide valuable information to supplement conventional dry 
eye diagnostic criteria. In this study, we investigated the use of lipocalin and lysozyme 
for such a purpose. We can conclude from these data that within a PMW population both 
proteins are invariant, irrespective of the presence and severity of dry eye symptoms. In 
addition, the concentration of either protein was not associated with tear stability or 
secretion. That previous studies have shown a difference in tear protein concentration and 
/or correlation with tear dynamics may be attributed to the subgroup of dry eye subjects 
studied. This is the first comprehensive study of lysozyme and lipocalin in dry-eyed 
PMW and our results suggest that neither protein would offer utility as a biomarker of 












1. The definition and classification of dry eye disease: report of the Definition and 
Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul 
Surf 2007;5:75-92. 
2. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee 
of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:93-107. 
3. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye 
syndrome among US women. Am J Ophthalmol 2003;136:318-26. 
4. Christen WG, Gaziano JM, Hennekens CH. Design of Physicians' Health Study 
II--a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in 
prevention of cancer, cardiovascular disease, and eye disease, and review of 
results of completed trials. Ann Epidemiol 2000;10:125-34. 
5. Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic 
Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul 
Surf 2007;5:108-52. 
6. Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical 
Trials in Dry Eyes. Clao J 1995;21:221-32. 
7. Korb DR. Survey of preferred tests for diagnosis of the tear film and dry eye. 
Cornea 2000;19:483-6. 
8. McCarty CA, Bansal AK, Livingston PM, Stanislavsky YL, Taylor HR. The 
epidemiology of dry eye in Melbourne, Australia. Ophthalmology 
1998;105:1114-9. 
9. Craig JP, Tomlinson A. Age and gender effects on the normal tear film. Adv Exp 
Med Biol 1998;438:411-5. 
10. McMonnies CW, Ho A. Responses to a dry eye questionnaire from a normal 
population. J Am Optom Assoc 1987;58:588-91. 
 212
11. Schein OD, Tielsch JM, Munoz B, Bandeen-Roche K, West S. Relation between 
signs and symptoms of dry eye in the elderly. A population-based perspective. 
Ophthalmology 1997;104:1395-401. 
12. McMonnies CW. Key questions in a dry eye history. J Am Optom Assoc 
1986;57:512-7. 
13. Nichols KK, Mitchell GL, Zadnik K. The repeatability of clinical measurements 
of dry eye. Cornea 2004;23:272-85. 
14. Nichols KK, Begley CG, Caffery B, Jones LA. Symptoms of ocular irritation in 
patients diagnosed with dry eye. Optom Vis Sci 1999;76:838-44. 
15. Nichols KK, Nichols JJ, Lynn Mitchell G. The relation between tear film tests in 
patients with dry eye disease. Ophthalmic Physiol Opt 2003;23:553-60. 
16. Research in dry eye: report of the Research Subcommittee of the International 
Dry Eye WorkShop (2007). Ocul Surf 2007;5:179-93. 
17. Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D. Altered cytokine balance in 
the tear fluid and conjunctiva of patients with Sjogren's syndrome 
keratoconjunctivitis sicca. Curr Eye Res 1999;19:201-11. 
18. Thakur A, Willcox MD. Cytokine and lipid inflammatory mediator profile of 
human tears during contact lens associated inflammatory diseases. Exp Eye Res 
1998;67:9-19. 
19. Hong JW, Liu JJ, Lee JS, Mohan RR, Mohan RR, Woods DJ, He YG, Wilson SE. 
Proinflammatory chemokine induction in keratocytes and inflammatory cell 
infiltration into the cornea. Invest Ophthalmol Vis Sci 2001;42:2795-803. 
20. Sullivan DA, Sullivan BD, Evans JE, Schirra F, Yamagami H, Liu M, Richards 
SM, Suzuki T, Schaumberg DA, Sullivan RM, Dana MR. Androgen deficiency, 
meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci 
2002;966:211-22. 
21. Grus FH, Podust VN, Bruns K, Lackner K, Fu S, Dalmasso EA, Wirthlin A, 
Pfeiffer N. SELDI-TOF-MS ProteinChip array profiling of tears from patients 
with dry eye. Invest Ophthalmol Vis Sci 2005;46:863-76. 
 213
22. Tomosugi N, Kitagawa K, Takahashi N, Sugai S, Ishikawa I. Diagnostic potential 
of tear proteomic patterns in Sjogren's syndrome. J Proteome Res 2005;4:820-5. 
23. Ohashi Y, Ishida R, Kojima T, Goto E, Matsumoto Y, Watanabe K, Ishida N, 
Nakata K, Takeuchi T, Tsubota K. Abnormal protein profiles in tears with dry eye 
syndrome. Am J Ophthalmol 2003;136:291-9. 
24. Argueso P, Balaram M, Spurr-Michaud S, Keutmann HT, Dana MR, Gipson IK. 
Decreased levels of the goblet cell mucin MUC5AC in tears of patients with 
Sjogren syndrome. Invest Ophthalmol Vis Sci 2002;43:1004-11. 
25. Seal DV. The effect of ageing and disease on tear constituents. Trans Ophthalmol 
Soc U K 1985;104 (Pt 4):355-62. 
26. Mackor AJ, van Bijsterveld OP. Tear function parameters in keratoconjunctivitis 
sicca with and without the association of Sjogren's syndrome. Ophthalmologica 
1988;196:169-74. 
27. deLuise VP, Tabbara KF. Quantitation of tear lysozyme levels in dry-eye 
disorders. Arch Ophthalmol 1983;101:634-5. 
28. Danjo Y, Lee M, Horimoto K, Hamano T. Ocular surface damage and tear 
lactoferrin in dry eye syndrome. Acta Ophthalmol (Copenh) 1994;72:433-7. 
29. Glasson M, Stapleton F, Willcox M. Lipid, lipase and lipocalin differences 
between tolerant and intolerant contact lens wearers. Curr Eye Res 2002;25:227-
35. 
30. Nielsen NV, Prause JU, Eriksen JS. Lysozyme, alfa-1-antitrypsin and serum 
albumin in tear fluid of timolol treated glaucoma patients with and without 
symptoms of dry eyes. Acta Ophthalmol (Copenh) 1981;59:503-9. 
31. Glasgow BJ, Abduragimov AR, Gasymov OK, Yusifov TN. Tear lipocalin: 
structure, function and molecular mechanisms of action. Adv Exp Med Biol 
2002;506:555-65. 
32. Fullard RJ, Kissner DM. Purification of the isoforms of tear specific prealbumin. 
Curr Eye Res 1991;10:613-28. 
 214
33. Fullard RJ. Identification of proteins in small tear volumes with and without size 
exclusion HPLC fractionation. Curr Eye Res 1988;7:163-79. 
34. Delaire A, Lassagne H, Gachon AM. New members of the lipocalin family in 
human tear fluid. Exp Eye Res 1992;55:645-7. 
35. Redl B. Human tear lipocalin. Biochim Biophys Acta 2000;1482:241-8. 
36. Gasymov OK, Abduragimov AR, Prasher P, Yusifov TN, Glasgow BJ. Tear 
lipocalin: evidence for a scavenging function to remove lipids from the human 
corneal surface. Invest Ophthalmol Vis Sci 2005;46:3589-96. 
37. Gasymov OK, Abduragimov AR, Gasimov EO, Yusifov TN, Dooley AN, 
Glasgow BJ. Tear lipocalin: potential for selective delivery of rifampin. Biochim 
Biophys Acta 2004;1688:102-11. 
38. Glasgow BJ, Marshall G, Gasymov OK, Abduragimov AR, Yusifov TN, Knobler 
CM. Tear lipocalins: potential lipid scavengers for the corneal surface. Invest 
Ophthalmol Vis Sci 1999;40:3100-7. 
39. Farris RL. Tear analysis in contact lens wearers. Trans Am Ophthalmol Soc 
1985;83:501-45. 
40. Gachon AM, Verrelle P, Betail G, Dastugue B. Immunological and 
electrophoretic studies of human tear proteins. Exp Eye Res 1979;29:539-53. 
41. Selsted ME, Martinez RJ. Isolation and purification of bactericides from human 
tears. Exp Eye Res 1982;34:305-18. 
42. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability 
and validity of the Ocular Surface Disease Index. Arch Ophthalmol 
2000;118:615-21. 
43. Hamano T, Mitsunaga S, Kotani S, Hamano T, Hamano K, Hamano H, Sakamoto 
R, Tamura H. Tear volume in relation to contact lens wear and age. Clao J 
1990;16:57-61. 
 215
44. Sakamoto R, Bennett ES, Henry VA, Paragina S, Narumi T, Izumi Y, Kamei Y, 
Nagatomi E, Miyanaga Y, Hamano H, et al. The phenol red thread tear test: a 
cross-cultural study. Invest Ophthalmol Vis Sci 1993;34:3510-4. 
45. Mathers WD, Lane JA, Zimmerman MB. Tear film changes associated with 
normal aging. Cornea 1996;15:229-34. 
46. Cho P, Yap M. The cotton thread test on Chinese eyes: effect of age and gender. J 
Br Contact Lens Assoc 1994;17:25-28. 
47. Patel S, Wallace I. Tear meniscus height, lower punctum lacrimale, and the tear 
lipid layer in normal aging. Optom Vis Sci 2006;83:731-9. 
48. Dougherty JM, McCulley JP. Tear lysozyme measurements in chronic blepharitis. 
Ann Ophthalmol 1985;17:53-7. 
49. Satici A, Bitiren M, Ozardali I, Vural H, Kilic A, Guzey M. The effects of chronic 
smoking on the ocular surface and tear characteristics: a clinical, histological and 
biochemical study. Acta Ophthalmol Scand 2003;81:583-7. 
50. Markusse HM, van Haeringen NJ, Swaak AJ, Hogeweg M, de Jong PT. Tear fluid 
analysis in primary Sjogren's syndrome. Clin Exp Rheumatol 1993;11:175-8. 
51. Boukes RJ, Boonstra A, Breebaart AC, Reits D, Glasius E, Luyendyk L, Kijlstra 
A. Analysis of human tear protein profiles using high performance liquid 
chromatography (HPLC). Doc Ophthalmol 1987;67:105-13. 
52. Janssen PT, van Bijsterveld OP. The relations between tear fluid concentrations of 
lysozyme, tear-specific prealbumin and lactoferrin. Exp Eye Res 1983;36:773-9. 
53. Evans V, Millar TJ, Eden JA, Willcox MD. Menopause, hormone replacement 
therapy and tear function. Adv Exp Med Biol 2002;506:1029-33. 
54. Tragoulias ST, Anderton PJ, Dennis GR, Miano F, Millar TJ. Surface pressure 
measurements of human tears and individual tear film components indicate that 
proteins are major contributors to the surface pressure. Cornea 2005;24:189-200. 
 216
55. Stuchell RN, Feldman JJ, Farris RL, Mandel ID. The effect of collection 
technique on tear composition. Invest Ophthalmol Vis Sci 1984;25:374-7. 
56. Choy CK, Cho P, Chung WY, Benzie IF. Water-soluble antioxidants in human 
tears: effect of the collection method. Invest Ophthalmol Vis Sci 2001;42:3130-4. 
57. Jones DT, Monroy D, Pflugfelder SC. A novel method of tear collection: 





8 Method Optimization for the Isolation of Total RNA and 
Total Protein from Human Conjunctival Epithelial Cells 
Collected via Impression Cytology 
 
Srinivasan S, Senchyna M, Heikkila E, Jones LW. Method optimization for the isolation 
of total RNA and total protein from human conjunctival epithelial cells collected via 




Purpose: To optimize a technique for the isolation of total RNA and total protein derived 
from human conjunctival epithelial cells collected in situ via impression cytology.  
 
Methods: Conjunctival epithelial cells were collected via impression cytology (CIC) 
using either Millipore (MP) or Poly Ether Sulfone (PES) membranes. RNA Isolation: 
Following collection with either MP or PES, total RNA was isolated using one of two 
commercially available methods: TRIzol™ (TZ) (Life Technologies) or RNeasy™ Mini 
(RN) (Qiagen). RNA concentration and integrity was assessed. RT-PCR of mRNAs 
coding for MUC1 and the housekeeping gene GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase) was performed to confirm the collection of high quality, DNA-free RNA. 
Protein Isolation: Following CIC with (MP), samples were either frozen immediately or 
soaked in extraction buffer and then frozen. Total protein was isolated following the 
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addition of extraction buffer and boiling. The supernatant was collected and frozen for 
future use.   Total protein was quantified with BioRad’s DC™ Protein Assay. Western 
blotting of a constitutively expressed protein (lipoxygenase type 2 protein (LOX2)) was 
performed to confirm the collection of intact total protein. 
 
Results: When the TZ and RN methods were compared, total RNA yield was greater 
with the MP membrane (p=0.05). However, both membranes consistently provided high 
quality (λ260:280 >1.8) RNA, with no significant difference between the kits (p=NS). 
All RNA isolated with the TZ and RN methods demonstrated positive amplification of 
MUC1 and GAPDH mRNAs as assessed by RT-PCR. The average yield of protein from 
a single membrane ranged from 3 µg to 64 µg. Positive identification of LOX2 protein 
via Western blotting confirmed the collection of intact total protein. 
 
Conclusion: For RNA isolation: MP membranes processed with either the TZ or RN 
methods are equally efficient for the isolation of high quality RNA from conjunctival 
cells collected in situ. The RN method is recommended, due to enhanced speed as well as 
on-column isolation and DNase digestion capabilities. For total protein isolation, the use 
of CIC using MP membranes followed by immediate freezing and then extraction and 
processing with methods optimized by our laboratory facilitates the collection of total 
protein from human conjunctival cells. Both methods will prove very useful to assess the 
expression of a variety of proteins involved in both normal and pathophysiological 
functions of the human ocular surface. 
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8.2 Introduction 
Conjunctival Impression Cytology (CIC) is a relatively simple, practical and 
minimally invasive technique, allowing the collection of 1 to 3 layers of cells from the 
conjunctival surface.1-6 This technique is rapid, convenient and is widely performed on 
subjects to confirm a variety of ocular surface diseases and to monitor changes in the 
conjunctival surface over a period of time.3, 7 CIC has been used since the 1970’s6 as a 
diagnostic procedure for the detection and grading of squamous neoplasia 8-10, dry eye 
syndrome6, 11 and squamous metaplasia4, 6, 12, 13 and remains used as a diagnostic 
procedure to this day.  
Significant biochemical insight into human ocular surface physiology and 
pathophysiology can be gained through the analysis of genes and proteins expressed in 
conjunctival epithelial cells that are collected via impression cytology. Researchers have 
used a variety of different membranes to collect the samples, including cellulose acetate 
membranes of different pore sizes and Biopore membrane devices.12, 14, 15 Among all 
these membranes, Millipore membrane (MP) (Millipore™, Billerica, Massachusetts, 
USA) and Poly Ether Sulphone membranes16-19 (PES) (Gelman Laboratory, Supor® 200, 
Ann Arbor, MI, USA) have been most commonly used.  
Isolation of intact RNA in sufficient quantity is essential for accurate gene 
expression analysis. However, RNA quality and yield can vary significantly depending 
on the cell source and method of RNA isolation. Even though elaborate procedures have 
been developed for RNA isolation, working with RNA is a practical challenge. RNA is 
well known to be highly susceptible to degradation due to its chemical structure and also 
because of contaminating RNAse from the environment.20  Hence it is necessary to use a 
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reliable, quick and user friendly method of RNA isolation to obtain high quality RNA 
from CIC samples.  One method that has been used frequently to isolate RNA from 
conjunctival or corneal cells is the TRIzol™ (TZ) (Life Technologies) RNA isolation 
technique.19, 21-27 The reagent, a mono-phasic solution of phenol and guanidine 
isothiocyanate, is an improvement to the single-step RNA isolation method developed by 
Chomczynski and Sacchi.28 Another fast and simple method for the preparation of up to 
100µg total RNA from animal cells and tissues is the RNeasy™ Mini (RN) (Qiagen). 
This kit is designed to isolate total RNA from small quantities of starting material.16-18, 20, 
29 This isolation technique combines the selective binding properties of a silica gel based 
membrane with the speed of microspin technology.  
Similarly, extraction and characterization of protein expression from epithelial 
cell populations is also dependant on the appropriate method used for isolation. To date, 
there is no simple method reported for extracting total protein from CIC samples.  
The purpose of this study was to optimize techniques for the isolation of both high 
quality total RNA and total protein derived from human conjunctival epithelial cells 
collected via CIC. As objective measures to assess yield and quality the following were 
required: 
a) RNA integrity gel to confirm the presence of intact RNA. 
b) RT-PCR of two mRNAs known to be expressed in the conjunctiva (GAPDH and 
MUC1) to confirm intact RNA and the lack of DNA contamination).  
c) Western blotting for the constitutively expressed 15-Lipoxygenase 2 (LOX 2) 




8.3.1 Isolation of RNA 
Conjunctival epithelial cells were collected from both eyes of 12 human 
volunteers (different from the postmenopausal women studies) (6 per kit) via CIC using 
either Millipore (MP) or Poly Ether Sulfone (PES) membranes. (Pore size: MP = 0.45 
µm, PES = 0.2 µm). After instillation of topical anesthesia, 10mm diameter filter paper 
discs were applied to the superior and temporal bulbar conjunctiva of each eye for five 
seconds (chapter 3 section 3.11.2). Following cell collection, filter papers were 
immediately immersed in extraction buffer consistent with the method being evaluated. 
The filters were vortexed vigorously for 10 seconds and then immediately placed on dry 
ice until placed in a -80ºC freezer for long term storage until further processing. The 
methods evaluated for total RNA isolation were: TRIzol™ (TZ) (Life Technologies) and 
RNeasy™ Mini (RN) (Qiagen). 100 µL of TRIzol reagent was used per isolation for TZ 
whereas 1.0 mL of RLT lysis buffer containing 1% β- mercaptoethanol was used for 
RN.16, 17  RNA extraction was carried out following manufacturers recommendations for 
both kits with few modifications. The step wise procedure of RNA isolation for 
RNeasy™ Mini (RN) (Qiagen) is explained in appendix G. The procedure for RNA 
isolation using TRIzol™ (TZ) (Life Technologies) was undertaken using the following 
steps: CIC samples were soaked in 100µl of TRIzol and frozen in -80oC until further 
isolation. Samples were not stored for more than 30 days based on manufacturer’s 
recommendations. Samples were allowed to come to room temperature and vortexed for 
15 seconds. The reagent was passed through several times (at least 5 times) using a 
pipette that was set for at 90µl and was left in room temperature for 5 minutes. 20µl of 
 222
chloroform was added and vortexed for 15 seconds. Following 15 seconds of vortexing, 
the sample was allowed to sit at room temperature for 3 minutes. Samples were spun at 
11,000g for 15 mins at 4º C, the upper colorless phase was transferred into a new sterile 
eppendorf and 10µg of glycogen was added. 50µl of isopropanol was then added and the 
sample was vortexed for 10 seconds followed by a 10 minute incubation at room 
temperature and centrifugations at 11,000g for 10 minutes at 4ºC.  Supernatant was 
removed and 500µl of 75% ethanol was added. Then the sample was vortexed for 5 
seconds and spun at 7,500g for 5 min at 4ºC. Ethanol was removed and the sample was 
desiccated to dryness. RNA was dissolved in 40µl of water and vortexed gently for 3-5 
seconds, following which a quick spin for 3-5 seconds was given. Samples were then 
heated at 55º C for 10 minutes (the time and the temperature were strictly adhered), 
vortexed gently for 3-5 seconds and spun for 3-5 seconds. 5 µl of the sample was used for 
spectrometry (chapter 3 section 3.13.7) and the remaining sample was stored in -80oC for 
RT-PCR. 
The two filter papers from the same eye were processed together in the same 
isolation. Both eyes from the same volunteer were processed in parallel (Figure 8-1).  
Samples isolated using the RN kit was subjected to on-column DNase-digestion using the 
supplied RNAse-free DNAse. Samples isolated with TZ were subjected to the addition of 
10 µg glycogen (Life Technologies) and RNase-free DNase-digestion (Life 
Technologies) as suggested by the manufacturer. The concentration and integrity 
(λ260:280) of RNA was assessed via UV spectrophotometry. RNA integrity was 
additionally assessed via electrophoresis on 1% agarose-formaldehyde denaturing gels, 
followed by ethidium bromide staining. 
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RT-PCR of mRNAs coding for MUC1 and the housekeeping gene GAPDH was 
performed to confirm the collection of high quality, DNA-free RNA.  
 
 
Figure 8-1: Flowchart showing the schematic of sample processing from the CIC 
disc for method optimization of RNA isolation 
 
8.3.2 Isolation of total protein 
Conjunctival epithelial cells were collected from both eyes of 12 human 
volunteers (different from the postmenopausal women studies) via CIC using 10mm 
Millipore (MP) membranes. Superior and temporal samples were always kept separate. 
Samples from each eye were processed separately. One set of CIC samples collected 
Impression Cytology 
N = 6 
TriZol Kit  
N = 6 
  MP (n=3) PES (n=3)
RN easy Kit  
  MP (n=3) PES (n=3)
  UV spectrophotometry 
        RNA integrity via 1% agarose-formaldehyde denaturing gels 
      RT-PCR Amplification of MUC1 
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from 6 volunteers were snap frozen in dry ice until further processing, while the discs 
collected from the remaining 6 volunteers were processed immediately as described 
below and then frozen at -70º C (Figure 8-2). CIC samples were laid on a glass plate with 
adhered cells facing up. Ten µL of Extraction Buffer (EB), containing 50mM Tris and 
1% SDS, or EB + 1X Complete™ Protease Inhibitor Cocktail (PI) (Roche Diagnostics, 
1X concentration) was applied to the cells.  
The discs were cut up using a scalpel into 1mm pieces, added to an eppendorf 
tube containing an additional 40µL of EB or EB + PI, boiled for 10 minutes, spun at 
14000g , aliquoted , and stored at -70º C. Total protein from 10µL of the sample was 
quantified using the BioRad’s DC™ Protein Assay (appendix D). Absorbances were read 
at 750 nm on a Multiskan Microplate Spectrphotometer (Thermo Labsystems, Franklin, 
MA, USA. Western blotting of LOX 2 was performed to confirm the collection of intact 
protein. To facilitate quantitation of tear samples, standard curves were run on each gel. 
A titration (500 to 31.25 pg/µL) of LOX 2 standards (Recombinant 15-LOX Form-2 
standard, Oxford Biomedical Research) was used. LOX 2 standards was used to quantify 
the amount of LOX 2 per sample. IC samples were diluted to 1µg/µL, 0.5µg/µL and 
0.25µg/µL. Once prepared, samples and standards were subjected to SDS-PAGE 
followed by Western blotting to PVDF membranes using the PhastSystem™ (GE 
Healthcare, Baie d'Urfe, QC, Canada). 
LOX 2 was identified using LX25 primary antibody (Oxford Biomedical 
Research) (1:10,000) in TBS + 0.05% Tween 20 (TBS-T) for 4 hours at room 
temperature, followed by goat anti rabbit IgG secondary antibody (1:20 000) (Jackson 
Immuno Research) in TBS-T with 1% blotto (skimmed milk powder + TBS-T) for 2 
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hour. Immunoreactivity was visualized by incubating with ECL Plus® chemiluminescent 
substrate (Amersham-Pharmacia Biotech). Optical densities of the resulting bands were 
quantified from digitized images created with a Molecular® Dynamics Storm™ 840 
Imager using ImageQuant™ 5.1. 
 
 
Figure 8-2: Flowchart showing the schematic of sample processing from the CIC 
disc for method optimization of protein 
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8.4 Statistical analysis 
One-way analysis of variance was performed on all data to assess differences 
between the RNA isolation kits and the filter papers and protein isolation methods 
(significance taken at a value of p<0.05). 
 
8.5 Results 
Table 8-1 summarises the RNA quality and yields obtained using the TZ and RN 
methods combined with MP and PES membranes. As indicated in Table 8-1, total RNA 
yield was greater with the MP membrane (p=0.05), however, both membranes 
consistently provided high quality (λ260:280 >1.8) RNA with no significant difference 
between the TZ and RN methods (p=NS).  
 
Table 8-1: Comparison of RNA quality and yield obtained via various cell collection 
and processing methods 





Number of Eyes 
Providing Data 6/6 6/6 6/6 6/6 
Range of λ260:280 1.7 - 2.2 2.0-2.3 1.7 - 2.2 1.8-2.2 
Mean Yield (μg) 14.9 18.1 9.6 11.1 










The integrity and size distribution of total RNA purified with the above 
mentioned kits were verified by denaturing formaldehyde agarose gel electrophoresis and 
stained with ethidium bromide. The respective ribosomal bands (Figure 8-3) appeared as 
sharp bands on the stained gel. The 28S ribosomal RNA bands appeared with intensity 
approximately twice that of the 18S RNA band. No lane had smeary or small sized RNAs 




Figure 8-3: RNA integrity gel  
5 μg of total RNA isolated from eight different conjunctival cell collections (lanes 1-8) was 
analyzed on a denaturing 1% formaldehyde agarose gel stained with ethidium bromide.  
 
Figure 8-4 represents the results of RT-PCR amplification of MUC1 and GAPDH 
(glyceraldehyde- 3-phosphate dehydrogenase - housekeeping gene) mRNA. Lanes 2, 4, 7, 












Figure 8-4: RT-PCR amplification of MUC1 and GAPDH mRNA  
Amplification of mRNAs coding for MUC1 (123 bp) and GAPDH (160 bp) from two different 
samples of total RNA (lanes 1 – 4 and 6 – 9) isolated using the RN method. Lanes  2, 4, 7 and 9 
represent negative controls, where RT reactions were run in the absence of reverse transcriptase 
enzyme. Lane 5 = molecular weight ladder. 
 
Figure 8-5a represents the impression cytology of normal human conjunctiva 
stained using Haematoxylin and Eosin (appendix G). The membrane to the left in Figure 
5a represents a PES membrane and the membrane to the right in Figure 8-5a represents a 
MP membrane. When these stained membranes were evaluated by light microscopy 
under 40X magnification, both membranes showed thousands of epithelial cells adhered 








Figure 8-5: Impression cytology of normal conjunctiva (Hematoxylin and Eosin stain- 
H&E) 
 (a) PES membrane to the left and MP membrane to the right (b) PES membrane stained in H&E 
stain under 40X magnification (c) MP membrane stained in H&E stain under 40X magnification 
 
When the mean yield of protein extracted from MP membrane was assessed, the 
four different procedures had no significant difference (p=NS) in the amount of protein 
extracted (Figure 8-6). Error bars represent standard deviation. However, the mean yield 
of protein obtained using flash freezing in EB+PI was higher than the rest of the 







Figure 8-6: Mean yield of protein using EB and EB + PI  
This graph represents the average amount of protein in µg found in 10µL of CIC samples. Error 
bars represent standard deviation. 
 
Figure 8-7a represents a LOX2 Western blot performed on CIC derived protein 
samples. Lanes 1-4 are Human Recombinant 15-LOX Form-2 Standard (Lane 1 = 2.89, 
Lane 2 = 1.44, Lane 3 = 0.72, Lane 4 = 0.36 ng/μL); Lanes 5 - 8 are CIC samples taken 
from the same subject (Lane 5 = Left Superior; Lane 6 = Left Temporal, Lane 7 = Right 
Superior; Lane 8 = Right Temporal regions of conjunctiva). Figure 8-7b represents a 
regression curve that was plotted by graphing applied concentration of LOX 2 standard 
against the optical density of the resulting band immunoreactivity.  Total LOX 2 
concentration was quantified by extrapolation from this curve (Lane 5 = 0.91, Lane 6 = 




Figure 8-7: Western blot and regression analysis for LOX 2 quantification   
(a) An example of a LOX 2 Western blot from CIC derived protein samples. Lanes 1-4 are 
Human Recombinant 15-LOX Form-2 Standard (Lane 1 = 2.89, Lane 2 = 1.44, Lane 3 = 0.72, 
Lane 4 = 0.36 ng/μL); Lanes 5 - 8 are CIC samples taken from the same subject (Lane 5 = Left 
Superior; Lane 6 = Left Temporal, Lane 7 = Right Superior; Lane 8 = Right Temporal regions of 
conjunctiva).  (b) A regression curve (graphing applied concentration of LOX 2 standard against 
the optical density of the resulting band immunoreactivity). Total LOX 2 concentration was 
quantified by extrapolation from this curve (Lane 5 = 0.91, Lane 6 = 0.58, Lane 7 = 2.38, Lane 8 
= 6.58 ng/µg of Total Protein). 
 
Figure 8-8 represents the average amount of LOX 2 in ng found in 1µg of total 
protein from the superior or temporal CIC samples. There was no significant difference 
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Figure 8-8: Mean yield of LOX 2 
This graph represents the average amount of LOX 2 in ng found in 1µg of total protein from the 




8.6 Discussion  
In this chapter, optimized methods for isolation of both total RNA and total protein 
isolation from conjunctival epithelial cells collected via impression cytology (CIC) were 
presented. In first section, details describing the use of two different filter paper 
membranes that are routinely used for CIC namely PES and MP, were used in 
conjunction with two different kits that are commercially available to isolate RNA form 
the cells. The second section explains the two techniques to isolate total protein from MP 
membrane. 
Studies characterizing the conjunctival surface have often used tissue samples and 
biopsies obtained during cataract surgery,27 conjunctival tissue collected from eye bank 
donors30 or have used animal models31 to describe conjunctival morphology32 or 
histological characteristics of the ocular surface epithelia.33 These procedures are 
obviously highly invasive and impractical to undertake on a routine basis. One of the 
main advantages of CIC is that it can be performed in a routine clinical setting, enabling 
clinicians and researchers to collect viable epithelial cells, which can be subsequently 
analyzed using an endless list of techniques, including microscopy,4, 12, 34 flow 
cytometry,35, 36 Western blotting37 and Reverse Transcription - Polymerase Chain 
Reaction (RT-PCR) 7, 16, 17, 22 Of all the various different membranes1-3, 9, 38, 39 and 
devices40 available to perform impression cytology; cellulose acetate membranes have 
attracted the most use.3, 12  
This study demonstrated that MP membranes processed with either the TZ or RN 
methods are equally efficient for the isolation of high quality RNA from conjunctival 
cells collected in situ via CIC. The phase separation method (TZ) is one of the least 
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expensive  procedures20 and is also a state of the art protocol if microRNA processing is 
required. During sample homogenization or lysis, TRIZOL Reagent maintains the 
integrity of the RNA, while disrupting cells and dissolving cell components. However, 
time consuming and tedious methods such as CsCl step gradient ultracentrifugation and 
alcohol precipitation steps, or methods involving the use of toxic substances such as 
phenol and /chloroform, are replaced by the RNeasy procedure. The advantage of the RN 
technique is that it can isolate all RNA molecules longer than 200 nucleotides, although it 
has a maximum loading capacity of 100 µg for each mini column. The RNA obtained 
using this technique is of high quality and integrity and can be used for downstream 
applications such as cDNA synthesis, RT-PCR, and gene array analysis. From a “user 
friendly” view point, the adoption of the RN method due to enhanced speed as well as 
on-column isolation and DNase-digestion is recommended. 
In addition, this study describes a method based on CIC to collect high quality 
protein from the human ocular surface. It should be noted that this is the first known 
account for isolation of total protein. Results suggested that there was no significant 
difference in the amount of protein extracted from membranes processed via the various 
methods assessed. All methods provided an adequate yield of intact protein as evidenced 
by successful Western blotting of a constitutively expressed protein (LOX2). In a clinical 
research set up, CIC followed by immediate flash freezing is useful. Thus, from a “user 
friendly” view point, we recommend the adoption of the flash freezing method post CIC 
and that EB+PI be used to extract protein. 
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8.7 Conclusion 
CIC has been used in many clinical studies and has attracted the attention of many 
researchers and clinicians. Due to its simplicity, ease of use and ability to facilitate both 
gene and protein analysis as demonstrated in this work, one can anticipate the increased 
utility of CIC in the years ahead as we strive to more thoroughly characterize the ocular 
surface.   
 236
References 
1. Calonge M, Diebold Y, Saez V, Enriquez de Salamanca A, Garcia-Vazquez C, 
Corrales RM, Herreras JM. Impression cytology of the ocular surface: a review. 
Exp Eye Res 2004;78:457-72. 
2. McKelvie P. Ocular surface impression cytology. Adv Anat Pathol 2003;10:328-
37. 
3. Nelson JD. Impression cytology. Cornea 1988;7:71-81. 
4. Tseng SC. Staging of conjunctival squamous metaplasia by impression cytology. 
Ophthalmology 1985;92:728-33. 
5. Dart J. Impression cytology of the ocular surface--research tool or routine clinical 
investigation? Br J Ophthalmol 1997;81:930. 
6. Egbert PR, Lauber S, Maurice DM. A simple conjunctival biopsy. Am J 
Ophthalmol 1977;84:798-801. 
7. Inatomi T, Spurr-Michaud S, Tisdale AS, Gipson IK. Human corneal and 
conjunctival epithelia express MUC1 mucin. Invest Ophthalmol Vis Sci 
1995;36:1818-27. 
8. Nolan GR, Hirst LW, Wright RG, Bancroft BJ. Application of impression 
cytology to the diagnosis of conjunctival neoplasms. Diagn Cytopathol 
1994;11:246-9. 
9. McKelvie PA, Daniell M. Impression cytology following mitomycin C therapy 
for ocular surface squamous neoplasia. Br J Ophthalmol 2001;85:1115-9. 
10. McKelvie PA, Daniell M, McNab A, Loughnan M, Santamaria JD. Squamous cell 
carcinoma of the conjunctiva: a series of 26 cases. Br J Ophthalmol 2002;86:168-
73. 
11. Divani SN, Margari C, Zikos GA, Zikos A, Papavassiliou GB. Diagnostic 
impression cytology: a simple technique for the diagnosis of external eye disease. 
Cytopathology 1997;8:373-80. 
 237
12. Nelson JD, Havener VR, Cameron JD. Cellulose acetate impressions of the ocular 
surface. Dry eye states. Arch Ophthalmol 1983;101:1869-72. 
13. Tole DM, McKelvie PA, Daniell M. Reliability of impression cytology for the 
diagnosis of ocular surface squamous neoplasia employing the Biopore 
membrane. Br J Ophthalmol 2001;85:154-8. 
14. Thiel MA, Bossart W, Bernauer W. Improved impression cytology techniques for 
the immunopathological diagnosis of superficial viral infections. Br J Ophthalmol 
1997;81:984-8. 
15. Vadrevu VL, Fullard RJ. Enhancements to the conjunctival impression cytology 
technique and examples of applications in a clinico-biochemical study of dry eye. 
Clao J 1994;20:59-63. 
16. Corrales R, Calonge M, Herreras J, Saez V, Mayo A, Chaves F. Levels of mucin 
gene expression in normal human conjunctival epithelium in vivo. Curr Eye Res 
2003;27:323-8. 
17. Corrales RM, Calonge M, Herreras JM, Saez V, Chaves FJ. Human epithelium 
from conjunctival impression cytology expresses MUC7 mucin gene. Cornea 
2003;22:665-71. 
18. Corrales RM, Galarreta DJ, Herreras JM, Calonge M, Chaves FJ. [Normal human 
conjunctival epithelium expresses MUC13, MUC15, MUC16 and MUC17 mucin 
genes]. Arch Soc Esp Oftalmol 2003;78:375-81. 
19. Narayanan S, Miller WL, McDermott AM. Expression of human beta-defensins 
in conjunctival epithelium: relevance to dry eye disease. Invest Ophthalmol Vis 
Sci 2003;44:3795-801. 
20. Mack E, Neubauer A, Brendel C. Comparison of RNA yield from small cell 
populations sorted by flow cytometry applying different isolation procedures. 
Cytometry A 2007;71:404-9. 
21. Argueso P, Spurr-Michaud S, Russo CL, Tisdale A, Gipson IK. MUC16 mucin is 
expressed by the human ocular surface epithelia and carries the H185 
carbohydrate epitope. Invest Ophthalmol Vis Sci 2003;44:2487-95. 
 238
22. Argueso P, Balaram M, Spurr-Michaud S, Keutmann HT, Dana MR, Gipson IK. 
Decreased levels of the goblet cell mucin MUC5AC in tears of patients with 
Sjogren syndrome. Invest Ophthalmol Vis Sci 2002;43:1004-11. 
23. Hori Y, Spurr-Michaud S, Russo CL, Argueso P, Gipson IK. Differential 
regulation of membrane-associated mucins in the human ocular surface 
epithelium. Invest Ophthalmol Vis Sci 2004;45:114-22. 
24. Chung SH, Lee JH, Yoon JH, Lee HK, Seo KY. Multi-layered culture of primary 
human conjunctival epithelial cells producing MUC5AC. Exp Eye Res 
2007;85:226-33. 
25. Lange C, Fernandez J, Shim D, Spurr-Michaud S, Tisdale A, Gipson IK. Mucin 
gene expression is not regulated by estrogen and/or progesterone in the ocular 
surface epithelia of mice. Exp Eye Res 2003;77:59-68. 
26. Gipson IK, Spurr-Michaud S, Argueso P, Tisdale A, Ng TF, Russo CL. Mucin 
gene expression in immortalized human corneal-limbal and conjunctival epithelial 
cell lines. Invest Ophthalmol Vis Sci 2003;44:2496-506. 
27. Inatomi T, Spurr-Michaud S, Tisdale AS, Zhan Q, Feldman ST, Gipson IK. 
Expression of secretory mucin genes by human conjunctival epithelia. Invest 
Ophthalmol Vis Sci 1996;37:1684-92. 
28. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 
1987;162:156-9. 
29. Werbrouck H, Botteldoorn N, Uyttendaele M, Herman L, Van Coillie E. 
Quantification of gene expression of Listeria monocytogenes by real-time reverse 
transcription PCR: optimization, evaluation and pitfalls. J Microbiol Methods 
2007;69:306-14. 
30. McKenzie RW, Jumblatt JE, Jumblatt MM. Quantification of MUC2 and 
MUC5AC transcripts in human conjunctiva. Invest Ophthalmol Vis Sci 
2000;41:703-8. 
31. Barabino S, Chen W, Dana MR. Tear film and ocular surface tests in animal 
models of dry eye: uses and limitations. Exp Eye Res 2004;79:613-21. 
 239
32. Dursun D, Wang M, Monroy D, Li DQ, Lokeshwar BL, Stern ME, Pflugfelder 
SC. A mouse model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci 
2002;43:632-8. 
33. Gipson IK, Argueso P. Role of mucins in the function of the corneal and 
conjunctival epithelia. Int Rev Cytol 2003;231:1-49. 
34. Adams AD. The morphology of human conjunctival mucus. Arch Ophthalmol 
1979;97:730-4. 
35. Brignole-Baudouin F, Ott AC, Warnet JM, Baudouin C. Flow cytometry in 
conjunctival impression cytology: a new tool for exploring ocular surface 
pathologies. Exp Eye Res 2004;78:473-81. 
36. Baudouin C, Brignole F, Becquet F, Pisella PJ, Goguel A. Flow cytometry in 
impression cytology specimens. A new method for evaluation of conjunctival 
inflammation. Invest Ophthalmol Vis Sci 1997;38:1458-64. 
37. Liu Z, Carvajal M, Carothers Carraway CA, Carraway KL, Pflugfelder SC. 
Increased expression of the type 1 growth factor receptor family in the 
conjunctival epithelium of patients with keratoconjunctivitis sicca. Am J 
Ophthalmol 2000;129:472-80. 
38. Meena MK, Khuteta A, Saxena H. Nylon paper: an alternative to cellulose acetate 
paper for use in conjunctival impression cytology. Br J Ophthalmol 
2005;89:1223-4. 
39. Singh R, Joseph A, Umapathy T, Tint NL, Dua HS. Impression cytology of the 
ocular surface. Br J Ophthalmol 2005;89:1655-9. 
40. Jackson JA, Perrigin JA. Relationship of impression cytology and tear ferning to 







9 Expression of MUC1 and MUC16 in tears and conjunctival 
epithelial cells collected from postmenopausal women 
experiencing symptoms of dry eye 
9.1 Abstract 
Purpose: To quantify the expression of MUC1 and MUC16 mRNA and protein in a 
group of symptomatic dry-eyed postmenopausal women (PMW) compared to 
asymptomatic controls and to investigate the potential relationship between mucin 
expression and tear film breakup time. 
 
Methods: 83 healthy PMW (>50 years of age) were categorized as being symptomatic of 
dry eye (DE) or asymptomatic (NDE)) based on their responses to the Allergan Ocular 
Surface Disease Index© (OSDI) questionnaire. Non-invasive tear breakup time 
(NITBUT) was evaluated using the ALCON Eyemap®. Tears were collected from the 
inferior tear meniscus using a disposable glass capillary tube and an eye wash method. 
Conjunctival epithelial cells were collected via impression cytology and from these 
specimens both total RNA and total protein were isolated. Expression of MUC1 and 
MUC16 mRNA was assessed via real time PCR. Expression of both membrane-bound 
and soluble MUC1 and MUC16 were quantified via Western blotting.  
 
Results: OSDI responses identified 44 symptomatic (age = 63.6±9.4 yrs) and 39 
asymptomatic (age = 59.5±6.6 yrs) participants. The DE group exhibited a significantly 
shorter NITBUT (DE = 5.3 ± 1.5 sec; NDE = 7.0 ± 2.7 sec; p=0.005). No difference in 
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MUC1 or MUC16 mRNA or protein (soluble or membrane bound) expression was found 
between DE and NDE. Weak correlations were found between the NITBUT values 
compared with MUC 1 and MUC16 mRNA and protein expression. 
 
Conclusions: No difference was found in the expression of either MUC1 or MUC16 
protein or mRNA expression between symptomatic PMW and asymptomatic controls. 
Symptomatic women did differ from controls with respect to significantly reduced 
NITBUT. NITBUT values do not appear to be associated with MUC1 and MUC16 
expression (protein or mRNA). Further research is required to investigate the potential 
use of biomarkers such as MUC1 and MUC16 in the characterization of dry eye disease.  
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9.2 Introduction 
Numerous compositional models of the tear film have been proposed. The first 
description by Wolff1 in 1946, presented a three-layered tear film, consisting of an 
anterior lipid layer, middle aqueous layer and inner mucin layer. As additional 
information became available, this model evolved to accommodate the possibility of 
soluble mucins in the aqueous layer, decreasing in concentration towards the lipid layer.2 
The present concept is that the tear film is a bilayered structure, consisting of an 
aqueous/mucinous phase and an outermost multi-layered lipid phase.3   
Of the various components of the tear film, mucins are thought to play a key role 
in the retention of water and other tear fluid components on the ocular surface, 
facilitating a healthy, wet ocular surface. Earlier, mucins were only thought to be secreted 
by goblet cells. However, studies have now shown that membrane-associated mucins also 
exist.4-7 To-date, at least twenty different mucin subtypes have been characterized.6, 8-16 
Both secreted (MUC2, MUC5AC, MUC5B, MUC7) and membrane bound (MUC1, 
MUC4, MUC16) forms have been reported to be expressed by ocular surface epithelia.17, 
18 Of the mucins identified on the ocular surface, two soluble (MUC2 and MUC5AC) and 
three membrane-bound (MUC1 and MUC 4, MUC 16) forms are considered “critical” for 
the maintenance of a “normal” tear film. 17 MUC2 and  MUC5B are present in very low 
quantities.17, 19  
Alternative forms of MUC120 and MUC1619 exist,21, 22 as recently illustrated by 
Hori et al,23 who described soluble MUC16 in the tears. The alternative forms of MUC1 
and MUC 16 lack the cytoplasmic tail portion of the protein and thus are secreted or shed 
into the tear film, as opposed to being anchored into epithelial cell membranes. Whether 
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these secreted species are present in all tear samples and/or whether their concentrations 
differ between subjects complaining of dry eye compared to asymptomatic subjects has 
yet to be investigated. The specific functions of secreted mucins are not known, although, 
evidence does suggest that MUC16 is an important hydrophilic molecule involved in the 
maintenance of a healthy ocular surface. 
Although alteration in mucin expression and / or mucin glycosylation have been 
implicated in the pathophysiology of dry eye, only a limited number of studies addressing 
these issues have been conducted. To date, the primary focus has been MUC5AC.24 The 
majority of these studies have focussed on Sjogren’s syndrome, young adults with dry 
eye complaints, contact lens wearers, allergic conjunctivitis or non-human (rodent) 
studies.24-30   
The results of large epidemiological studies31  conducted in the United States 
clearly suggest that the prevalence of dry eye is greater in women than in men and that 
approximately 3.2 million women and 1.6 million men aged 50 years or older suffer from 
moderate to severe dry eye and women frequently consult clinicians with symptoms of 
ocular dryness and discomfort.32, 33 To date, no work has focused on whether post 
menopausal women (PMW) complaining of dry eye disease show any difference in the 
expression of ocular muicns.  Such information is needed to help understand the role 
played by various mucins in dry eye disease and would help to guide the development of 
mucin secretagogues intended for the therapeutic treatment of dry eye.  
As highlighted in earlier chapters of this thesis, due to the complicating factors in 
the diagnosis and management of dry eye, an enhanced biochemical understanding of the 
pathophysiological / biochemical processes underlying dry eye would enable both the 
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proper utilization and continued development of specific and sensitive diagnostic tests to 
facilitate objective reproducible and standardized diagnostic tests and methods to 
evaluate treatment efficacy. 
In light of the above, the aim of this study was to quantify the expression of 
MUC1 and MUC16 protein (soluble and membrane bound) and mRNA in a group of 
symptomatic dry eyed PMW compared to asymptomatic controls and also to investigate 




Informed consent was obtained from all participants following explanation of the 
purpose of the study and its various procedures, prior to participation in the study. A case 
history and complete ocular surface examination was performed to determine participant 
eligibility. Participants on hormone replacement therapy (HRT) were excluded, as were 
contact lens wearers and participants receiving any topical ocular medication or systemic 
medication known to exacerbate dry eye. Participants with a prior history of blepharitis 
and/or active blepharitis at the time of recruitment were also excluded from the study. For 
the purpose of this study, “postmenopausal” was defined as no menses for at least one 
year, not associated with hysterectomy. Eighty three healthy PMW greater than 50 years 
of age were recruited. 
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9.3.2 Subjective symptoms 
Participants completed the Allergan Ocular Surface Disease Index© (OSDI) 
questionnaire34 and were categorized as being symptomatic (44 individuals; age = 
63.6±9.4 yrs) or asymptomatic (39 individuals; age = 59.5±6.6 yrs) of dry eye, based on 
their response to OSDI, as described in chapter 4 section 4.3 of this thesis and in detail 
elsewhere.34   This study was conducted in two sections. The first section was named post 
menopausal women study 1 (PM1) that consisted of 37 participants. Post menopausal 
women study 2 (PM2) consisted of 46 participants.  
9.3.3 Objective measurements 
Tear stability was assessed by performing non invasive tear breakup time 
(NITBUT) using the ALCON Eyemap® model EH-290 topography system (ALCON, 
Inc., Forth Worth, Texas, USA). This is explained in detail in chapter 3, section 3.4. 
9.3.4 Analytical techniques 
9.3.4.1 Reagents and materials 
A SE600 vertical gel unit was purchased from E Biosciences (Amersham, San 
Diego, California, USA). Agarose was purchased from Cambrex Bio Science  (Rockland, 
ME, USA). Gel buffer, tank buffer, vacuum blotter, nitrocellulose membrane and, 
blotting paper were purchased from BioRad (Mississauga, ON, Canada). Glycerol and 
transfer buffer were purchased from EMD, USA. Molecular weight standards (Himark 
prestained protein standard) were purchased from Invitrogen (Carlsbad, California, 
USA). ECL-Plus™ kits were purchased from GE Healthcare (Baie d'Urfe, QC, Canada). 
Immuno-Blot® PVDF (polyvinylidene difluoride) membrane and DC Protein Assay 
Kit® were purchased from BioRad Laboratories (Mississauga, ON, Canada). Mouse 
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monoclonal anti-human MUC 1 antibody (DF3) was purchased from Signet (Dedham, 
MA, USA), monoclonal mouse anti-human MUC16 antibody (OC125) was purchased 
from DAKO (Glostrup, Denmark), and goat anti-mouse IgG-HRP from Santa Cruz 
Biotechnology Inc (Santa Cruz, California, USA). Millipore™ Membrane Filters were 
purchased from Millipore™ (Billerica, MA, USA).  RNeasy® Mini kit was purchased 
from Qiagen Inc. (Mississauga, ON, Canada). Beckman DU530 Life Science UV/Visible 
Spectrophotometer from Beckman Coulter (Fullerton, CA, USA) and Taqman® Universal 
PCR Master Mix and 7500 Real Time PCR System (Applied Biosystems, Foster City, 
CA) were used in the study.  
9.3.4.2 Capillary tear collection 
Using a graduated disposable 5 μl microcapillary tube (Wiretol-Micropipettes, 
Drummond Scientific Co., Broomall, PA, USA) up to 5 μl of tears / eye were collected 
from the inferior temporal tear meniscus of the PM1 and PM2 participants. Further 
details are presented in chapter 3, section 3.6.  
9.3.4.3 Eye wash tear collection 
A second method of tear collection, using an eye wash method, was undertaken 
on only PM2 participants, as described elsewhere.24 Further details are presented in 
chapter 3, section 3.10. The two collections were separated by 15 – 25 minutes to allow 
for tear film regeneration.  
9.3.4.4 Conjunctival impression cytology (CIC) 
Conjunctival epithelial cells were collected from all volunteers via impression 
cytology using 10mm Millipore (MP) membranes placed on both the superior and 
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temporal conjunctiva of both eyes. The left eye and right eye samples were kept separate. 
The CIC samples from the right eye were used for mRNA expression work. Samples 
from the left eye were used for analysis of MUC1 and MUC16 protein. Preparation of 
CIC membranes and the entire CIC procedure is described in detail in chapter 3, section 
3.11. CIC samples were collected from both PM1 and PM2 participants. 
9.3.4.5 Electrophoresis and immunoblotting 
Total protein was isolated from epithelial cells (left eye) collected using 50µl of 
extraction buffer (50 mM Tris, 2% SDS, 1X Protease Inhibitor™, (PI) (Roche 
Diagnostics, Indianapolis, Indiana, USA). Total protein in 5 µL of cell lysate, 0.5 µL of 
capillary tear samples or 5 µL of the eyewash samples were quantified using BioRad’s 
DC™ protein assay. Step-wise procedures are detailed in chapter 3, sections 3.13.1 and 
3.13.2 and appendices D & E. 
Protein samples were subjected to agarose gel electrophoresis using a SE600 
vertical gel unit, then transferred to nitrocellulose membranes in a vacuum blotter. A 
titration of MUC16 standard antigen (CA125, Biodesign) or MUC 1 standard antigen 
(CA15-3, Biodesign) was run on each gel to normalize data and facilitate semi-
quantitation of samples, through linear regression analysis. For MUC1 identification, 6 
µg/lane of total protein for tears and 20µg/lane of total protein for IC samples was loaded 
per lane.  For MUC16, 4.0 µg/lane of total protein for tears and 5.0 µg/lane of total 
protein for IC samples was loaded per lane.  MUC1 was identified using a mouse 
monoclonal DF3 primary antibody, followed by an anti-mouse IgG secondary antibody. 
MUC 16 was identified using a mouse monoclonal OC 125 primary antibody, followed 
by goat anti-mouse IgG secondary antibody. This is explained in detail in methods 
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chapter 3, section 3.13.4. Immunoreactivity was visualized with ECL Plus® 
chemiluminescent substrate (GE Health Care) and the optical densities of the resulting 
bands were quantified from digitized images created with a Molecular® Dynamics 
Storm™ 840 Imager using ImageQuant™ 5.1. 
9.3.4.6 RNA isolation and reverse transcription 
Total RNA was isolated from impression cytology samples using RNeasy™ Mini 
(RN) kit (Qiagen), according to the manufacturer’s protocol, with several modifications. 
This is explained in detail in Appendix G. RNA quantity and quality was assessed by 
measuring the optical density using a Beckman DU530 Life Science UV/Visible 
Spectrophotometer at 260nm and 280nm. DNA was synthesized from 8µL of RNA 
sample using random hexamer primers with Superscript™ III First-Strand Synthesis 
System for RT-PCR (Invitrogen, Carlsbad, CA), according to the manufacturer’s 
instruction.  
 
9.3.4.7 Real time- qPCR 
Relative expression of genes of interest was performed in multiplex PCR 
reactions containing target and endogenous control oligonucleotide primers in the 
presence of gene-specific dye-labeled Taqman probes (Table 9- 1). Step wise procedures 





Table 9-1: Sequence of primers and probes used for gene amplification in Real Time 
RT-PCR 




















Conventional RT-PCR experiments were performed to confirm the identity of the 
PCR products. Following 40 cycles of cDNA amplification using the MUC1 and MUC16 
primers detailed above, unique bands corresponding to the predicted size for MUC1 and 
MUC16 was obtained. PCR products were electrophoresed in 1.0% agarose gels 
containing ethidium bromide. The bands in the agarose gel were excised and extracted for 
sequencing analysis (Alcon Research Ltd, USA) to verify the identity of the MUC1 and 
MUC16 PCR products. For real-time qPCR, the expression levels of mRNA were 
normalized by the median expression of the housekeeping gene (glyceraldehyde-3-
phosphate dehydrogenase). 
 
9.3.5 Statistical analysis 
Statistical analysis was performed using Statistica Ver7.1 (StatSoft Inc., Tulsa, 
OK, USA) and Microsoft Excel™ XLfit© software. Graphs were plotted using Statistica 
Ver7.1.  All data are reported as mean ± standard deviation. Mann Whitney U test was 
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used for comparison of OSDI questionnaire and NITBUT data. Statistical differences 
between groups for biomarker data were identified by using one-way ANOVA, and when 
necessary, Dunnett’s comparison of means and by Tukey’s test. Significance was 
identified at p<0.05 (α = 0.05). Pearson correlations between NITBUT and mucin 
expression were calculated in Statistica Ver7.1 (StatSoft Inc., Tulsa, OK, USA). 
 
9.4 Results 
The mean age of the participants was 63.6 ± 9.4 yrs in the symptomatic group 
(n=44) and 59.5 ± 6.6 yrs in the asymptomatic group (n=39). Of the 83 participants 
enrolled, only one participant reported severe dry eye symptoms. So as to work with two 
defined dry eye sub-groups (mild and moderate), this “severe” subject was excluded from 
analysis, resulting in 43 participants in the dry eye group.  
9.4.1 Subjective symptoms 
In this study, the presence and severity of dry eye was determined based on 
symptoms only, as quantified by total OSDI score, using the following criteria: control 
(non-dry eye, NDE) OSDI score = 0-12; mild dry eye OSDI score = 13-22 and moderate 
dry eye OSDI score=23-32 (see Table 9-2). Based on this criterion, 39 subjects were 
defined as controls. 16 subjects presented with mild dry eye and the remainder (n=27) 
were classified as moderate. Mean ages (mean ± SD) of the control, mild and moderate 
groups were 59.6 ± 6.6, 63.5 ± 10.5 and 63.4 ± 8.5 years respectively. There was no 
significant difference between the ages of the three groups (p=0.07). The total OSDI 
scores for the two dry eyed groups were significantly higher compared to the NDE group 
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(p<0.0001), as was the total score of the moderate group compared to the mild group 
(p=0.01). Analysis of the individual OSDI sub scores revealed a significantly elevated 
score for the mild and moderate DE groups in each category compared to the NDE group, 
with the exception of the Vision Related Function score, where there was no distinction 
between NDE and mild dry eye. Mild and moderate dry eye sub scores were statistically 
similar, with the exception of the Vision Related Function score, which was significantly 
elevated in the moderate group (p<0.01).  
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p (α =0.05) 
(NDE vs 
Mild) 
p (α =0.05) 
(NDE vs 
Moderate) 
p (α =0.05) 
(Mild vs 
Moderate) 






13.02 <0.001* <0.001* 0.01* 


























27.21 <0.001* <0.001* 0.68 
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Figure 1 reports the NITBUT determined by the corneal topographer. NITBUT 
was significantly reduced in both mild (p=0.02) and moderate (p=0.008) DE subjects 
compared to the NDE group, and no difference was found between the two dry-eyed 
groups (p=0.88).   
 
 
Figure 9-1: Box plots of non invasive tear film break-up measurements  
Inner boxes represent mean, dotted boxes represent standard error and whiskers represent 
standard deviation of NITBUT measurements from non dry-eyed (NDE), mild dry eye and 






Stratification of total protein values based on dry eye symptom severity was not 
performed with eye wash data due to the relatively small sample size of both DE groups.   
Table 9-3 reports all the data of PM1. Table 9-4 represents data from PM2. All data are 
expressed as mean ± standard deviation. Tear collection through the eye wash method 
was not performed in PM1. Tear collection using the capillary technique for PM2 is not 
reported in this chapter, as the tears were used for lipocalin and lysozyme analysis 
(reported in chapter 7) and cytokine analysis (not reported in thesis). 
9.4.2 Tear total protein 
The total protein in the tears collected by glass capillary tube samples from PM1 
are highlighted in Table 9-3. No difference in protein concentration was found comparing 
DE to NDE groups in tear samples (p=0.056). Similar findings were noted in PM2 (Table 
9-2), showing no difference between eye wash methods between the two groups (p= 
0.26). Although protein concentration was lower in tears collected using the eye wash 
method due to dilution with saline, no difference (p=0.26) was found in protein 
concentration between the NDE (1.91 ± 0.94 µg/µL) and pooled DE groups (1.61 ± 0.81 
µg/µL).  
9.4.3 Expression of MUC1 protein in tears and conjunctival epithelial cells 
Quantification of all chemiluminescent signals  >150 kDa, revealed no significant 
differences in either tear or IC MUC1 protein expression between DE and NDE as 
calculated by extrapolation from linear regression plots constructed from CA15-3.  
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9.4.4 Expression of MUC16 protein in tears and conjunctival epithelial cells 
Electrophoretic patterns of all samples suggested numerous isoforms of both 
soluble and membrane bound MUC16 exist. Quantification of all chemiluminescent 
signals >150 kDa, revealed no significant differences in either membrane bound or 
soluble mucin expression between DE and NDE for PM1 as calculated by extrapolation 
from linear regression plots constructed from CA125 (Figure 9-3).  MUC16 expression in 
eyewash samples showed no difference in the DE and NDE groups as shown in Table 9-











Figure 9-2: Western blot for MUC16 
(a) An example of membrane bound MUC 16 Western blot from IC protein samples. Last 5 lanes 
are the MUC 16 Standard, CA 125, 5-70 units (b) The same blot showing how the lanes were 









Figure 9-3: Regression analysis for MUC 16 quantification  
A regression curve was created by graphing applied concentration of MUC 16 standard against 
the optical density of the resulting band immunoreactivity. Total MUC 16 concentration was 
quantified by extrapolation from this curve. 
(a) (b)
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Table 9-3: Summary of PM1 study biomarker data 
 
ID 1 to 39 (PM1 study) 
 Biomarker Sample type 
Normal Dry eye p value 
Total Protein 
(µg) Capillary tears 
6.6 ±2.6 
(n=19) 




MUC1* (AU) Capillary tears 
0.04 ± 0.08 
(n=19) 





Capillary tears 2.66 ± 1.29 (n=15) 






IC 0.014 ± 0.013 (n=19) 
























*  MUC 1 ≤ 250 kDa; ** MUC 16 ≤ 350 kDa; +   Denotes Membrane bound fraction 
of MUC1 or 16 derived from epithelial cells  collected via conjunctival impression 
cytology; IC = Impression cytology samples; AU = arbitrary units based on 
extrapolation from internal standard; RQ = mean value for gene of interest 
normalized to expression of GAPDH mRNA; n/a = not applicable; § = significant 
difference 
 
9.4.5 Expression of MUC1 mRNA in conjunctival epithelial cells 
Real time PCR results showed that the levels of the MUC1 remained unaltered in 
both groups in PM1 and PM2 (p=0.077 and 0.27 respectively). The internal standard that 
allows pooling the samples between studies 1 and 2 failed (a single sample was 
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designated and used as a "reference” and the amplification of that sample failed in PM2); 
hence the results from MUC1 from PM1 and 2 are reported individually.  
9.4.6 Expression of MUC16 mRNA in conjunctival epithelial cells 
PM1 (n= 34) showed a significant increase in the MUC16 mRNA expression in 
the DE group (p=0.01). Upon addition of data from PM2, (n=78), there was no 
significant difference in the MUC16 expression (p=0.06).  
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Table 9-4: Summary of PM2 study biomarker data 
 




Normal Dry eye p value 
Total Protein EW 1.91±0.94 (n=20) 1.61±0.81 (n=24) 0.26 







MUC1* EW 0.37±0.34 (n=14) 0.56±0.47 (n=15) 0.25 










IC 0.57±0.21 (n=20) 0.62±0.28 (n=24) 0.476 
 
MUC1 mRNA 





mRNA (RQ) IC 
0.35±0.11 
(n=20) 





IC 0.36±0.21 (n=38) 0.67±0.83 (n=40) 0.06 
 
IC = Impression cytology samples; EW  = Eye wash tear samples; *  MUC 1 ≤ 250 
kDa ** MUC 16 ≤ 350 kDa; +   Denotes Membrane bound fraction of MUC1 or 16 
derived from epithelial cells  collected via conjunctival impression cytology; RQ = 
mean value for gene of interest normalized to expression of GAPDH mRNA; AU = 





9.4.7 Correlation between mucin expression and NITBUT 
Correlation analysis between NITBUT and mucin expression showed weak and 
insignificant correlation for both PM1 and PM2, as highlighted in Tables 9-5 and 9-6. 
MUC16 mRNA expression and NITBUT showed a weak but significant correlation for 
PM1 only. 
 
Table 9-5: Summary of correlations between NITBUT and mucin expression in 
PM1 study 
 
ID 1 to 39 (PM1 study) 
Biomarker NITBUT p value 
Tear Film MUC1 -0.23 0.16 
Tear Film MUC16 -0.21 0.30 
Membrane Bound 
MUC1 -0.10 0.60 
Membrane Bound 
MUC16 -0.21 0.20 
MUC1 mRNA -0.13 0.46 
MUC16 mRNA -0.37 0.04* 








Table 9-6: Summary of correlations between NITBUT and mucin expression in 
PM2 study 
 
ID 40 to 86 (PM2 study) 
Biomarker NITBUT p value 
Eye wash MUC1 -0.17 0.37 
Eye wash MUC16 -0.20 0.37 
Membrane Bound 
MUC1 0.10 0.59 
Membrane Bound 
MUC16 -0.30 0.84 
MUC1 mRNA -0.20 0.25 
MUC16 mRNA -0.16 0.30 
 
9.5 Discussion 
In this study we quantified the expression of MUC1 and MUC16 mRNA and 
protein in a group of symptomatic dry-eyed PMW compared to asymptomatic controls. 
Such information is needed to help understand the role played by mucins in dry eye 
disease and will help to guide the development of mucin secretagogues intended for the 
therapeutic treatment of dry eye. We also have attempted to explore the potential 
relationship between mucin expression and tear film breakup time. 
We chose to stratify subjects solely on symptoms, as quantified by the OSDI 
questionnaire. It is a validated questionnaire recommended by the DEWS 2007 report and 
it is one way of potentially classifying participants based on symptom scores. Based on 
the OSDI criteria, we enrolled three statistically distinct groups: those without symptoms 
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of dry eye and those with either mild or moderate dry eye. Review of objective 
measurements suggested that both tear secretion and NITBUT were significantly reduced 
in moderately symptomatic dry-eyed subjects relative to controls. Additionally, mildly 
symptomatic dry-eyed subjects presented significantly reduced NITBUT relative to 
controls. 
Power analysis to determine sample size is based on historical data. Studies on 
mucin biomarkers and its impact on dry eye disease have started to attract researchers’ 
interest only in the past decade. Ocular mucin studies to date (summarized below) have 
utilized only small sample sizes and largely have failed to demonstrate significance. In 
addition, data from these studies has suggested significant variability in the concentration 
or expression of mucin biomarkers. Preliminary data from our lab have shown that up to 
25% of recruited subjects fail to provide sufficient biological material to facilitate reliable 
and repeatable analysis. Thus, all taken together, it was not possible to perform 
mathematical power calculations, but rather we recruited a sample size larger than any 
study published to date. 
There have been very few studies on mucin gene expression, mucin protein or 
mucin glycosylation in dry eye syndromes. Of these, data indicate that mucin gene 
expression and translation, as well as mucin post-translational processing, may be 
implicated in the pathophysiology of dry eye.17 Most of the mucin expression studies 
conducted have focused on MUC5AC.24, 35-38  Studies have shown the relationship 
between dry eye disease and decrease in the expression of goblet cell MUC5AC in KCS 
and Sjogren’s syndrome. Such a result is expected, as goblet cells are the sole source of 
MUC5AC and goblet cells are reduced in conditions of dry eye.24, 35-38  Very little is 
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known about the membrane spanning mucins such as MUC1 and MUC16 and their role 
in dry eye disease, hence, we chose to focus our efforts on these species. 
Our study is novel in the fact that a unique subset of participants (PMW) was 
studied and that MUC1 and MUC16 were the focus. The data reported in table 9-3 and 
table 9-4 are different due to the fact that the standard curve used in PM1 was different 
from the standard curve that was used in PM2 (the analysis was performed in two 
different labs - each used its own scale for the standard curve). The data are expressed in 
arbitrary units (AU) and the relative expression (not the absolute values) was compared 
and statistical analysis was performed.  
Few studies have shown an increased expression of mucins,28, 39 although 
literature on ocular surface expression of MUC1 and MUC16 is sparse. Gipson et al,19  
using sensitive and semi-quantitative methods for the assay of mucins in tears, very 
recently demonstrated the presence of a soluble form of MUC16 in human tears collected 
using an eye wash technique similar to the technique employed in this study.19 No 
relationship to dry eye was found.   
Argueso et al24 has demonstrated that the number of RNA transcripts for 
MUC5AC in the conjunctival epithelium and protein levels of MUC5AC in tears of 
patients with Sjogren’s syndrome were significantly lower than in normal individuals.24  
However, the same study by Argueso et al24 showed no significant change in MUC1 or 
MUC4 mRNA expressed by the stratified epithelium of the conjunctiva.24 This study 
compared Sjogren’s (n=11) subjects to normals (n=16). This result is in agreement with 
our mRNA data MUC 1 data obtained via CIC samples, showing no significant 
difference between the two groups evaluated in this study. 
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Danjo et al26 demonstrated a significant difference in the binding pattern of an 
antibody against a carbonate epitope antibody (H185) carried by MUC16 to conjunctival 
epithelium obtained by impression cytology in normal eyes (n= 13), compared with those 
of patients with non-Sjogrens dry eye (n=22). However, the study was not age matched 
(37 vs 63 years). The results of our PM1 showed also a significant difference between the 
MUC16 mRNA between the two groups. However, the combined PM1 and PM2 data 
showed no significant difference, showing the variability in the population studied. 
Additional data is required to determine whether or not a true difference in MUC16 
mRNA expression exists. Danjo et al26 in the same study reported that MUC1 and MUC4 
mRNA were not significantly different, although a trend toward a decrease in MUC1 
mRNA was speculated.26  Interpretation of these results is of concern because of the age 
range and the sample size.  
The majority of the O-glycosylation sites on the transmembrane mucins are found 
in a highly polymorphic core region containing a variable number of tandem repeats 
(VNTR). Analysis of brush cytology of the conjunctiva by Imbert et al40 has shown a 
decreased expression of MUC1 mRNA splice variant MUC/1A in dry eye patients (n=9) 
compared to controls (n=15), indicating that protein has fewer VNTRs in dry eye, which 
the investigators speculated may lead to poor lubrication of the ocular surface and hence 
ocular surface inflammation. Our data with a larger sample size did not show a variation 
in the MUC1 mRNA levels in the PMW dry eyed group for both PM1 or PM2. 
Pflugfelder et al27 has shown a reduction in the expression of mucosal epithelial 
membrane mucin in bulbar conjunctiva in Sjogrens syndrome (n=11) and non-Sjogrens 
syndrome dry eye (n=9) compared to normals (n=10). This study examined a small 
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sample size and was not age or sex matched (controls = 18-46, 5 male/5 female versus 
older and all female).27 This study focused on the correlation between the goblet cell 
density and expression of mucosal epithelial membrane mucin in bulbar conjunctiva. 
Dry eye disease is a symptom based disease and often studies fail to focus on mild 
and moderate forms of dry eye, which in our data set contributed to the majority of the 
dry eye data. Studies have shown increases in mucin expression in mild to moderate 
symptoms of dry eye and in allergy related studies. Hayashi et al39 showed that mild (n = 
19) and moderate (n = 17) dry eyed patients displayed increased expression of MUC1 
protein as detected by KL6 antibody compared to normals (n=23) in the temporal cornea 
and conjunctiva. Severe dry eyed (n = 7) individuals showed a decrease in MUC1 in the 
cornea only and no change was noted from normals in the conjunctiva.39 In atopic 
ketatoconjunctivitis (AKC), patients with significant epithelial disease and staining (n=10 
eyes) showed an increase in mRNA expression for MUC1, MUC2 and MUC4 mRNA 
compared to normals (n=22 eyes).28 A recent study on AKC versus vernal 
keratoconjunctivitis (VKC) showed higher level of tear instability, lower corneal 
sensitivity, up-regulation of MUC1, 2, and 4, and down regulation of MUC5AC were 
important differential features of the ocular surface disease in AKC (n=12), compared 
with VKC (n=6) and normals (n=10).41 No tears were examined in this study. 
Animal studies have also shown inconsistent results. Density gradient analysis of 
canine KCS tears (n=3) showed increased expression of some of the glycoprotein 
fractions and alteration in size and extent of mucin glycosylation.29 Mice that have 
defective parasympathetic innervation of their lacrimal glands showed a reduction in the 
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expression of MUC1 and MUC4 mRNA in their corneal epithelium. However, no 
significant difference was reported.30 
Thus, in summary, very little has been reported on MUC1 and MUC16 in dry eye 
and none in the population we studied. Our study was larger than any study conducted to 
date. Based on our data, we conclude that no difference exists in the expression of MUC1 
or MUC16 mRNA or protein. Although differences in function or glycosylation cannot 
be ruled out, at this time, our data suggest the lack of involvement of these 
transmembrane mucin species in symptomatic dry eye reported by PMW. 
We compared both MUC1 and MUC16 expression data with NITBUT and found 
weak statistically insignificant correlations. Although our work demonstrates that PMW 
with symptoms of dry eye had reduced tear stability, tears that were produced were 
biochemically within normal limits in this unique participant pool with respect to two 
measured ocular mucins, as well as total protein content.   
All of the above mentioned studies have employed different techniques to study 
different species of mucins. Research in the area of “functions of mucin and the ocular 
surface” are relatively new and has attracted many researchers over the past 10 years. The 
development of sensitive assays for mucins in the tear film will permit further studies on 
mucin on the ocular surface and of tears from patients with ocular surface disease. Such 





We can conclude that a mixture of shed membrane-associated and secreted 
mucins accounts for the mucin content of tears.  From our data, we can conclude that 
within a PMW population, expression of both MUC1 and MUC16 are unvarying, 
irrespective of the presence of dry eye symptoms. In addition, the concentration of either 
biomarker studied was not associated with tear stability. That previous studies have 
shown a difference in MUC1 and MUC16 concentration and/or correlation with tear 
dynamics may be attributed to the subgroup of dry eye subjects studied and the 
classification of their dry eye. This is the first comprehensive study of MUC1 and 
MUC16 mRNA and protein in symptomatic dry-eyed postmenopausal and our results 
suggest that neither would offer utility as a biomarker of dry eye.     
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10 General discussion and conclusions 
In this PhD project over 125 participants were screened to successfully recruit 86 
participants who matched the inclusion criteria. Of these, a few were unable to complete 
the study, due to the reasons highlighted in the Methods section of the thesis. However, 
some of the participants who successfully completed the study were unable to provide 
sufficient tear and conjunctival cell samples to perform the required analytical tests, 
emphasizing the difficulty in subject recruitment and sample collection in studies of this 
type.  
The low amounts of tear and cell sample yield often limits dry eye researchers 
from conducting analysis on a significant number of different dry eye biomarkers. Even 
though elaborate procedures have been developed for RNA isolation, working with RNA 
is a practical challenge. Minimal starting material and the high susceptibility of RNA to 
degradation were some of the major challenges faced while working with RNA samples 
in this study. One major draw back in this study was the inability to use vital stains to 
clinically diagnose dry eye. However, the presence of vital dyes in the samples may 
interfere with the subsequent analysis of biomarkers, especially isolation of RNA from 
the conjunctival epithelial cells. 
 
Table 2-1 clearly demonstrates that none of the dry eye prevalence studies have 
undertaken all of the potential tests to examine the tear film and the ocular surface, and 
also that different studies have used different cut-off criteria for the various tests. This is 
primarily because of the lack of agreement amongst researchers on the diagnostic 
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standard for dry eye diagnosis, and also because it is far too time-consuming to conduct 
all the potential tests.  
 
Chapter 4 highlights the use of dry eye questionnaires in determining the 
frequency and intensity of symptoms in PMW. Both the OSDI and the DEQ were 
valuable tools in grouping participants into those who were symptomatic and 
asymptomatic of dry eye. In a clinical set up, it is important to collect a range of 
information from a patient during the history taking. However, this task can be time 
consuming and the use of a questionnaire is a good alternative. One major disadvantage 
of questionnaires (especially in elderly individuals) is the lack of understanding of the 
question itself, and patients can be confused, for example, between the blurry vision 
induced by a dry eye condition or that induced by out-of-date spectacles. Shorter 
questionnaires are more “user friendly” and less time consuming, but may not provide 
significant information. Although lengthy questionnaires may help to gather more 
information, it can result in fatigue may lead to the collection of erroneous data.  
 
Chapter 5 compared a variety of clinical tests and symptom scores between the 
two groups of PMW and showed a significant difference between the groups. One 
potential omission from this study was the inclusion of the Schirmer test, which has some 
disadvantages in that it may cause some reflex tearing, but it remains the “gold standard” 
test to confirm tear film volume and would have provided some more information on tear 
film dynamics in this group of PMW.  
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Chapter 6 demonstrated that a novel nanolitre osmometer provided data 
comparable to earlier studies which used other instruments. Osmolality in the dry eyed 
PMW group was higher than in the non dry eye group. In addition, a tendency towards 
less tear ferning in people aged over 40 years of age, regardless of their symptoms, was 
noted.  Mild to moderate forms of dry eye show varying ferning grades. There was no 
significant correlation between tear osmolality and ferning patterns. 
 
In Chapter 7 no difference was found in tear film lipocalin or lysozyme 
concentration between dry eyed and non dry eyed PMW, using two tear collection 
methods (capillary tear collection and an eyewash technique). Comparison of clinical 
signs, including non-invasive tear break up time and phenol red thread test, with lipocalin 
and lysozyme concentrations failed to reveal statistically significant correlations. The 
results showed significant inter subject tear variability. Trends of decreasing tear 
lipocalin and lysozyme levels in the symptomatic PMW group were detected, but 
statistical significance was not achieved using either tear collection method. 
 
Chapter 8 showed that Conjunctival Impression Cytology (CIC) is a relatively 
simple, practical and minimally invasive technique to collect epithelial cells from the 
conjunctiva. The Millipore (MP) filter paper membrane used in the CIC procedure, when 
processed with either the TRIzol™ (TZ) RNA isolation technique or RNeasy™ Mini 
(RN) methods, are equally efficient for the isolation of high quality RNA from 
conjunctival cells collected in situ. The RN method was recommended, due to enhanced 
speed as well as on-column isolation and DNase digestion capabilities. For total protein 
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isolation, the use of CIC using MP membranes followed by immediate freezing and then 
extraction and processing with methods optimized by our laboratory, facilitates the 
collection of total protein from human conjunctival cells. Both methods will prove very 
useful to assess the expression of a variety of proteins involved in both normal and 
diseased conditions affecting the ocular surface. From a researchers’ perspective, flash 
freezing of CIC membrane and then isolation of protein is recommended due to practical 
difficulties of isolating each sample immediately after collection. 
 
Chapter 9 demonstrated the collection of tear samples and CIC samples from PM 
women to analyze the expression of MUC1 and MUC16. No difference was found in the 
expression of either MUC1 or MUC16 protein or mRNA expression between 
symptomatic PMW and controls. NITBUT values did not appear to be associated with 
MUC1 and MUC16 expression (protein or mRNA). Our results showed huge variability 
in MUC expression levels with each group, emphasizing the variability within subjects in 
the two groups studied. This may also be due, in part, to the grouping criteria (based on 
symptoms alone). Further research is required to investigate the potential use of 
biomarkers such as MUC1 and MUC16 in the characterization of dry eye disease 







11 Future work 
Technological advancements in instrumentation and analytical methods over the 
past 10 years have resulted in a better understanding of the pathogenesis of dry eye 
disease. However, even though there are many tests available to evaluate dry eye, there 
remains no “gold standard” measurement1 or combination of tests available for dry eye 
diagnosis, with the contentious exception of tear film osmolality. Attempts are being 
made to devise minimally invasive techniques for tear film and ocular cell sampling to 
study dry eye.   
The various studies undertaken within this PhD project did raise a number of 
interesting and worthwhile questions. A major concern that is raised when any dry eye 
study is conducted relates to the grouping criteria used to decide upon those who have 
dry eye, as this will clearly impact on the results obtained. Dry eye is generally 
considered to be a symptom-based disease. However, symptoms may be under-estimated2 
or over-estimated and is, obviously, very subjective.2 It is therefore better to group 
participants based on both clinical signs and symptoms.  However, even this approach 
may not be simple to undertake, as it is a well established fact that clinical signs and 
symptoms do not correlate well in dry eye, except for severe cases.  
From a research standpoint, subject recruitment must include “strict” inclusion 
and exclusion criteria, with the incorporation of both clinical signs and symptoms, to 
avoid the “over lap” of non-dry eyed individuals with those with only mild disease. 
Studies with multiple visits to monitor dry eye over a period of time would be beneficial, 
as opposed to single visit studies which attempt to obtain many variables.  
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Various issues which were not addressed in this study would be valuable 
additions to the literature, on PMW who are not on HRT. These include: 
 
• Staining of the ocular surface with vital dyes: This study design did not permit us to 
grade ocular surface staining, which is a valid criticism of this thesis. Future studies 
should investigate the staining obtained with both fluorescein and rose 
Bengal/lissamine green. These stains could then be graded using a variety of grading 
scales.3-5 
• Confocal microscopy to monitor corneal changes: An increase in osmolality and 
inflammation are related to apoptosis and changes in the cellular structure of the 
surface of the eye, including the cornea and conjunctiva.6, 7  The use of corneal 
confocal microscopy would be useful in understanding the cellular changes that occur 
in dry eye, and could be used to investigate any correlation between ocular surface 
staining and surface cell structural changes.  
• Evaluation of corneal cells: Harvesting corneal epithelial cells using non-contact 
corneal irrigation chamber which enables non-invasive collection of epithelial cells 
from the corneal surface of human subjects8-10 may be beneficial to study the 
structure of the sloughed off corneal epithelial cells under a microscope using 
different dyes in a group of dry eyed participants.  
• Conjunctival and corneal sensitivity assessment: The issue of ocular surface 
sensitivity, especially corneal sensitivity, and its role in the development of dry eye 
symptoms requires further investigation, particularly in PMW. Symptomatic 
individuals have shown a decrease in dry eye symptoms with advancing age,11  which 
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may be due to the decrease in corneal sensitivity.12 On the contrary, increased corneal 
sensitivity in dry eye has also been noted.13  
• Analysis of meibomian gland secretions: Androgen levels play an important role in 
dry eye disease, especially in Sjogren’s syndrome. There is very limited information 
available about androgen levels and its impact on dry eye in PMW.14-17 The majority 
of elderly women suffer from some form of meibomian gland dysfunction, which is a 
major causative factor in dry eye. Understanding the constituents of meibum and lipid 
within the tear film would prove to be very useful in the development of future dry 
eye therapies. 
• Analysis of cytokines: With the evolution of the new definition of dry eye,18 one area 
that is of current interest to dry eye researchers includes the inflammatory mediators 
involved in the pathogenesis of dry eye, including cytokines. Novel, user friendly, 
reliable and repeatable instruments that allow researchers to analyse cytokines, 
MMP’s and other inflammatory mediators in tears and ocular surface cells will be 
beneficial to gain insight in this area of dry eye.  
• Analysis of mucins in severe dry eye: In this thesis, focus was drawn towards soluble 
and membrane bound MUC 1 and MUC 16. Moreover, the participant pool in this 
thesis were divided symptomatically and the majority categorized themselves as 
having mild to moderate symptoms. It will be interesting to study other mucin species 
in more severe forms of dry eye. Studies of this nature may be beneficial in terms of 
potential secretagogues that can be used in the treatment of dry eye. 
The DEWS report also gives a summary of specificity and sensitivity of dry eye 
tests and templates to perform dry eye tests. This can serve as a good starting point to 
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choose validated clinical and analytical tests in designing dry eye studies to explore 
different areas (both clinical and analytical) in this group of participants. 
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Appendix A 
OCULAR SURFACE DISEASE INDEX© 
 
Please answer the following questions by checking the box that best represents 
your answer. 
     Have you experienced any of the following during the last week: 
 










1. Eyes that are sensitive to light? ….      
2. Eyes that feel gritty? ……………      
3. Painful or sore eyes? ……………..      
4. Blurred vision? ……………………      
5. Poor vision?………………………..      
 
 
    Have problems with your eyes limited you in performing any of the following 
during the last  week: 
 











6. Reading? …………………….       
7. Driving at night? ..…………..       
8. Working with a computer or bank 
machine (ATM)? ……….. 
      
9. Watching TV?..………………..       
 
 
    Have your eyes felt uncomfortable in any of the following situations during the 
last week: 
 











10. Windy conditions? ………….       
11. Places or areas with low humidity 
(very dry)? ……..… 
      
12. Areas that are air conditioned?       
 





SUBJECTIVE EVALUATION OF SYMPTOM OF DRYNESS 
 
 
 Please evaluate your ocular discomfort due to the symptom of “Dryness” on a 
scale of 0 (none) to 4 (severe). You may use the following descriptions to assist in 
your score. 
 
 None (0) = I do not have this symptom 
 Trace (1) = I seldom notice this symptom, and it does not make 
me uncomfortable. 
 
 Mild (2) = I sometimes notice this symptom, it does make me 
uncomfortable, but it does not interfere with my 
activities. 
 
 Moderate (3) = I frequently notice this symptom, it does make me 
uncomfortable, and it sometimes interferes with my 
activities. 
 
 Severe (4) = I always notice this symptom, it does make me 























Total protein isolation from the Conjunctival Impression 
Cytology (CIC) samples 
 
Total protein isolation from the CIC samples was performed for sample IDs # 1 to 86. 
1. Four tubes (each tube contained 2 membranes taken from the impression cytology 
of the left eye) were removed from -80ºC freezer and placed on wet ice. 
2. One membrane from the tube was removed and placed with cell side facing up on 
a glass slide. 5µL of extraction buffer (50 mM Tris, 2% SDS, 1X Protease 
Inhibitor™, (PI) (Roche Diagnostics)) was added to the membrane.  
3. The second membrane was placed on top of first membrane and an additional 5µL 
of extraction buffer was added onto top membrane. 
4. Using a #10 carbon steel scalpel blade, the membranes were cut into small pieces, 
(1-2 mm square) and the cut membrane pieces were placed in a 600µL eppendorf 
tube (Axygen MAXYMum Recovery; Axygen Scientific, Inc, Union City, CA). 
5. The eppendorf tube was placed on wet ice until the remaining samples were 
processed (all the four samples were coded and placed in separate tubes). An 
additional 50 µL of extraction buffer was added to all tubes. 
6. Following a 10 second vortexing, the tubes were placed into boiling water for 10 
minutes. The tubes were vortexed briefly for an additional five seconds and the 
tubes were then placed into cap removed, 1.7 mL eppendorf tubes (Axygen 
MAXYMum Recovery; Axygen Scientific, Inc, Union City, CA).  
7.  The caps were pierced to release pressure. While the smaller tube was inside the 
larger tube, the bottom of smaller tube was pierced twice with an 18g needle. 
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8. The samples were spun at 12,000 relative centrifugal force (rcf) for 6 minutes. 
9. An additional 20 µL of extraction buffer was added onto IC membrane of each 
tube and the samples were re-spun for 6 minutes at 12,000 rcf (VWR Mini 
Vortexer, VWR International, USA). 
10. The smaller tubes were removed; the supernatant was collected in the large 
eppendorf tube. Approximately 5µL of the supernatant was used for protein assay 
and the remaining sample was aliquoted into a separate tube and stored at -80oC 
for Western blot analysis.  
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Appendix E 
Total protein determination for tear and CIC samples 
Total protein determination was performed using the BioRad DC™ protein assay (Cat # 
500-0116). The various steps involved in the procedure are described below:  
Microplate DC Assay Protocol: 
1. Sample preparation (each sample contained the following):  
a. Tears: 0.5µL of tears was added to 9.5µL of Milli-Q water. 
b. Eye Wash: 5µL of eye wash was added to 5µL of Milli-Q water. 
c. IC supernatant: 5µL of IC supernatant was added to 5µL of Milli-Q water. 
2. Preparation of working reagents as per manufacturer’s guidelines: 
a. For those samples that contained SDS, 20µL of Reagent S was added to 
each mL of Reagent A that was required (= Reagent A').  
b. If the samples did not contain the detergent (SDS), step #2a was omitted 
and Reagent A as supplied was used.  
3. Prediluted dilutions of Pierce BSA Protein Assay Standard Kit (Pierce Cat# 
23208) were used. There are 7 dilutions, ranging from 125 µg/mL to 2000 µg/mL, 
with Milli-Q water being used for the zero. A standard curve was platted each 
time the assay was performed.  
4. Triplicate 5µL standards or duplicate 5µL diluted samples were pipetted into a 
clean, dry 96 well microplate.  
5. 25µL of Reagent A' or Reagent A (see note from step 2) was added into each 
well. 
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6. 200µL Reagent B was added into each well. Using the microplate reader (96 well 
Micro-Well plates by NUNC, VWR International) mixing function, the plates 
were gently mixed for 5 seconds.  
7. Following 15 minutes, absorbances were read at 750 nm on a Multiskan 
Microplate Spectrphotometer (Thermo Labsystems Cat# 28010).  
8. Graphs were plotted on an excel sheet from the standard readings.   
9. Using the standard linear regression equation, the amount of protein per well and 




Quantification of individual lacrimal gland tear proteins (lysozyme and 
lactoferrin) 
Electrophoresis and immunoblotting for Lysozyme: 
1. Human neutrophil lysozyme (Sigma #L-8402; Lot#104K1040) standards of 10, 7, 
4, and 1 ng/µL lysozyme were prepared in Tear Dilution Buffer (TDB; 10mM 
Tris (pH 8.0), 1 mM EDTA, 0.9% NaCl) and Gel Loading Buffer (GLB; 60mM 
Tris (pH 6.8), 2% glycerol, 2% SDS, and 0.01% bromophenol blue).  
2. Samples were diluted with an equal volume of Laemmli’s buffer (50mM Tris 
pH6.8, 2.5% glycerol, 2.5% SDS, and 0.03% bromophenol blue) and frozen. 
These were called stock tears. 
3. Samples were briefly warmed to room temperature, mixed, and 0.5µL was 
removed from each and diluted with GLB to prepare sample stocks of 25 ng/µL 
for eye wash and 50 ng/µL for tears. 
4. The stocks were further diluted to 25, 15, or 7.5 ng/µL as appropriate for 
electrophoresis. 
5. Prepared sample extracts and standards were boiled for five minutes after which 
0.8μl each was loaded onto a parafilm-covered template for loading of 12 X 0.3μl 
combs by capillary action.  
6. All samples were subjected to SDS-PAGE on precast 10-15% gradient gels with a 
13 mm stacking zone and 32 mm gradient zone on an automated minigel system 
(Amersham Pharmacia Biotech PhastSystem™), using the manufacturer’s 
specified conditions. 
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7. Standard curves were run on each Western blot so that four points falling within 
the linear range of detection were produced, to facilitate regression analysis of 
sample extracts.  
8. Once separated, proteins were analyzed via Western blotting. The gels were 
transferred onto PVDF membranes (BioRad, 0.2μm) pre-equilibrated with 
transfer buffer (20mM Tris, 150mM glycine; 10% (v/v) methanol) using a 
PhastSystem™ following the manufacturer’s specified conditions. 
9. Once transfer was complete, the PVDF membranes were dried for 10 minutes at 
room temperature and then baked for 60 minutes at 50ºC, allowed to cool for 5-10 
minutes, briefly rewetted with methanol, and then blocked overnight (4ºC, with 
shaking) with 20% (w/v) skim milk powder in Tris-buffered saline (TBS-t; 50mM 
Tris; 100mM NaCl pH 7.4, 0.05% (v/v) Tween®-20). 
10. Following blocking, membranes were washed 3 times, each 5 minutes in duration 
in 50 mL of TBS-t. The membranes were probed with primary antibody at room 
temperature with shaking for 2 hours [1:1000 polyclonal rabbit anti-human 
lysozyme (Cedarlane #RAHU/LYS/7S) in 5% blocking solution]. 
11. Blots were washed with TBS-t 3 x 5 minutes (50mL each) and then incubated 
with secondary antibody for 1 hour [1:20 000 goat anti-rabbit IgG-HRP (Sigma 
A-0545), room temperature with shaking]. 
12. Blots were washed 5 x 5 minutes (50mL TBS-T each), and 1 x 1 minute with TBS 
(no Tween).   
13. Bound antibody was visualized by enhanced chemiluminescence (ECL Plus®) 
detection and results were captured with a Storm840® Imaging System 
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(Molecular Dynamics, Sunnyvale, CA, USA). Data was used to generate a 
regression plot upon which lysozyme concentration in samples was extrapolated. 
 
Electrophoresis and immunoblotting for Lipocalin: 
1. Standards for Lipocalin-1 were pooled tear samples from non dry eyed volunteers 
(evaluated by questionnaire).   
2. Pooled tears were initially diluted with reduced 2X Laemmli’s in a 1:1 ratio and 
then diluted with 1X reduced Laemmli’s buffer to 30ng/µL, 20ng/µL, 10ng/µL, 
and 5 ng/µL. 
3. Tear samples were diluted with an equal volume of Laemmli’s buffer (50mM Tris 
pH6.8, 2.5% glycerol, 2.5% SDS, and 0.03% bromophenol blue) and frozen. This 
was called stock tears and stock eyewash. 
4. Tear samples were diluted to 10ng/µL and eye wash samples were diluted to 
15ng/µL.  (NOTE: If a Lipocalin concentration from a sample did not lie within 
the pooled tears standard range, then a second blot was done with more or less 
total protein depending upon the previous result.) 
5. All samples were subjected to SDS-PAGE on precast 10-15% gradient gels with a 
13 mm stacking zone and 32 mm gradient zone on an automated minigel system 
(Amersham Pharmacia Biotech PhastSystem™) using the manufacturer’s 
specified conditions. 
6. Standard curves were run on each Western blot so that four points falling within 
the linear range of detection were produced, to facilitate regression analysis of 
sample extracts.  
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7. Once separated, proteins were analyzed via Western blotting. The gels were 
transferred onto PVDF membranes (BioRad, 0.2μm) equilibrated with transfer 
buffer (20mM Tris, 150mM glycine; 10% (v/v) methanol) using a PhastSystem™ 
following the manufacturer’s specified conditions. 
8. After blocking overnight with 10% blotto(5g skim milk, 50mL TBS –T), lipocalin 
was identified through incubation with a mouse anti-human lipocalin monoclonal 
antibody (1:20 000) diluted in TBS + 0.05% Tween 20 (TBS-T) for 2 hours. 
9. This was followed by a 1 hour incubation with peroxidase-conjugated goat anti-
mouse secondary antibody (1:10 000) diluted in TBS-T.  
10. Blots were washed 5 x 5min (50mL TBS-T each), and 1 x 1min with TBS (no 
Tween).  
11. Bound antibody was visualized by enhanced chemiluminescence (ECL Plus®) 
detection and results were captured with a Storm840® Imaging System 
(Molecular Dynamics, Sunnyvale, CA, USA). Data was used to generate a 




Isolation of RNA from Conjunctival Impression Cytology (CIC) 
samples 
RNA was isolated from right eye CIC samples using a commercially available 
RNeasy Mini Kit™ (Qiagen Cat # 74106) and the DNAse step was performed using the 
RNase-Free™ DNase Set (Qiagen Cat# 79254). The step-wise procedure is described 
below: 
RNA isolation using commercially available RNeasy Mini Kit: 
RNA was isolated from the samples according to manufacturer’s guidelines with 
several modifications as explained below: 
1. Samples collected via impression cytology (as described in 3.11.2 of methods 
chapter) were removed from -80°C storage and allowed to thaw. These samples 
contained the Millipore membranes soaking in 1 mL of RLT buffer (+10 µL of β-
mercaptoethanol). All thawed samples were vortexed well for 30 seconds. Up to 
four samples were processed at the same time. 
2. The Millipore membranes were removed from the RLT buffer using sterile 
forceps and the samples were vortexed again for 15 seconds. 
3. 20 gauge needles were used to homogenise each of the samples by passing the 
samples several times (at least 20 times) through the syringe. 
4. One volume (1 mL) of 70% ethanol was added to the homogenized samples and 
vortexed again for 15 seconds. 
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5. 700µL of the sample was added to the RNeasy mini spin column and centrifuged 
(VWR Mini Vortexer, VWR International, USA) for 15 seconds at 8000g. 
6. Flow-through was discarded and step 5 was repeated with the remaining volume 
of the samples.  
DNAse step 
1. 350µL of buffer RW1 was pipetted to the above sample and centrifuged for 15 
seconds at 8000g. Flow-through was discarded. 
2. 22µL of DNAse I stock solution was added to 154µL of Buffer RDD and mixed 
gently by careful inversion. 
3. 80µL of DNAse I was directly added on to the spin column membrane.  
4. The spin column was incubated with DNAse I for 15 minutes at room 
temperature. 
5. 350µL of buffer RW1 was added to the spin column and centrifuged for 15 
seconds at 8000g. Flow-through was discarded. 
6. 500µL of buffer RPE was then added to the column and centrifuged for 15 
seconds at 8000g and the flow-through was discarded. 
7. A second RPE buffer wash was performed by adding an additional 500µL of the 
buffer to the column and this was centrifuged for 2 minutes at 8000g to dry the 
membrane. 
8. The dry RNeasy mini spin column was placed in a new 2mL collection tube and 
the old collection tube was discarded with the flow-through (care was taken not to 
allow the column to touch flow-through). 
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9. The new 2mL collection tube with the dry column was then centrifuged for 
additional 15 seconds at 8000g to completely dry the membrane. 
10. The column was transferred again in to a new 1.5mL collection tube. The old 
2mL collection tube was discarded. 
11. 40µL of RNAse free water was pipetted into the column and centrifuged for 1 
minute at 8000g to collect RNA samples. 
12.  The sample flow through was carefully pippetted out into a new 1.5mL collection 
tube and the RNA sample was immediately placed in a -80°C freezer for storage 
until use for RT-PCR. 
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Appendix H 
Staining Conjunctival Impression Cytology (CIC) Samples 
1. Samples (CIC membranes) were fixed in 95% ethanol and were hydrated for 1-2 
minutes in distilled water (ddH2O)  
2. Samples were then soaked in Gill’s hematoxylin for 2 minutes. 
3. Samples were then repeatedly rinsed in ddH2O for several dips for at least 3 minutes.  
4. Samples were differentiated in 0.5% hydrochloric acid in 70% ethanol (0.5 
mL/100mL) until nuclei were distinct against a pale blue cytoplasm.  
5. Samples were washed gently in water for 1 -2 minutes until nuclei were clear blue.  
6. Samples were dipped in ammonium hydroxide water (bluing agent consisted of 
1.5mL NH4OH in 750 mL dH2O) several times and then rinsed in ddH2O for 1 
minute. 
7. The membrane was stained in eosin for 1-2 mins (Eosin stain recipe: eosin Y 1.0 g + 
1000 mL 70% EtoH + 5 mL glacial acetic acid). Volume to be used when staining 
were diluted with equal volume of 70% ethanol and 2-3 drops of glacial acetic acid 
was added (For example: To obtain10 mL for stain, 5 mL of the eosin and 5 mL of 
70% ethanol and 2 to 3 of drops of glacial acetic acid were used).  
8. Sample was rinsed in 95% ethanol for a 3 to 4 dips. The samples were then 
dehydrated through 1 X 95% and 2 X 100% ethanol (1 min each with agitation).  
9. The membrane was placed in xylene and placed on a slide and mounted. 
10. The cells were evaluated under a microscope set at 40X magnification (Zeiss 
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